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ABSTRACT 
 
Joseph Carl Gaiteri: Development of a Microfluidic Immunoassay  
for Determination of Kinase Phosphorylation 
(Under the direction of J. Michael Ramsey) 
 
 Extracellular signal-related kinases 1 and 2 (ERK1/2) are signaling proteins involved in 
cell survival and proliferation and are overactive/phosphorylated (forming pERK1/2) in 
approximately 1/3 of human cancers.  Measuring pERK1/2:ERK1/2 is therefore common in 
cancer-related research, but conventional methods are some combination of slow, expensive, and 
labor-intensive, and large samples are often required.  Microfluidic devices offer the possibility 
of determining pERK1/2:ERK1/2 rapidly, with lower costs, and with substantially reduced labor 
and reagent requirements compared to conventional methods.  This would facilitate more 
expedient medical decisions and increase experimental throughput in research that requires 
determining pERK1/2:ERK1/2, such as that related to tumor cell signaling and anti-cancer drug 
development.  This dissertation describes the development of a microfluidic immunoassay for 
determining the ratio of pERK1/2:ERK1/2 in human cell lysate.   
 Early experiments used antibody-coated beads loaded into chips with 
poly(dimethylsiloxane) (PDMS) microwell arrays.  The fluorophore, assay buffer, incubation 
protocol, and capture antibody used in all subsequent experiments were chosen here, but these 
experiments suffered from high (>10%) coefficients of variance.  To improve the sensitivity and 
clinical relevance of the pERK1/2:ERK1/2 assay, the assay was systematically examined until it 
iv 
was determined that the process of loading beads into the PDMS arrays was mechanically 
damaging their capture antibodies. 
 The next chapter introduced a new chip design for performing pERK1/2:ERK1/2 assays 
without harsh mechanical loading.  These chips were used to optimize assay conditions and 
determine pERK1/2:ERK1/2 in human Jurkat cell lysate at physiologically relevant 
concentrations.  Further improvement of the assay called for automation to minimize labor/user 
interaction during experiments, and this required valves to control fluid flow on-chip.  The next 
chapter therefore focused on developing computer-controlled, Peltier-based freeze-thaw valves 
for microfluidic chips.  In the final chapter, these valves were coupled with a chip design for 
assaying up to 8 samples simultaneously.  These chips could be used to perform multiple 
replicate measurements of a sample or to produce a calibration curve on the same device used to 
measure samples.  Finally, the 8-sample chips were used with the freeze-thaw valves to 
determine pERK1/2:ERK1/2 in cell lysate with automated fluid control, marking a significant 
advance toward the realization of automated kinase assays. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
 Benchtop assays that yield accurate, reproducible results now exist for a vast range of 
medical and research purposes.  However, these conventional assays can be slow and labor-
intensive.  In research terms, this leads to lower experimental throughput, while in medical 
terms, this often increases the time required to make healthcare decisions.  These delays are 
exacerbated by the fact that medical tests are often performed at centralized facilities, requiring 
the samples to be packaged and shipped with the results communicated back to the healthcare 
provider and then the patient.  In recent decades, these considerations have led to a trend towards 
miniaturizing conventional benchtop assays.  Ideally, these miniaturized devices would meet or 
exceed the performance of their conventional counterparts in terms of accuracy, reproducibility, 
and sensitivity.  They should also offer further advantages including portability, reduced 
reagent/sample consumption and lower cost in general, and greater speed due to the reduced 
incubation/migration times that come with the small dimensions of the miniature devices.1–7 
 A well-known example of miniaturized medical testing is the self-monitoring of blood 
glucose, where a patient places a drop of blood on a test strip and their blood glucose level is 
determined by a portable meter.8  Even more simply, home pregnancy tests utilize the lateral-
flow immunoassay technique, are accurate and rapid, and do not require any power.9  Useful 
miniature devices exist in laboratory settings as well.  One such example is Millipore’s handheld 
Scepter™ hemocytometer, which determines the concentration and size distribution of cells in a 
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sample in approximately thirty seconds, much faster than conventional microscope-based 
hemocytometers.10 
 The speed and accuracy of miniaturized assays make them well-suited to the domain of 
cancer research and medicine, where time – in terms of discovering treatments and making 
medical decisions related to a patient’s ongoing therapy – is of the utmost concern.  One of the 
fundamental characteristics of cancer is the dysregulation of the cell signaling process on 
multiple fronts such that cancer cells have overcome the normal processes that tightly regulate 
tissue growth.11,12  In approximately one-third of human cancers, the extracellular signal-related 
kinase 1 and 2 (ERK1/2) signaling cascade is involved in this dysregulation.13  ERK1 and ERK2 
are proteins involved in regulating fundamental processes such as apoptosis and growth and are 
activated by dual phosphorylation.  Upon becoming phospho-ERK1/2 (pERK1/2), they migrate 
to the cell nucleus and activate transcription factors and genes related to growth and 
proliferation.13–17  Cancer-related mutations in the ERK1/2 pathway often lead to excessive 
ERK1/2 phosphorylation and activity.13–16,18–21  It is therefore a pathway whose activity is 
commonly monitored in cancer research.  Also, many drugs have been and are being designed to 
inhibit mutationally activated proteins in the ERK1/2 cascade.21  The most successful of these is 
imatinib (Gleevec®), a drug that inhibits the kinase domain in the mutant BCR-ABL kinase 
(upstream from ERK1/2) in patients with chronic myelogenous leukemia (CML).  Prior to the 
invention of imatinib and related drugs in its class, the prognosis for CML was extremely poor; it 
is now considered highly treatable.22 
 However, these mutant proteins sometimes acquire further mutations that prevent their 
inhibitory drugs from binding.21,23  Monitoring the extent of ERK1/2 phosphorylation is, 
therefore, desirable to assess the efficacy of an ongoing treatment plan or to determine a patient’s 
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response to a new one.  Various methods24–28 currently exist for determining pERK1/2 and/or 
total ERK1/2 in cell lysate.  These include the Western Blot, enzyme-linked immunosorbent 
assay (ELISA), and AlphaScreen™, Li-Cor®, and Meso-Scale Discovery® systems.  These 
methods are effective, but each has one or more of the following drawbacks: being labor-
intensive, requiring large samples (hundreds of thousands to millions of cells in some cases), 
requiring long incubation times (up to overnight), and being difficult to automate or not being 
automatable at all.  A miniaturized or microfluidic device for determining pERK1/2:ERK1/2 in a 
sample can potentially solve many of these issues.  This is desirable from a medical standpoint, 
as the time required to make a crucial medical decision may be reduced.  It is also desirable from 
a scientific standpoint, as it can increase experimental throughput in studies that involve 
determining cellular pERK1/2 expression.  Such research includes examining cell signaling in 
tumors under various circumstances or studying the effects of kinase inhibitor drugs on the 
ERK1/2 pathway.16,20,21,29  The remainder of this chapter will provide a general overview of the 
field of microfluidics and explain why it is well-suited for addressing this problem.  
Immunoassays, the central technique in the device, will then be reviewed.  Finally, the ERK1/2 
signaling pathway will be explained in greater detail and the research goals for the project 
outlined. 
1.2 General microfluidics, point-of-care devices, and poly(dimethylsiloxane) 
 Microfluidics is an interdisciplinary science concerned with using micrometer-scale 
systems for manipulating and studying liquids in nanoliter to attoliter volumes.1  The field of 
microfluidics has multiple progenitors.  For molecular biology, analytical chemistry, and 
biodefense, the possibility of conducting high-throughput, high-resolution analysis with 
miniature, portable devices was a major driver of the field’s development.1,2  Technologies 
4 
developed in the microelectronics industry also contributed to the growth of microfluidics, as 
photolithography and other techniques were adapted to fabricate microfluidic devices.  These 
techniques make it possible to create micrometer- or nanometer-scale features in silicon and 
glass.  It was in these materials1,2 that much of the early work in microfluidics was conducted 
using such techniques as liquid chromatography (LC) and capillary electrophoresis (CE).2,30–33 
 In 1990, Manz and co-workers30 proposed the possibility of constructing a micro total 
chemical analysis system (µTAS), also called a lab-on-a-chip (LOC).2,3,30,34  A LOC would 
incorporate all the steps from a conventional benchtop technique into a single miniaturized 
device.  These steps could include sample pretreatment,31,35 analysis through techniques such as 
immunoassays,36,37 the polymerase chain reaction,35,38 or CE,31,39–41 and detection of the results 
through optical,2,31,37 electrochemical,4,42,43 mass spectrometric,39,40 or other means.1,2,5,6  Ideally, 
all this would be possible while maintaining or exceeding the performance of the corresponding 
conventional technique.  In addition,1,2,5,6 the high surface area-to-volume ratio reduces 
incubation or reaction times due to the reduced time required for molecules to diffuse across the 
dimensions of the device, thus reducing analysis times.4  Microfluidic devices also have the 
advantage of requiring significantly lower volumes of sample and reagent than conventional 
techniques.1–3,7  This reduces costs given the lowered consumption of expensive reagents such as 
enzymes and monoclonal antibodies, and it enables the analysis of samples of which only micro-
quantities are available, as is the case with many biological samples.44,45   
 Since Manz and co-workers’ proposal, many examples of LOC devices have been 
demonstrated, aided by developments in technology for such components as pumps, valves, 
mixers, and detectors.1,2,6,46  The integration of these techniques into a single chip have also 
made it possible to automate the devices,1,7 thus allowing a user to input a sample and receive a 
5 
result with minimal or no additional interaction with the system.1,2,47  These devices are ideal for 
point-of-care (POC) diagnostics, where a test is performed at or near the site of patient care.48,49  
Performing analyses at the POC instead of a separate testing facility can reduce the results’ 
turnaround time from days or weeks to minutes or hours.7,48–50  Devices such as these have the 
potential to improve a patient’s outcome in time-critical decisions as well as reduce costs 
associated with labor and shipping/handling the samples.49,50  A recent example of POC devices 
is the microfluidic paper-based class of devices developed by the Whitesides group, which are 
usable in a low- or zero-resource setting.51  As the results of these devices can be captured with a 
cell phone camera and transmitted anywhere in the world for diagnosis, these devices can bring 
healthcare to places where there are no physicians or other medical professionals.52 
 Since the early years of microfluidics, polymers such as poly(dimethylsiloxane) (PDMS) 
have become extremely popular as the base material.1,2,6  PDMS is widely used because it is 
optically transparent from 240 nm to 1100 nm, impermeable to water, and compatible with 
biological molecules.53,54  Unlike glass and silicon, it is flexible, making it compatible with 
useful components like mixers, pumps, and valves that are mechanically or pneumatically 
actuated.1,55–57  It is gas-permeable, permitting microfluidic cell culture.1  PDMS is also favored 
in research because it is possible to rapidly create prototype devices in PDMS to test new 
ideas.1,54,58  Master molds for PDMS can be fabricated with a variety of materials and methods 
and used to make an indefinite number of castings/chips.4,54,59  Molds with low aspect-ratio 
features may be fabricated with isotropic wet etching techniques such as the buffered hydrogen 
fluoride etching of glass,36 whereas molds with high-aspect-ratio features and vertical sidewalls 
may be fabricated with focused ion beam (FIB) milling36 or dry etching techniques such as deep 
reactive-ion etching (DRIE).2,37,43,60  Simpler chips that require no etching may also be fabricated 
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directly from molds consisting of photoresist patterned on a substrate such as a silicon wafer.61–63  
After a device is fabricated in PDMS, access holes (vias) to the channels can be cut from the 
bulk material and the channels irreversibly sealed by bonding the PDMS to glass following 
plasma treatment.36,53,54  The bonded device may then be used in an experiment or its surface 
modified64,65 if necessary prior to use. 
1.3 Microfluidic valving 
 In LOC devices, multiple solutions are typically used simultaneously, so valves play an 
important role in controlling the fluid flow throughout the chip by opening/closing channels or 
otherwise modulating the flow direction.  Some valves are closed until intentionally opened and 
are referred to as “normally-closed,” while others are generally open and are referred to as 
“normally-open.”  Many valving strategies have been demonstrated, one of the earliest of which 
was the electrokinetic valve.31,41,66–68  These are normally-closed valves in which voltages 
applied to channels are used to dispense plugs of sample through electrokinetic flow.  Major 
types of electrokinetic valves include the double-T valve,33,69 pinched valve,67,70,71 and gated 
valve.31,41,68  The volume of sample delivered through each injection will primarily be a function 
of either the spatial dimensions of the chip (for pinched and double-T valves) or the field 
strength and duration of the injection (for gated valves).67  Depending on the chip design, 
electrokinetic valves may require only a single voltage source while exhibiting excellent 
reproducibility (<0.5% RSD) in the sample volumes delivered.41 
 Hydrogel valves are another means of controlling flow in microfluidic chips.72–75  These 
consist of posts or other shapes that are fabricated in situ on a chip through photopolymerization.  
The volume of the posts varies greatly depending on an environmental stimulus, most commonly 
pH, although electrical control of hydrogels has also been demonstrated.75  This expansion is 
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reversible given a change in the stimulus.  Generally, valving is accomplished when the posts 
swell to occlude the channel they occupy, but if fluidic isolation of the analysis channels is a 
requirement, it is also possible for an expanding post to deflect an impermeable PDMS layer to 
close an adjacent channel.73,74 
 The final hydrogel example above is also an example of a larger class of valves known as 
pinch valves.37,55–57,61,62,76,77  These consist of a membrane made from an elastomeric material 
such as PDMS that is deflected to open or close a channel.  Several primary means of controlling 
the valve exist.  Pneumatic actuation is used in one of the most well-known types of microfluidic 
valves, the Quake-style valve.55–57  These are normally-open valves in which a thin (~30 µm) 
membrane of PDMS separates a fluidic channel and a pneumatic channel in a multilayer chip.  
Pressure is applied through the pneumatic channel to deflect the PDMS membrane into the 
fluidic channel, closing it.  A similar design adds a post on the fluidic side of the PDMS 
membrane to make the valve normally-closed, and negative pressure is used to pull the 
membrane into the pneumatic channel and open the valve.77  Quake-style valves can be actuated 
at approximately 100 Hz, enabling them to act as a peristaltic pump when multiple valves are 
arranged sequentially in the same channel.55  Pinch valves can also be actuated through 
mechanical rather than pneumatic pressure.  The Whitesides group has demonstrated numerous 
examples of this, include manually-actuated screw valves and computer-driven solenoid 
valves.61,62  A recent device developed by the Ramsey group in collaboration with the Walt 
group also utilizes computer-controlled normally-closed pinch valves.37   
 Thermal actuation is another means of controlling fluid flow in microfluidic channels.  
The use of paraffin wax is one such method of thermally-driven valving.78–80  Paraffin is 
immiscible with water and expands from 10-30% upon melting,78 and this has been exploited to 
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close normally-open channels by melting the wax in both reversible and irreversible 
configurations.78,79  Paraffin can also be used in a normally-closed configuration if a solid plug 
initially seals a channel but opens the channel upon heating.80  Finally, a type of thermal valve 
that does not require extra material inside the device is the freeze-thaw valve.63,81–84  This 
strategy uses an external cooling source to freeze a segment of a microfluidic channel, thus 
stopping flow.  Early examples of freeze-thaw valves used low-temperature fluids such as liquid 
nitrogen81 or carbon dioxide82,83 to induce freezing, while thawing was initiated by removal of 
the coolant.  A freeze-thaw strategy that is recently emerging in the literature utilizes Peltier 
devices to effect freezing and thawing.63,84  Peltiers consist of alternating semiconductor pellets 
sandwiched between two insulating layers.85  The application of voltage creates a temperature 
gradient across the device, and the use of multiple Peltiers stacked on top of one another can 
generate successively lower temperatures that are sufficiently cold to rapidly freeze aqueous 
solutions in microfluidic channels.  They can also generate heat for thawing/opening a channel if 
their voltage is reversed.  Peltiers are easily computer-controlled, indefinitely reusable, 
inexpensive, compatible with a wide range of materials, and do not require the manipulation of 
high-pressure gases.63 
1.4 Immunoassays 
 Immunoassays are a widely-used analytical technique whose defining characteristic is the 
utilization of capture antibodies (CAbs) to bind molecules of interest (“antigens”) with high 
specificity and affinity.86  Antigens range in size from <1000 daltons (“haptens”) up to large 
proteins.  In addition to their specificity, immunoassays are highly sensitive and relatively easy 
to perform.87  While all immunoassays utilize CAbs, two major classes of immunoassays – 
competitive and non-competitive – differ in their measurement methods.88,89  In competitive 
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immunoassays, sample analytes are incubated along with labeled antigens (most commonly more 
analyte molecules) such that the unlabeled antigens compete with the labeled antigens for 
binding sites on the CAbs.  Measurements are therefore made of sites unoccupied by the sample 
analytes and the signal is inversely proportional to the sample concentration. 
 The other major type is non-competitive immunoassays, which usually takes the form of 
a “sandwich assay” because the analyte molecules are sandwiched between two antibodies.  
Here, analyte molecules are bound by CAbs before a second detection antibody (dAb) is 
incubated that completes the sandwich by binding to another epitope (binding site).  These dAbs 
are labeled, or are themselves detected with a third labeled antibody following a third incubation, 
and after excess dAb is washed away, the occupied sites are measured.88,89  These assays have 
the disadvantage of requiring two antibodies with specificity for two epitopes on the analyte.  
This two-antibody characteristic means that sandwich assays are rarely suitable for haptens, as 
immunoglobulin-G (IgG) antibodies are more than two orders of magnitude larger than haptens 
and steric effects generally preclude sandwich formation.90  However, use of sandwich 
immunoassays for proteins is specific enough that it is possible to distinguish between otherwise 
identical proteins with different post-translational modifications, such as phosphorylation states.  
Also, sandwich assays tend to be more sensitive than non-competitive assays because the signal 
is directly proportional to the analyte concentration.42   
 Several broad types of detection labels have been used in immunoassays.  The first 
immunoassay technique, described in 1959, was a competitive radioimmunoassay for human 
insulin.91  The competitive antigen in this case was 131I-labeled human insulin.  Assays with 
radiometric labels are extremely sensitive due to the ease of detection of decay events, but their 
use has been largely displaced in favor of techniques that do not require radioactive labels.87,89  
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In particular, fluorescent labels have become extremely popular,42,86 especially in microfluidic 
systems.92  A wide range of fluorescent labels with varying spectral profiles exist, ranging from 
small organic molecules to quantum dots.  Enzyme labels on dAbs are also used in 
immunoassays in enzyme-linked immunosorbent assays (ELISAs).93  In ELISAs, following the 
washing away of unbound dAb, a substrate for the enzyme is introduced to the system and the 
enzyme-substrate reaction products are detected.  It is also common to utilize detection 
antibodies labeled with biotin.42  Biotin binds rapidly and strongly to streptavidin,94 and while 
the use of biotin has the drawback of requiring an additional incubation step for the detection 
label, it has several advantages.  First, biotin is small (molecular mass = 244 daltons) and can 
generally be conjugated to antibodies without reducing their activity.  Any label that can be 
conjugated to streptavidin may then be used, and streptavidin may be conjugated to multiple 
detection labels for further signal amplification.95 
 There are two types of antibodies used in immunoassays: polyclonal antibodies (pAb) 
and monoclonal antibodies (mAb).  Polyclonal antibodies are a mixture of antibodies that target 
many epitopes on an antigen.96  Compared to mAbs, they are relatively easy to produce, but they 
lack the mono-specificity of mAbs.  The single-epitope specificity of mAbs enables them to 
target and discriminate between extremely similar molecules, such as differing phosphorylation 
states of the same protein.  Developing mAbs for highly specific sequences, e.g. a particular 
peptide sequence on a protein, is often accomplished by using the peptide itself rather than the 
intact protein.  The injected peptide sequence may be unfolded or otherwise not have the same 
shape as the epitope on the target native molecule.96,97  During an assay, therefore, it may be 
necessary to unfold the analyte protein so that its target epitope resembles the shape of the 
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peptide used in generating the mAb.  Multiple means of accomplishing this are possible, but 
adding a denaturing agent such as urea98 to the assay buffer may be the simplest. 
1.5 ERK1/2 signaling pathway 
 Profound dysregulation of the cell signaling process is one of the defining characteristics 
of cancer.  In order to become cancerous, cells must acquire characteristics dubbed “hallmarks” 
by Hanahan & Weinberg.11,12  Among these hallmarks is the ability to continue to survive and 
proliferate in spite of contrary signals from other cells in their environment.  Cancers utilize 
many strategies11,12 to accomplish this, one of which is the deregulation of the extracellular 
signal-related kinase 1 and 2 (ERK1 and ERK2, or ERK1/2 collectively) signaling cascade.  This 
pathway is involved in regulating cellular processes such as apoptosis, proliferation, and growth 
in response to extracellular signals, and its dysregulation presents in approximately 33% of 
human cancers.13  The ERK1/2 cascade begins with epidermal growth factor receptors (EGFR) at 
the cell membrane.  Signals from EGFR are sent through other membrane proteins to Ras.  
Signals then travel from Ras to Raf, then to mitogen-activated protein kinase kinases 1 and 2 
(MEK1/2).  ERK1/2 are themselves activated by MEK1/2.  The activation of ERK1/2 consists of 
dual phosphorylation at one serine and one threonine residue each,14,15 leading to a conformation 
change and 1,000-fold increase in activity.15  Activated ERK1/2 translocate to the cell nucleus, 
where they activate transcription factors and genes related to cell survival and proliferation.13,16,17   
 In this signaling cascade, cancer-related mutations have been documented in EGFR, Ras, 
and Raf.  Notably, Raf is mutationally active in 70% of melanomas and 50% of papillary thyroid 
cancers, Ras is mutationally active in 90% of pancreatic cancers, 60% of papillary thyroid 
cancers, and 50% of colon cancers, while overexpression or mutations in EGFR are present in up 
to 80% of lung cancers, up to 91% of non-small cell lung cancers, up to 77% of colorectal 
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cancers, over 50% of carcinomas, up to 50% of pancreatic cancers, and 20% of 
glioblastomas.13,16  These mutational activations upstream from ERK1/2 often lead to excessive 
activation of ERK1/2 to the extent that some tumors are dependent upon ERK1/2 for survival 
and are “ERK-addicted.”18  Excessive ERK1/2 activation is also seen because of downstream 
signal amplification, wherein relatively few molecules are needed to activate a relatively large 
number of molecules further down the signaling cascade.14,99  For example, activation of just 5% 
of a cell’s Ras molecules has been estimated to be sufficient for fully activating that cell’s 
ERK1/2.100   
 Several factors call for the development of assays for determining the phosphorylation 
extent (pERK1/2:ERK1/2) of ERK1/2.  Because of the commonality of mutations in the ERK1/2 
cascade leading to elevated ERK1/2 activity, the pERK1/2:ERK1/2 ratio is a useful biomarker in 
many cases.14,16,19–21  Drugs have been and continue to be developed to inhibit mutationally 
activated proteins in the pathway by binding to and antagonizing their kinase domains.  
However, the mutated proteins sometimes acquire further mutations that prevent the drugs from 
binding.  The pERK1/2:ERK1/2 ratio in these cells is thus a useful diagnostic here as well, as it 
changes in response to the specific drug and mutation21 and can be used in the monitoring of 
treatment efficacy.  Finally, because they are present at approximately micromolar 
concentrations,21 ERK1 and ERK2 are among the most abundant proteins in their signaling 
cascade, making them an attractive analytical target.  They also possess a sequence homology of 
approximately 83-85% and share many structural features.14,17  A single antibody can therefore 
capture ERK1 and ERK2 by targeting an epitope common to both.  Monoclonal antibodies 
specific for the phosphorylation loop (in pERK1/2) and a second common site on all forms of 
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ERK1/2 can then be used to determine pERK1/2 and ERK1/2 and thus the pERK1/2:ERK1/2 
ratio in cells.29   
 These strategies and considerations open the door for developing a microfluidic device 
for determining pERK1/2:ERK1/2 in a sample.  Current methods of pERK1/2:ERK1/2 
determination (namely the Western Blot) are time- and labor-intensive and can require millions 
of cells.  A device with the advantages of microfluidics – relatively small sample size and 
reagent consumption, fast incubation times, high sensitivity, and the potential for automation – 
can provide a substantial improvement over these methods in terms of time and cost. 
1.6 Research goals 
 The goal of this project is to develop a bead-based microfluidic immunoassay device for 
determining pERK1/2:ERK1/2 in human cell lysate.  The microfluidic device would be 
automated such that once sample and reagents were added to vias on the microfluidic device, no 
other user interaction would be needed.  Early efforts centering on the selection of fluorophores, 
optimizing incubation times, determining suitable antibody pairs for a pERK1/2 and ERK2 
sandwich immunoassay, and the development of a general on-chip assay protocol are described 
in Chapter 2.  Based on these early results, troubleshooting efforts to improve the reproducibility 
of the assay to clinically relevant standards are the subject of Chapter 3.  The results of Chapter 3 
led to an improved chip design investigated in Chapter 4, wherein an on-chip assay for 
determining pERK1/2:ERK1/2 in human cell lysate is demonstrated.  Chapter 5 focused on 
automating the assay using a computer-controllable valving method (freeze-thaw valves, FTVs).  
Finally, a chip design where fluid flow is controlled by automatable FTVs is described in 
Chapter 6, and the utility of it for the pERK1/2:ERK1/2 assay is demonstrated.  The final device 
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represents a significant advance toward a microfluidic pERK1/2:ERK1/2 assay that is automated 
and requires relatively few cells compared to conventional methods. 
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CHAPTER 2 
 
BEAD-BASED SANDWICH IMMUNOASSAY FOR pERK1/2 AND TOTAL ERK2 
2.1 Introduction 
 This work builds on a microfluidic device previously designed and reported on by the 
Ramsey group and collaborators (Figure 2.1).1,2  The device incorporated an array of antibody-
coated microspheres (beads) and used multiplex sandwich immunoassays to determine the 
concentrations of cytokines in human saliva.  Four reagent inlets/vias introduced sample, 
biotinylated detection antibody (dAb), a streptavidin-conjugated fluorescent complex, and wash 
buffer to the chip.  Fluid flow from the reagent inlets was controlled by pinch valves.  While the 
device was designed to be used in a single experiment with an automated reader,2 its 
experimental parameters were developed through use of a simpler version of the chip that 
facilitated running many assays simultaneously.  The simplified device (Figure 2.2A) featured 
eight single straight channels with bead arrays at their center, vias for introducing beads/reagent 
to the chip, and vias for applying waste/vacuum.  A 1,024-microwell array and its corresponding 
location on one of the straight channels is shown in Figure 2.2B.  With this simple design, 8 
assays/chip can be run simultaneously in addition to running multiple chips as well.  With the 
large throughput capability, the device was used to develop the immunoassay by testing different 
experimental conditions.  This included the testing of antibody pairs for sandwich 
immunoassays, the optimization of reagent concentrations and incubation times, and the lengths 
of wash steps between each incubation. 
 Several aspects of this simple array chip are applicable for determining 
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pERK1/2:ERK1/2 in human samples.  The first is its utilization of the sandwich immunoassay.  
Figure 2.3 shows the steps of a sandwich immunoassay with the first step involving an antibody 
capturing a target analyte during a sample incubation period (Figure 2.3A).  After a wash step, a 
dAb is introduced to bind to a second epitope site on any captured target analyte (Figure 2.3B).  
The dAb in these particular assays has been conjugated with multiple molecules of biotin.  After 
the dAb incubation, a streptavidin-conjugated fluorescent label is introduced and incubated with 
the beads (Figure 2.3C).  Streptavidin and biotin bind together rapidly with extremely high 
affinity,3 and the fluorescent label thus becomes bound to the antibody-analyte complex.  
Unbound streptavidin-fluorescence complex is washed away and a fluorescence image of the 
beads taken (Figure 2.3D).  The amount of fluorescent label present corresponds directly to the 
amount of analyte captured. 
 This two-antibody feature of sandwich immunoassays can be applied for determining the 
phosphorylation ratio of ERK1/2.  Due to the ~83-85% sequence homology of ERK1 and 
ERK2,4 they share many epitopes, making it possible to capture all phosphorylation states of 
ERK1 and ERK2 with one monoclonal capture antibody.  As phosphorylation considerably 
changes the shape of ERK1 and ERK2,5 a monoclonal dAb that recognizes only pERK1 and 
pERK2 can be used to distinguish them from non-phosphorylated ERK1 and ERK2 (nERK1 and 
nERK2).  Two assay strategies are possible based on this. 
 In the first strategy (Figure 2.4), a single dAb for pERK1/2 is used to determine both 
pERK1/2 and nERK1/2.  For this assay, two successive pERK1/2 dAb incubations are used with 
a phosphorylation step in between to convert captured nERK1/2 to pERK1/2.  The assay begins 
by capturing both pERK1/2 and nERK1/2 and determining the pERK1/2 concentration using the 
sandwich immunoassay steps shown in Figure 2.4A-D.  After quantifying the pERK1/2, 
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mitogen-activated protein kinase kinases 1 and 2 (MEK1/2), the enzymes responsible for 
phosphorylating ERK1/2 in vivo,4 are then incubated with the necessary cofactors in order to 
convert all captured nERK1/2 to pERK1/2 (Figure 2.4E).  The pERK1/2 dAb is incubated a 
second time (Figure 2.4F) in tandem with the fluorescent streptavidin complex (Figure 2.4G) and 
the captured complex’s fluorescence is measured (Figure 2.4H).  The ratio of the fluorescence 
from the initial pERK1/2 measurement and the second pERK1/2 measurement corresponds to the 
sample’s ratio of pERK1/2 to total ERK1.2 (pERK1/2:ERK1/2).  An initially highly 
phosphorylated sample would yield a relatively high fluorescence ratio between the two 
measurements.  In a clinical sample, this would be seen in many cancers due to overexpression 
of the ERK1/2 pathway, though the extent of overexpression varies by patient, disease, and 
disease stage.6  A sample from a healthy patient would have a low proportion of pERK1/2 and 
would experience a greater degree of phosphorylation during the MEK1/2 incubation.  The 
fluorescence from the second measurement would thus be greater than from the first. 
 The second assay strategy for determining pERK1/2:ERK1/2 utilizes two distinct dAbs 
(Figure 2.5).  In addition to the pERK1/2 dAb, a dAb that recognizes all phosphorylation states 
of ERK1/2 is used to determine the total amount of ERK1/2 captured.  A standard immunoassay 
as in Figure 2.3 would be performed with a pERK1/2 dAb, followed by introduction of the total 
ERK1/2 dAb and subsequent measurement of the total ERK1/2.  It is also possible to reverse the 
dAb incubation steps, first using the total ERK1/2 dAb and then the pERK1/2 dAb. 
 The approach as proposed in Figure 2.3 and Figure 2.4 has the advantage of requiring 
only a single dAb as only one analyte (pERK1/2) is targeted.  The disadvantages lie with using 
the MEK1/2 enzyme to convert the nERK to pERK.  The MEK1/2 enzymes are expensive, and 
they may require the nERK1 and nERK2 to be in their native conformation.  This is a potential 
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issue because target epitopes for many monoclonal antibodies may be poorly accessible in the 
native protein, requiring the protein to be unfolded with a denaturing agent like urea7 to expose 
the binding site.  The two-dAb approach has the advantage of not requiring nERK1/2 to be in 
their native conformations in order for dAb recognition.  The cost may also be lower since 
MEK1/2 is not required.  A disadvantage is the need for a total ERK1/2 dAb in addition to the 
pERK1/2 dAb.  Ideally, the total ERK1/2 dAb would be capable of binding to ERK1/2 
molecules captured by the pERK1/2 capture antibody, as only one capture bead type would then 
be needed.  The use of a total ERK1/2 dAb not capable of such binding would require at least 
two bead types, further complicating experimental procedures and data analysis. 
 While capture antibodies for sandwich immunoassays can be affixed to many surfaces, 
including microtiter plate wells8 and microfluidic channels,9 covalently binding antibodies to 
beads has several advantages over these approaches.  A single coupling reaction can produce 
enough antibody-coated beads for months or even years of experiments, while other approaches 
often require a long incubation step to immobilize the capture antibody on the surface prior to 
sample introduction for each experiment.  The use of beads from a single antibody-bead reaction 
for many assays improves interexperimental reproducibility as well as experimental throughput.  
Beads can be spatially placed within a device without the need for such steps as photoinitiated or 
passive antibody-surface binding, and through the use of internal encoding dyes, beads coated 
with different capture antibodies can be distinguished to assay numerous analytes 
simultaneously.1,2  The arrays used in our devices facilitate this by placing up to 1,024 beads in a 
single fluorescence microscope image.  The chips are fabricated from poly(dimethylsiloxane) 
(PDMS), an elastic material where the beads can be easily loaded by pressing on the PDMS to 
force the beads into the microwells. 
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 This chapter covers efforts in developing a microfluidic bead-based immunoassay for 
determining pERK2 and nERK2 using the simple array device shown in Figure 2.2.  Several 
assay parameters including the detection fluorophore and the reagent incubation times are 
examined, and different capture and dAbs are also tested.  The two assay strategies (single-dAb 
and dual-dAb) for determining pERK1/2:ERK1/2 are developed and compared in terms of their 
sensitivity and the signal levels they yield for various pERK2 and nERK2-containing samples. 
2.2 Materials and methods  
2.2.1 Materials and reagents 
 Dow Corning's Sylgard 184 PDMS was purchased from Ellsworth Adhesives 
(Germantown, WI) and was prepared according to the manufacturer's instructions at a 10:1 
elastomer/cross-linker ratio.  Tris-buffered saline with 0.05% Tween-20 (TBS-Tween), 1-ethyl-
3-(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC), N-hydroxysulfosuccinimide 
(sulfo-NHS), octyltrichlorosilane, sodium fluoride, ethylene diamine tetraacetic acid (EDTA), 
urea, and Triton X-100 were purchased from Sigma-Aldrich (St. Louis, MO).  Sodium phosphate 
monobasic, 2-(N-morpholino)ethanesulfonic acid (MES), 10x phosphate-buffered saline (PBS, 
pH = 7.4), 10% bovine serum albumin (BSA) in PBS, sodium azide, optically clear 
polypropylene plate-sealing tape (PCR tape), Contrad 70 detergent, and microscope slides (75 
mm x 25 mm x 0.99 mm) were purchased from Thermo Fisher Scientific (Waltham, MA).  
Purified recombinant human vascular endothelial growth factor (VEGF), phosphorylated and 
non-phosphorylated extracellular signal-related kinase 2 (pERK2 and nERK2), biotinylated 
detection antibodies for VEGF, pERK1/2, and ERK2, capture antibodies for pERK1/2, VEGF, 
ERK2, and a control capture antibody were purchased from R&D Systems (Minneapolis, MN).  
All proteins and antibodies were reconstituted according to the manufacturer’s instructions.  
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Tween-20 and MagPlex Luminex beads were purchased from Bio-Rad Laboratories (Hercules, 
CA).  Non-magnetic Luminex beads were purchased from Luminex Corporation (Austin, TX).  
Polyethylene glycol (PEG) with an average molar mass of 10,000 g (PEG10k) was purchased 
from Alfa Aesar (Ward Hill, MA).  MF-319 photoresist developer, KMPR 1010 photoresist, and 
SU-8 thinner were purchased from MicroChem (Newton, MA); the SU-8 thinner was mixed with 
KMPR 1010 to prepare 35% (w/w) KMPR solutions.  P-type 6” crystalline Si wafers were 
purchased from University Wafer (Boston, MA).  Streptavidin-B-phycoerythrin (SA-PE) and 
streptavidin-Alexa Fluor 488 (AF488) were purchased from Invitrogen (Carlsbad, CA).  All 
aqueous solutions were prepared with deionized (DI) water from a NANOpure Diamond system 
(Barnstead International, Dubuque, IA). 
 Several different blocking buffers are used during immunoassay experiments, all of 
which are prepared in 1x PBS buffer.  PBS-PEG contains 0.1% PEG-10k.  PBS-B contains 0.1% 
BSA and 0.05% Tween-20.  PBS-BTBL contains 1% BSA and 0.05% Tween-20.  ERK buffer 
contains 5 mM sodium fluoride, 1 mM EDTA, 1 M urea, and 0.5% Triton X-100.  A variant of 
ERK buffer without 1 M urea is also used in one experiment. 
2.2.2 Bead-antibody coupling 
 Luminex beads are carboxyl-terminated polystyrene microspheres available with or 
without a superparamagnetic core.  The magnetic beads are 6.5 μm in diameter while the non-
magnetic beads are 5.6 μm in diameter.10,11  Early work described in Chapter 2 used non-
magnetic beads, while all subsequent experiments used magnetic beads.  The beads are 
impregnated with two different fluorescent dyes.  By varying the concentration ratio of both 
dyes, Luminex produces 100 unique bead types (called “regions”) suitable for up to 100-plex 
assays.12  A custom optical filter cube (632 nm/22 nm excitation, 685 nm dichroic, 677 nm/50 
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nm emission) purchased from Semrock (Lake Forest, IL) was used for distinguishing between 
beads containing different concentrations of Luminex’s infrared-emitting dye. 
 Through use of the carboxyl groups covering the beads’ surfaces, antibodies and other 
ligands of interest can be covalently bound to the beads.  Antibody linkage to the beads was done 
via the carbodiimide chemistry of EDAC and sulfo-NHS.  EDAC is a heterobifunctional cross-
linker, one end binding to the carboxyl groups on the beads, and the other binding to surface 
amine groups on amino acid residues in immunoglobulin-G (IgG) antibodies.  Sulfo-NHS is used 
in conjunction with EDAC to yield a less labile chemical intermediate, which allows for a much 
longer bead-antibody coupling period and thus greater coupling efficiency.13 
2.2.2.1 Coupling procedure for non-magnetic beads 
 The procedure for coupling antibodies to beads was provided by the vendor14 and is 
summarized here.  It utilizes four buffers that are prepared prior to each bead coupling.  The 
activation buffer is 100 mM sodium phosphate monobasic at a pH of 6.2.  The coupling buffer is 
50 mM MES at a pH of 5.0.  Sodium hydroxide and hydrochloric acid were used to adjust buffer 
pH.  The wash buffer is PBS + 0.05% Tween-20.  The storage/blocking buffer is PBS + 0.1% 
(BSA) + 0.02% Tween-20 with 0.05% sodium azide as a preservative.  The stock beads are at a 
concentration of 12.5 million beads/mL.  All buffers and beads were brought to room 
temperature prior to use.  Region 1 beads were used with the control antibody and region 50 
beads were used with the VEGF capture antibody. 
 Stock beads were vortexed at 3000 rpm for 30 s and sonicated for 15 s.  5 million beads 
(400 µL bead stock) were transferred to a 500-µL LoBind microcentrifuge tube (Eppendorf, 
Hauppauge, New York) and pelleted by centrifuging them at 8,000 rcf for 3 min.  The 
supernatant was removed and replaced with 100 µL of wash buffer.  The beads were 
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resuspended by vortexing them for 30 s at 3000 rpm, then pelleted.  The supernatant was 
removed and replaced with 80 µL of activation buffer.  10 μL of 50 mg/mL sulfo-NHS and 10 
μL of 50 mg/mL EDAC (both prepared in activation buffer) were added and the beads were 
vortexed at 3000 rpm for several seconds.  The beads were activated by placing them on a plate 
shaker (MS1 S7, Fisher Scientific) at 1000 rpm for 20 min at room temperature.  The activated 
beads were pelleted and the supernatant was replaced with 250 µL of coupling buffer.  The beads 
were resuspended and then pelleted.  The supernatant was removed and replaced with 250 µL of 
coupling buffer.  16 µg capture antibody (prepared in PBS) was added and the total volume of 
the mixture was brought to 500 µL with coupling buffer.  The bead tube was covered with foil, 
gently vortexed, and placed on a 25 rpm rotator (H5500; Labnet International Inc., Edison, NJ) 
for 2 h at room temperature to couple the beads to the antibodies. 
 Coupled beads were pelleted and resuspended in 500 µL storage/wash buffer.  They were 
then pelleted, resuspended in 1 mL storage/wash buffer, and this step was repeated once more.  
The beads were finally resuspended in 250 µL storage/wash buffer and stored at 4 ºC until use. 
2.2.2.2 Coupling procedure for magnetic beads 
 The procedure for coupling antibodies to beads was provided by Bio-Rad.15  The buffers 
used for coupling antibodies to magnetic beads are the same as those for the non-magnetic beads, 
except the coupling buffer is PBS at a pH of 7.4.  The stock beads are at a concentration of 12.5 
million beads/mL.  All buffers and beads were brought to room temperature prior to use.   
 Stock beads were vortexed at 3000 rpm for 30 s and then sonicated for 15 s.  100 μL of 
stock beads were transferred to a 500-μL LoBind microcentrifuge tube and pelleted on the 
bottom of the tube with a large rare-earth magnet.  The supernatant liquid was removed and 
replaced with 100 μL of wash buffer.  The beads were resuspended in the wash buffer by 
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vortexing at 3000 rpm for 30 s and then pelleted with the magnet.  With the bead tube still on the 
magnet, the wash buffer was removed and replaced with 80 μL of activation buffer, then the 
beads were vortexed at 3000 rpm for 30 s.  10 μL of 50 mg/mL sulfo-NHS and 10 μL of 50 
mg/mL EDAC (both prepared in activation buffer) were added and the beads were vortexed at 
3000 rpm for several seconds.  The beads were then placed on a plate shaker (MS1 S7, Fisher 
Scientific) at 1000 rpm for 20 min at room temperature.  150 μL of coupling buffer was added 
and the beads were pelleted on the magnet.  The supernatant liquid was removed and then 150 
μL of coupling buffer was added.  The beads were resuspended by vortexing at 3000 rpm and 
pelleted again.  The supernatant was removed and replaced with 100 μL of coupling buffer.  9 µg 
of capture antibody (prepared in PBS) was added and the total volume of the solution was 
brought to 500 μL with coupling buffer.  The beads were vortexed and then incubated on a 25 
rpm rotator for 2 h at room temperature to couple them to the antibody. 
 The coupled beads were pelleted from solution and the supernatant was removed.  250 μL 
of storage/blocking buffer was added and the beads were vortexed at 1500 rpm for 15 s.  The 
beads were pelleted, the supernatant was removed, and 500 μL of storage/blocking buffer was 
added.  The beads were vortexed for 20 s at 1500 rpm and pelleted again.  The supernatant was 
removed and 100 μL storage/blocking buffer was added.  The antibody-coupled beads were 
stored at 4 ºC when not in use. 
2.2.3 Fabrication of master molds and assay chips 
 The chips used to determine appropriate antibodies/incubation buffers/wash buffers 
consisted of eight linear channels with a microarray centered in each (Figure 2.2).  With the 8 
channels, replicate measurement can be made simultaneously.  The linear channel is 
approximately 1.5 cm long, 100 μm wide, and the array chamber is 400 μm wide.  Each channel 
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is spaced 5.6 mm apart.  Once fabricated, a 3-mm hole is made at each end of the channel for 
sample/reagent delivery and waste/vacuum.  The chips are filled with a blocking buffer (varied 
by experiment) by pipetting buffer into the reagent inlet and pulling vacuum on the opposite end.  
The bead array consists of 1,024 circular wells with 11 μm center-to-center spacing; as the beads 
have an average diameter of 6.5 μm, the 11-micron well spacing corresponds to slightly less than 
two bead diameters.  This spacing was previously found to prevent the problem of fluorescence 
overlap between the beads when imaging.  The wells are approximately 5.2 μm in lateral 
diameter with a depth of approximately 5 μm.   
 Designs for the straight-channel chips were created in TurboCAD Professional 14 
drafting software (IMSI/Design, Novato, CA) and the corresponding photolithography mask 
received from Infinite Graphics (Minneapolis, MN).  This mask was divided into two halves, one 
with the microwell array features and the other with the channels. 
2.2.3.1 Fabrication of silicon masters 
 In a clean room, 35% (w/w) KMPR photoresist was poured on a P-type 6” crystalline Si 
wafer (University Wafer, Boston, MA) and spin-coated at 500 rpm for 10 s, then 3000 rpm for 
30 s to produce a 3-µm-thick layer of photoresist.  The coated wafer was pre-baked at 100 °C for 
4 min on a level hot plate.  Once cool, the wafer was photolithographically exposed to the array 
features using a mask aligner (MA6/BA6; SUSS MicroTec, Garching, Germany).  Exposures 
were performed for 30 s (approximately 300 mJ/cm2 exposure energy) in hard contact mode.  
The exposed wafer was baked at 100 °C for 2 min, air cooled, developed in MF-319, and baked 
again at 100 °C for 5 min.  The microwell array features were then etched via the Bosch process 
into the wafer to a depth of approximately 5 µm using deep reactive-ion etching (DRIE) (Alcatel 
AMS-100).  Remaining photoresist was stripped from the wafer with a 2800 W oxygen plasma 
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in the DRIE and the etched feature sizes were determined with profilometry (P-15; KLA-Tencor, 
San Jose, CA). 
 The procedure to fabricate the channel layer was the same as that used for the microwell 
arrays except for the following details.  55% (w/w) KMPR was used instead of 35% to produce a 
9-µm-thick layer in order to protect the microwell array.  Exposure of the channel layer features 
required topside alignment of the mask’s and mold’s fiducials in the mask aligner.  Channels 
were etched to a depth of approximately 20 µm.  The completed master mold was silanized in a 
vacuum desiccator for 1 h with 500 µL of octyltrichlorosilane. 
2.2.3.2 PDMS chip fabrication 
 To make chips, 10:1 PDMS was mixed and degassed.  Approximately 13 g of PDMS 
were poured onto the center of the silicon master and spun in a two-step process at 150 rpm for 
10 s followed by 200 rpm for 30 s.  The coated wafer was degassed under vacuum then cured on 
a hot plate at 150 °C for 3 min.  Two additional PDMS layers were cast and cured in the same 
manner, although air bubbles were removed with a nitrogen gun or via the spin-coating process, 
not with vacuum, as vacuum could delaminate the first PDMS layer.  The PDMS was peeled 
from the wafer and laid upon glass cleaned with 5% Contrad and deionized water.  Reagent/bead 
and waste/vacuum vias were created in the channels with a 3 mm biopsy punch (Sklar 
Instruments, West Chester, PA) and individual chips were cut from the bulk PDMS with a razor 
blade.  Microscope slides were cleaned with 5% Contrad, rinsed with water, and dried with 
nitrogen.  The PDMS chips were placed channel-side up in an oxygen plasma cleaner (PDC-
32G; Harrick Plasma, Ithaca, NY) along with the cleaned slides and activated for 12 s at 18 W.  
The chips were irreversibly bonded by pressing the activated sides of the glass and PDMS 
together.  Bonded chips were placed in a 95 °C oven for at least 1 h prior to use in order to 
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stabilize the PDMS.16 
2.2.4 Loading beads into microarrays 
 To load antibody-coupled beads into the arrays, the chips are first filled with a blocking 
buffer consisting of PBS + 1% BSA + 0.05% Tween-20 (PBS-BTBL).  A bead slurry containing 
a 1:1 mix of both target and control beads was then pipetted into the sample inlet and vacuum 
applied on the outlet to pull the beads into the channel (Figure 2.6A).  As the beads flow into the 
microarray chamber, the PDMS above the array is pressed down to force beads into the wells 
(Figure 2.6B).  As the diameter of an unloaded microwell is smaller than the bead diameter, the 
microwell stretches to accommodate the bead, which is held in place by the elastic force of the 
PDMS attempting to relax to its native state (Figure 2.6C).  The extent of the microarray’s 
loading is monitored using an epifluorescent microscope, and the loading process stopped when 
approximately 90%+ of the microwells are loaded (Figure 2.6D).  Remaining bead slurry is 
removed from the inlet and the chips are filled with fresh PBS-BTBL (Figure 2.6E).  The 
inlet/outlet are sealed with PCR tape and stored at 4 ºC for at least 24 h prior to use (Figure 
2.6F). 
 Storing the chips under blocking buffer results in the surfaces of the glass and PDMS 
being dynamically coated with molecules of protein and surfactant from the buffer.17,18  This 
prevents nonspecific adsorption from proteins and other biomolecules present in the sample, 
which is critical for reducing background and ensuring that the chips are biocompatible with 
assay reagents and samples.  PDMS is especially prone to this nonspecific adsorption as its 
surface is hydrophobic.18–21  While it is possible to functionalize the surface of PDMS,22 the use 
of a dynamic coating from a blocking buffer is preferable because it is simpler to implement and 
has proven effective. 
35 
2.2.5 Data collection 
 All assay data was collected on an Eclipse Ti-U inverted microscope with an Intensilight 
C-HGFIE mercury lamp (Nikon, Melville, NY) and an electron-multiplying charge-coupled 
device (EM-CCD) camera (Cascade II-512; Photometrics, Tucson, AZ).  Custom optical filter 
cubes for the encoding dye (632 nm/22 nm excitation, 685 nm dichroic, 677 nm/50 nm emission) 
and B-phycoerythrin (531 nm/40 nm excitation, 562 nm dichroic, 593 nm/40 nm emission) were 
purchased from Semrock (Lake Forest, IL).  A Nikon B-2E/C filter cube (465 nm/30 nm 
excitation, 505 nm dichroic, 515 nm/40 nm emission) was used for AF-488.  The beads were 
brought into focus by imaging the encoding beads with 100 ms exposure times.  Assay images 
were taken at either 531 nm (for B-phycoerythrin) or 465 nm (for AF-488) for a total of 8 s.  
Micro-Manager23 was used to control the camera and images were analyzed with ImageJ24 
(National Institutes of Health, USA) and Excel (Microsoft, Inc., Redmond, WA).  The methods 
of analysis evolved with the project and will be discussed as necessary. 
2.2.6 Data analysis 
 Micro-Manager23 was used to collect two images for each assay: an encoding image and 
an assay image.  The encoding image, taken at 632 nm, collected fluorescence from the internal 
dyes in the beads.  The assay image, taken immediately after the encoding image at 531 nm (SA-
PE) or 465 nm (AF-488), collected fluorescence from the dye in the antibody-analyte complex 
on the bead surfaces.  As the control beads contained significantly less dye than the assay beads, 
the two types could be easily distinguished.  The encoding images were decoded by selecting 
each bead in ImageJ.24  A sample encoding image with three different bead types selected is 
shown in Figure 2.7A.  Control beads are within the blue boxes, total ERK2 beads are in the 
yellow pentagons, and pERK1/2 beads are in the red circles.  These selections were overlaid on 
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the assay image (Figure 2.7B) to extract the corresponding fluorescence data from each bead.  
The raw average signal and standard deviation are obtained from the fluorescence from each 
bead’s brightest pixel.  Outliers are removed25 by rejecting fluorescence values not within 2.2 
standard deviations of the raw mean, and the corrected signal is calculated from the remaining 
values.  The net signal is finally calculated by subtracting the fluorescence of the control beads 
from the fluorescence of the assay beads. 
2.2.7 Sandwich assay procedure 
 The sandwich immunoassay procedure used was adapted from one previously developed 
and recently described elsewhere.1,2  A schematic of the process is provided in Figure 2.3.  All 
chips used in assays were loaded with beads and passivated with blocking buffer.  Solutions are 
introduced to the chips by using vacuum to remove the fluid in the chip inlets, filling the inlets 
with 10 μL of liquid, and pulling vacuum on the vacuum/waste via for 10 s to fill the chip with 
the new reagent.  Washing is performed by introducing the appropriate buffer to the chip inlet 
vias and pulling vacuum for the time specified. 
 Two incubation protocols – short and long – were used in early experiments.  In the short 
protocol, incubations were performed at 37 °C.  Sample was introduced to the chips and 
incubated for 20 min.  Detection antibody at 3 µg/mL was incubated for 15 min.  Fluorescent dye 
was incubated for 10 min.  The reagent vias were filled with TBS-Tween, washed for 10 min, 
and then imaged. 
 In the long protocol, incubations were performed at room temperature.  Sample was 
introduced to the chips and incubated for 1 h.  Detection antibody at 3 µg/mL was incubated for 
30 min.  SA-PE at either 2 µg/mL or 20 µg/mL was incubated for 20 min.  The chips were filled 
with TBS-Tween, washed for 10 min and imaged. 
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2.3 Results and discussion 
2.3.1 Fluorophore selection 
 Early sandwich immunoassays in the group1 utilized AF-488 as the detection 
fluorophore.  AF-488 was used because of its high fluorescence quantum efficiency and 
excitation/emission spectra that do not overlap with the encoding dye.  However, different beads 
were used in those experiments and AF-488 was untested in conjunction with the Luminex 
beads.  SA-PE is recommended as the fluorophore for Luminex beads by the vendor so a 
comparison between the two fluorophores was made.  B-phycoerythrin26 is an exceptionally 
bright multi-chromophore protein with a quantum yield of 0.98 and a molar extinction 
coefficient of 2.41 x 106 cm-1 M-1; it was thus hypothesized to yield substantially more 
fluorescent signal than AF-488,27,28 which possesses a quantum yield of 0.92 and an extinction 
coefficient of 73,000 cm-1 M-1.   
 VEGF was used as a model analyte at 0, 300, 600, and 900 pg/mL in two separate chip 
sets (consisting of 3 arrays per sample) loaded with non-magnetic VEGF and control beads.  
Anti-VEGF at 3 µg/mL was used as the dAb.  The assay was run according to the short assay 
protocol and AF-488 at 20 µg/mL was used as the detection fluorophore in one chip set while 
SA-PE at 20 µg/mL was used in the other.  All reagent solutions were prepared in PBS-PEG 
buffer.  The results in Figure 2.8 show that the arrays imaged with SA-PE produced over 10 
times greater signal than AF-488 arrays at the tested concentrations of VEGF.  SA-PE was 
therefore used as the detection fluorophore in all future experiments. 
2.3.2 Reagent incubation time and concentration 
 The short assay protocol was originally developed in an attempt to minimize the total 
assay time while trying to maintain sensitivity.  This is desirable for a point-of-care (POC) 
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device as a rapid assay is preferable for a situation in which a patient waits at a clinic for 
results.29,30  The protocol used a higher incubation temperature to overcome the limitations of 
shorter incubation times,2 as immunoassay analyte capture is diffusion-limited31 and the reagent 
diffusion rate is directly proportional to the incubation temperature.32  A disadvantage of using 
the elevated temperature to increase reagent capture is that it requires a heating source.  A second 
strategy for increasing reagent capture in a diffusion-limited situation is to simply perform 
incubations for longer time periods.  As the pERK1/2:ERK1/2 assay does not have the same 
stringent time demands as a POC device, the second strategy was pursued in order to increase the 
sensitivity. 
 VEGF was again used as a model analyte at concentrations of 0, 300, 600, and 900 
pg/mL in two separate chip sets (consisting of 3 replicate arrays per VEGF concentration per 
incubation protocol) loaded with non-magnetic VEGF and control beads.  The long assay 
protocol (1 h sample incubation, 30 min dAb incubation, 20 min SA-PE incubation at room 
temperature) was followed in one chipset and the short assay protocol (20 min sample 
incubation, 15 min dAb incubation, 10 min SA-PE incubation at 37 °C) was used in the second 
chipset.  2 µg/mL SA-PE was used as the detection fluorophore in both, and all solutions were 
prepared in PBS-PEG buffer. 
 The long assay protocol yielded over 3 times the signal as the short protocol for each 
concentration tested (Figure 2.9) while using the lower SA-PE concentration.  Besides improving 
the signal, the reduction in non-specific adsorption of the SA-PE is another important 
consideration.  Figure 2.10 shows that there is a reduction in non-specific binding to the control 
beads with 2 µg/mL SA-PE compared to using a 20 µg/mL SA-PE, in spite of the fact that the 
incubation times are much longer.  Based on these results, the long assay format and the lower 
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SA-PE concentration were used in all future experiments. 
2.3.3 Development of pERK1/2 assay 
 The assay buffers used in the pERK1/2 experiments differed from those used in the 
VEGF experiments.  Rather than PBS-PEG buffer, sample incubations were performed in ERK 
buffer, while dAb and SA-PE incubations were performed in PBS-B buffer.  These changes were 
made in accordance with the recommendation of the pERK1/2 Ab’s manufacturer.  Chips were 
loaded with magnetic pERK1/2 and control beads.  Assays were performed with and without 
urea to determine the effect on sensitivity.  This was investigated because synthetic peptides are 
often used to create antibodies for specific epitopes, and these peptides do not necessarily have 
the same shape as the epitope in the native protein.33  The epitope may also become more 
sterically accessible if the protein is denatured.  Urea is used to unfold the protein without 
disrupting other components of the assay.  Figure 2.11 shows the results of both assays where the 
undenatured pERK2 is detectable but with poorer sensitivity compared to the denatured state.  
Adding urea to the ERK incubation buffer results in more than a six-fold improvement in 
sensitivity. 
 These results suggest that the single-dAb strategy using the MEK1/2 phosphorylation 
step (Figure 2.4) would only be feasible if a suitable dAb for nERK1/2 was unavailable.  
MEK1/2 would likely be incapable of phosphorylating denatured ERK1/2, and given the poor 
sensitivity of the assay with native pERK1/2, a protocol in which both pERK1/2 and nERK1/2 
are assayed in their denatured state would be preferable if it considerably improves the 
sensitivity.  That is because an improvement in sensitivity translates to an improvement in the 
range of ERK1/2 phosphorylation ratios distinguishable by the assay. 
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2.3.4 Protocol development for dual-dAb pERK2:ERK2 assay 
 The successful detection of pERK2 was followed by the development of the nERK2 
portion of the assay.  Once both forms of ERK2 are detectable, a general method for determining 
the pERK2:ERK2 ratio could be developed.  If that could be extended to include pERK1 and 
nERK1 as well, the assay would be capable of determining pERK1/2:ERK1/2.  A total ERK2 
(tERK2) detection kit (DYC1230-C; R&D Systems) was purchased that included capture 
antibody, nERK2 standards, and a biotinylated dAb that recognizes both pERK2 and nERK2.  
Total ERK2 beads were prepared by coupling the kit’s capture antibody to magnetic beads.  
Multiplex assays were then run with both pERK1/2 and tERK2 beads in the same arrays to 
determine whether the tERK2 dAb would bind to ERK2 molecules captured by pERK1/2 beads, 
as well as whether the pERK1/2 dAb would bind to pERK2 molecules captured by the tERK2 
beads.  The fluorescence signal obtained from the beads would be reflective of the degree of 
binding.  Ideally, the tERK2 and pERK1/2 dAbs would identify their respective antigens using 
one capture antibody, as future assays could then be run using only one bead type.  The dual-dAb 
pERK2:ERK2 assay was developed by incubating some of the chips with the pERK1/2 dAb first 
(as shown in Figure 2.5) and other chips with the tERK2 dAb first to see if the incubation order 
mattered. 
 Chips were loaded in triplicates with an equal-parts mixture of pERK1/2 beads, tERK2 
beads, and control beads.  Assays were performed with five sample solutions consisting of 
various combinations and concentrations of stock pERK2 and nERK2: 5 ng/mL pERK2, 10 
ng/mL pERK2, 5 ng/mL nERK2, 10 ng/mL nERK2, and a mixture of 5 ng/mL each pERK2 and 
nERK2 (total ERK2 = 10 ng/mL).  Half of the chips were incubated with the pERK1/2 dAb for 
30 min, and the other half were incubated with the tERK2 dAb for 30 min.  The chips were then 
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washed for 1 min, incubated with SA-PE, washed for 1 min, and imaged.  Following this, the 
chips that were initially incubated with the pERK1/2 dAb were incubated with the tERK2 dAb, 
and vice versa.  They were then washed, incubated with SA-PE, washed, and imaged a second 
time. 
 A comparison of the signals from the pERK1/2 beads and tERK2 beads after the first 
dAb incubation showed the pERK1/2 beads with up to 5X the signal of the tERK2 beads.  Since 
the pERK1/2 beads were more responsive than the tERK2 beads, further studies relied solely on 
the pERK1/2 beads.  Figure 2.12A shows the results for the pERK1/2 beads first incubated with 
the pERK1/2 dAb.  The first incubation/imaging step with the pERK1/2 dAb (gray bars) only 
showed fluorescence signals with samples containing pERK2.  The nERK2 samples and blank 
signals were indistinguishable.  The fluorescence increased with pERK2 concentration while the 
signals for the mixed sample were similar to those of the low-concentration pERK2 sample.  
This is in accordance with the pERK1/2 dAb only recognizing the pERK2 in the mixed sample.  
After these beads were incubated with the total ERK2 dAb (red bars), they showed an increase in 
fluorescence signal in samples containing nERK2.  The fluorescence again increases as the 
nERK2 concentration increases; this includes the mixed sample, which contained equal parts 
pERK2 and nERK2.  This opens the possibility of using the dual dAb assay strategy.  There also 
appears to be a slight increase in signal with the pERK2 samples, suggesting that the tERK2 dAb 
recognizes pERK2 molecules captured by the pERK1/2 beads and is capable of specifically 
binding to them.  This signal increase, however, may not be statistically significant due to 
overlapping error bars between the signals from the two imaging steps.   
   The beads first incubated with the tERK2 dAb showed somewhat different trends (Figure 
2.12B).  Between the two dAb/imaging cycles (represented by the white bars for the tERK2 dAb 
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and blue bars for both dAbs), they showed a small increase in fluorescence for the pERK2 
samples, a small increase for the mixed pERK2 and nERK2 sample, and a large reduction in 
fluorescence for the nERK2 samples.  The large decrease in signal for the nERK2-only samples 
follows from the fact that the first dAb recognizes nERK2 while the second does not, so the 
fluorescence seen on the beads is from the SA-PE complex formed in the first dAb/dye cycle.  
Many of those tags had photobleached during the first imaging step, and imaging the same 
complexes a second time yielded less signal as no additional tags were specifically added during 
the second incubation.  The fluorescence increase for the pERK2 samples between steps is not 
nearly as drastic as was the signal increase for the nERK2 samples in the other chip set, 
suggesting that the tERK2 dAb has sterically interfered with the binding of the pERK1/2 dAb 
here. 
 These results show that the pERK1/2 beads can be used in the capture and detection of 
pERK1, pERK2, and nERK2.  They also suggest that the pERK1/2 dAb should be used before 
the tERK2 dAb as the results obtained from the former protocol are much more straightforward 
to interpret; the signal from the first imaging step corresponds to the amount of pERK1/2 
present, while the second step is indicative of total ERK2.  In the tERK2 dAb-first protocol, the 
first imaging step’s signal is dependent upon total ERK2, while the second imaging step shows a 
sharp reduction in signal from the nERK samples and a slight increase from the pERK samples. 
2.4 Conclusions 
 In this chapter, several experimental parameters were optimized for the on-chip sandwich 
immunoassay.  The cytokine-based assay protocol was considerably improved upon through the 
use of a new fluorophore (SA-PE) and longer reagent incubation times.  The addition of urea to 
the assay incubation buffer was shown to improve the sensitivity of the pERK2 assay more than 
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six-fold compared to the same assay with no urea.  A detection antibody for total ERK2 suitable 
for use with the pERK1/2 beads was identified and tested.  Finally, the dual-dAb approach with 
the pERK1/2 dAb incubated first was shown to be appropriate for determining both pERK2 and 
nERK2 in a sample.  One unresolved problem with the assays was that the percent relative 
standard deviations (%RSDs) are too high to be clinically useful.  The chip-to-chip %RSD was 
often in the 20-30% range or more, while most clinically-accepted assays have %RSDs below 
10%.34  As this high variance impacts the assay’s ability to distinguish differing phosphorylation 
levels of ERK1/2, as well as its clinical relevance, the next chapter covers efforts to discover the 
source of this variation and remedy it. 
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2.5 Figures 
 
Figure 2.1.  Photograph of saliva cytokine chip filled with ink for visualization.  Each inlet via is 
labeled to indicate its corresponding reagent, as is the waste/vacuum via.  The locations at which 
the inlet vias/inlets are valved are circled in white.  The location of the array on the chip is 
indicated with a yellow circle.   
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Figure 2.2.  Schematic of 8-channel chip with array.  (A) Photograph of 8-channel chip filled 
with ink for visualization.  One set of vias is used for introducing reagents and beads while the 
other is used for waste and applying vacuum.  (B) Bead array location with white light image of 
1,024 unloaded microwells. 
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Figure 2.3.  Schematic of single-analyte sandwich immunoassay.  (A) Sample containing analyte 
molecules (and often other molecules) are incubated with and specifically captured by antibody-
conjugated beads.  (B) A biotinylated dAb is incubated and binds to a second epitope on the 
captured analyte.  (C) A fluorescent dye conjugated to streptavidin is incubated, and the 
streptavidin binds to a biotin molecule on the dAb.  (D) Unbound fluorophores are washed away 
and the beads are imaged with a fluorescence microscope. 
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Figure 2.4.  Schematic of single-dAb strategy for determining pERK1/2:ERK1/2.  (A) Sample 
containing ERK1/2 is incubated with the beads, and all phosphorylation states of pERK1/2 are 
captured.  (B) pERK1/2 is then determined through use of a biotinylated monoclonal antibody 
specific for pERK1/2, (C) a streptavidin-conjugated fluorescent dye complex, and (D) an 
imaging step.  (E) The beads are then incubated with a cocktail containing MEK1/2 and its 
cofactors, which dually phosphorylates nERK1/2 to produce pERK1/2.  (F) The pERK1/2 dAb, 
(G) dye complex, and (H) imaging steps are repeated to determine ERK1/2. 
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Figure 2.5.  Dual-dAb strategy for determining pERK1/2:ERK1/2 in which pERK1/2 is 
determined first.  The assay begins with steps (A)-(D) from Figure 2.4.  (A) A total ERK1/2 dAb 
is used after the first imaging step with (B) the fluorescent dye complex in order to (C) determine 
ERK1/2. 
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Figure 2.6.  Schematic of loading process for PDMS arrays.  (A) Bead-containing slurry is 
pulled through the chips and under the arrays.  (B) The PDMS is pressed down into the beads 
and some beads are forced into the wells.  (C) The wells are smaller than the diameter of the 
beads, and loaded beads are held in place by the elasticity of the PDMS.  (D) The process is 
repeated until approximately 90% of arrays are loaded.  (E) The bead slurry is removed from the 
bead via on the chip, replaced with blocking buffer, and excess beads are washed away.  (F) The 
array is ready for an assay following passivation with blocking buffer. 
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Figure 2.7.  Encoding image and corresponding assay image from a 3-bead assay.  Control beads 
are the dimmest in encoding image (A) and are enclosed in blue boxes.  Total ERK2 beads are 
medium brightness in assay image (B) and are in yellow boxes.  The brightest beads are in red 
boxes and correspond to pERK1/2 beads.  Control beads are within blue boxes, total ERK2 
beads are within the yellow pentagons, and pERK1/2 beads are within the red circles. 
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Figure 2.8.  Comparison of reporter dye complexes used for detection in VEGF assay.  
Streptavidin-B-phycoerythrin far outperforms streptavidin-AlexaFluor 488 in terms of signal at 
each VEGF concentration.  Error bars represent the standard deviation of three arrays. 
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Figure 2.9.  Comparison of reagent incubation strategies.  In the short incubation protocol, 
sample, dAb, and SA-PE were incubated at 37 °C for 20 min, 15 min, and 10 min, respectively.  
Long incubations were performed at room temperature for 1 h, 30 min, and 20 min, respectively.  
The longer incubations resulted in significantly more fluorescence despite the difference in 
incubation temperature. 
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Figure 2.10.  Comparison of non-specific binding on control beads from two different 
concentrations of fluorescent dye.  Reducing the SA-PE concentration to 2 µg/mL results in less 
non-specific binding, but does not result in less signal from VEGF beads. 
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Figure 2.11.  Comparison of pERK2 assay results with and without urea in the assay buffer.  
Urea results are indicated by black squares and the no-urea results with red triangles.  The 
sensitivity of the assay is improved more than sixfold with the use of urea due to the denaturation 
of the analyte. 
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Figure 2.12.  Results from pERK2:ERK2 protocol development experiment.  (A) Results from 
pERK1/2 dAb-first beads.  Incubation with pERK1/2 dAb (gray bars) produces relatively high 
signal for pERK2 and mixed samples and zero signal from nERK2 samples.  Subsequent 
incubation with the tERK2 dAb (red bars) produces mild (though statistically insignificant) 
signal increases for the pERK2 and mixed samples and substantial signal increases for the 
nERK2 samples.  This is consistent with the pERK1/2 dAb recognizing only pERK2 and the 
tERK2 dAb recognizing all the samples.  (B) Results from tERK2 dAb-first experiment.  
Following incubation with the tERK2 dAb (white bars) and subsequent incubation with the 
pERK1/2 dAb (blue bars), the trends for the pERK2 samples and mixed sample are similar to 
those from the pERK1/2 dAb-fist experiment.  However, the nERK2 samples show signal loss 
instead of gain after the pERK1/2 dAb incubation and imaging.  This is also consistent with the 
tERK2 dAb binding to all the samples and the pERK1/2 dAb only binding to pERK2. 
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CHAPTER 3 
INVESTIGATING SOURCES OF ERROR IN MICROBEAD ARRAY ASSAYS 
3.1 Introduction 
 This chapter covers efforts to reduce the array-to-array variance in the assay signal to less 
than 10% relative standard deviation (%RSD), as most accepted clinical assays meet or exceed 
this level of precision.1  The high standard deviations shown by the microbead array assays 
negatively impacts their ability to distinguish between different pERK1/2:ERK1/2 ratios.  While 
the development of a pERK1/2:ERK1/2 assay is the goal, experiments in this chapter primarily 
used vascular endothelial growth factor (VEGF) as a model analyte in place of ERK1/2.  This 
was done because an optimized assay for VEGF had previously been developed, it is easier to 
work with than ERK1/2, and the principles being explored apply to any analyte that might be 
assayed by the microbead array chips.   
 Major determinants of sandwich immunoassay sensitivity include the antibodies’ affinity 
for their target epitopes,2 instrumental noise, the signal of the blank, non-specific binding of 
reagent or analyte proteins to the beads,3 and mass transport rates throughout the chips.4,5  Some 
of these factors, such as instrumental noise and non-specific binding, are expected to be constant 
from chip to chip.  This is because the same equipment and software are used for all 
experiments, and the chips were fabricated from the same materials and passivated with the same 
buffers prior to use.  These factors were thus hypothesized to not be significant contributors to 
the high variance.   
 Mass transport rates were one candidate due to the possibility of varied flow rates from 
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chip to chip.  This may be caused by differences in sample volume, or by fabrication issues 
leading to differences in channel properties.  While antibody affinity should nominally be the 
same from chip to chip due to the same bead stock and reagents being used in all experiments, 
the possibility that capture antibody affinity varied significantly from array to array was another 
candidate cause of the variance.  This may stem from the bead surfaces – either the beads 
themselves or the bound antibodies – being damaged by the mechanical loading process.  The 
mechanical loading process involves pressing PDMS, a hydrophobic material, onto hydrophobic 
polystyrene beads coated with monoclonal antibodies.  As more than 90% of monoclonal 
antibody activity can be lost due to denaturation when passively adsorbed onto a hydrophobic 
surface,6,7 it is possible that higher losses occur during the repeated hydrophobic contact from 
loading.  Differences in the contact time with the PDMS experienced by beads may lead to 
varied abilities to capture analyte molecules, and thus, differences in their fluorescent signal. 
 To explore the contribution of mass transfer rates to the high variance, two types of 
experiments were run.  In the first, a chip featuring four arrays that share common reagent and 
waste/vacuum vias was designed (Figure 3.1).  These chips were symmetrical relative to both the 
vias and the arrays, thus ensuring equalized reagent flux through all channels.  The use of an 
internal standard to account for differences in sample delivery to the beads8 was also 
investigated.  At the same time, to speed up data analysis times and experimental throughput, 
chips featuring 100-bead arrays instead of 1,024-bead arrays were used for some experiments. 
 To systematically test whether any particular reagent incubation step was the cause of the 
variance, incubations were performed by using a vortexer to suspend the beads in solution.  This 
ensured uniform delivery of reagent to the bead surfaces, and as the Walt group at Tufts has 
performed highly sensitive immunoassays involving suspension incubations,9,10 the possibility of 
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high variance stemming from this incubation technique was not a concern.  While initial 
experiments in this vein imaged the beads after loading them into arrays, chip designs that did 
not require mechanical loading were used to assess the assay’s performance in the absence of 
potentially harsh loading conditions.  Finally, experiments were run with the single-array chips 
in which the extent and type of mechanical manipulation of the beads during their loading was 
quantified. 
3.2 Materials and methods 
3.2.1 Materials and reagents 
 Sylgard 184 PDMS was purchased from Ellsworth Adhesives (Germantown, WI) and 
prepared at a 10:1 elastomer/cross-linker ratio.  Tween-20 and MagPlex Luminex beads were 
purchased from Bio-Rad Laboratories (Hercules, CA).  Non-magnetic Luminex beads were 
purchase from Luminex (Austin, TX).  Purified recombinant human vascular endothelial growth 
factor (VEGF), phosphorylated and non-phosphorylated extracellular signal-related kinase 2 
(pERK2 and nERK2), biotinylated detection antibodies for VEGF, pERK1/2, and ERK2, capture 
antibodies for pERK1/2, VEGF, and a control capture antibody were purchased from R&D 
Systems (Minneapolis, MN).  All proteins and antibodies were reconstituted according to the 
manufacturer’s instructions.  Glass photolithography substrates (4” x 4” B270, 5” x 5” soda lime) 
were purchased from Telic Corp. (Valencia, CA).  Nano-Strip was purchased from KMG 
Chemicals (Fremont, CA).  Octyltrichlorosilane, sodium fluoride, ethylene diamine tetraacetic 
acid (EDTA), urea, and Triton X-100 were purchased from Sigma-Aldrich (St. Louis, MO).  AZ-
400K (3:1 developer) was purchased from AZ Electronic Materials USA (Somerville, NJ).  
Chromium etchant 1020 and 10:1 buffered oxide etch (BOE) were purchased from Transene Co. 
Inc. (Danvers, MA).  Acetone, 10x phosphate-buffered saline (PBS, pH = 7.4), 10% bovine 
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serum albumin (BSA) in PBS, optically clear polypropylene plate-sealing tape (PCR tape), 
Contrad 70 detergent and microscope slides (75 mm x 25 mm x 0.99 mm) were purchased from 
Thermo Fisher Scientific (Waltham, MA).  Shipley S1813 photoresist (S1813), MF-319 
photoresist developer, KMPR 1010 photoresist, and SU-8 thinner were purchased from 
MicroChem Corp. (Newton, MA); the SU-8 thinner was mixed with KMPR 1010 to prepare 35% 
(w/w) KMPR solutions.  P-type 6” crystalline Si wafers were purchased from University Wafer 
(Boston, MA).  Streptavidin-B-phycoerythrin (SA-PE) was purchased from Invitrogen (Carlsbad, 
CA).   
 All aqueous solutions were prepared with deionized (DI) water from a NANOpure 
Diamond system (Barnstead International, Dubuque, IA), including PBS-T (PBS + 0.05% 
Tween-20), PBS-BB (PBS + 1% BSA), ERK diluent (PBS + 5 mM sodium fluoride + 1 mM 
EDTA + 0.5% Triton X-100), and ERK buffer (ERK diluent + 1 M urea). 
3.2.2 Fabrication of multi-array chips and 100-bead arrays 
 The experiment in Section 3.3.1 used a multi-array chip (Figure 3.1) in place of the 
single-array chip.  The multi-array mask was designed for use with the 1,024-bead array mask 
used in Chapter 2.  Later experiments used the single-array, 8-channel chips from Chapter 2 with 
100-bead arrays in place of the 1,024-bead arrays. 
 Designs for the multi-array chips and 100-bead arrays were produced in TurboCAD 
Professional 14.  Two masks were created, one featuring the multi-array channels and the other 
featuring the 100-bead arrays.  A laser writer system (DWL 66FS; Heidelberg Instruments, 
Heidelberg, Germany) was used to pattern the designs into 5” x 5” glass substrates pre-coated 
with chromium (120 nm thick) and positive photoresist (AZ1815, 530 nm thick).  The substrate 
was developed for 45 s in AZ-400K to remove the photoresist and then immersed in chromium 
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etchant for 3 min to remove the exposed chromium.  The remaining photoresist was stripped 
with acetone and residual resist was removed with Nano-Strip.  DI water and nitrogen were used 
to rinse and dry the masks in between each wet chemistry step. 
 The photolithography, DRIE, and silanization procedures described in Chapter 2 were 
used to prepare silicon master wafers for both the multi-array chips and 100-bead chips.  The 
arrays were etched to a depth of approximately 5 µm and the channels were etched to a depth of 
approximately 20 µm.  PDMS chips were fabricated from the master molds, punched and bonded 
to microscope slides, and loaded with magnetic analyte and control beads.  
3.2.3 Fabrication of simple column chips 
 In Section 3.3.5, chips consisting of straight channels with weirs (referred to as simple 
column chips) were used to assess assay performance without having to mechanically load the 
beads into arrays.  Beads were pulled into the chips through the inlet via and packed against the 
weirs.  The channels were 70 µm wide, 4.1 cm long, spaced 560 µm apart, and shared common 
bead/buffer and waste/vacuum vias.  A top-down schematic of the chips is shown in Figure 3.2 
and a side view schematic is shown in Figure 3.3.  An ultraviolet photoexposure system (OAI, 
San Jose, CA) was used to pattern each quadrant of a 4” x 4” B270 glass substrate coated with 
chromium and positive photoresist to create a negative master of the chip design.  The resist was 
developed in AZ-400K for 45 s.  Exposed chromium was removed with chromium etchant for 3 
min and the remaining photoresist was stripped with acetone.  The exposed glass was etched to a 
depth of 6 µm with 10:1 buffered oxide etch.  The weir was fabricated by coating the desired 
location for the weir with S1813 photoresist, then baking the substrate at 95 °C for 30 min.  This 
resist protected the glass underneath from subsequent etching and thus fixed the depth at 6 µm.  
Etching was resumed until the channels were 9 µm deep.  The S1813 was stripped with acetone 
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and all remaining chromium was stripped with chromium etchant.  The substrate was rinsed with 
DI water and nitrogen between each of the above steps, and its depth was determined with 
profilometry (P-15; KLA-Tencor, San Jose, CA) 
 A dicer (Basic Dicer II, Dicing Technologies) was used to dice the 4” x 4” substrate into 
four 2” x 2” glass masters, each of which contained two 5-channel chips.  Prior to dicing, the 
substrate features were coated with S1813 and baked for 30 min at 95 ºC to protect the channels.  
The S1813 was stripped with acetone following dicing.  The diced masters were treated in an 18-
W oxygen plasma for 12 s (PDC-32G; Harrick Plasma) and placed face-up in a vacuum 
desiccator with 500 µL of octyltrichlorosilane.  Vacuum was applied for approximately 3 min to 
fill it with silane vapor, and then it was sealed and left to react for 30 min.  This process 
covalently coated the masters with the silane and reduced PDMS adhesion to the masters. 
 Complementary molds were prepared from the masters by placing them face-up in 3” x 
3” x 1” rectangular acrylic containers and filling the containers with 10:1 PDMS to a depth of 
approximately 1 cm.  The PDMS in the container was degassed under vacuum for approximately 
20 min in a vacuum desiccator, then baked at 95 ºC for 30 min to cure the PDMS.  The mold was 
allowed to cool after curing, and a razor was then used to cut the molds from the containers and 
the masters from the molds.  The razor was used to trim excess PDMS from the edges of the 
molds as well.  The molds were then silanized in the same way as the glass masters. 
 To fabricate the chips, ~4 mL PDMS was poured over the faces of the molds and 
degassed under vacuum.  The mold faces were sealed with a 2” x 2” glass slide to exclude excess 
PDMS and ensure uniform chip thickness, then baked at 95 °C for 20 min.  The PDMS chips 
were removed from the molds and excess PDMS was cut from the edges with a razor blade.  
Reagent/bead inlets and waste outlets were created with a 3-mm biopsy punch (Sklar 
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Instruments).  The prepared PDMS chips were bonded to glass microscope slides after plasma 
treatment. 
3.2.4 Fabrication of stage-weir chips 
 The chips used in Section 3.3.6 (referred to as stage-weir chips due to their features) are 
similar to the simple column chips, but feature a shallower zone prior to the weir for imaging the 
beads in the same focal plane (Figure 3.4).  They were fabricated in the same way as the simple 
column chips with one modification.  After the weir was fabricated, chips were etched to either 
6.7 µm, 7.25 µm, or 7.8 µm depths.  A region immediately before the weir was coated with 
S1813 and baked to prevent its etching.  This formed the viewing stage.  After coating the area of 
the stage with resist, the chips were etched to a 12 µm total depth. 
3.2.5 Assay procedures 
 All experiments in this chapter with array chips followed the long assay protocol 
described in Chapter 2 unless otherwise noted.  Off-chip incubations were conducted by 
incubating the beads with reagents in 500-µL microcentrifuge tubes (Eppendorf, Hauppauge, 
New York).  An MS3 Basic Mixer (Fisher Scientific) was utilized to suspend the beads in 
solution at 3000 rpm during each incubation.  Incubations were performed at room temperature.  
1 µL of a 1:1 mixture of stock VEGF and control beads was incubated in 100 µL of reagent; this 
amounted to approximately 6,250 of each bead type.  Washing in the tubes was performed by 
using a rare-earth magnet to pull the magnetic beads to the bottom of the tube, removing the 
supernatant, pipetting in 100 µL of PBS-T, and resuspending the beads via vortex.   
 PBS-BB (PBS + 1% BSA) was used to passivate chips and prepare assay solutions, 
except for the samples in the internal standard experiment in Section 3.3.2, which were prepared 
in ERK buffer.  PBS-T (PBS + 0.05% Tween-20) was used to wash the chips in between assay 
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steps.  Unless otherwise specified, the dAb concentration was 3 µg/mL and the SA-PE 
concentration was 2 µg/mL. 
3.2.6 Improved data analysis procedure 
 All data to this point was analyzed as described in Chapter 2; fluorescence values from 
the raw data that were not within 2.2 standard deviations of the mean were rejected, and the 
recalculated mean was used as the fluorescence value for the signal.  As extreme outliers can 
inflate the standard deviation such that other true outliers are not rejected, an improved method 
of analysis was instituted beginning with the off-chip incubation experiments in Section 3.3.3.  
Rather than perform a single correction cycle involving the rejection of outliers and recalculation 
of the mean and standard deviation, multiple correction cycles are performed in which the 
standard deviation and mean from the previous cycle are used to detect and reject outliers in the 
next.  This process is repeated until no further outliers are removable.11  This eliminates extreme 
anomalies and true outliers in order to produce a more accurate estimate of the mean. 
3.3 Results and discussion 
3.3.1 Assay with multi-array chips 
 Heterogeneity in flow conditions from chip-to-chip in terms of the flow rate or reagent 
concentration was the first potential cause of the high variance to be explored.  This issue may 
stem from differential evaporation of reagent droplets during incubations, which would change 
the reagent concentration differently from chip to chip.  Mass transfer is also a major determinant 
of antibody-antigen binding kinetics4,5 and heterogeneities here may be the result of differences 
in sample volume from chip-to-chip.  Experiments using the multi-array chips (Figure 3.1) with 
their symmetrical nature coupled with laminar flow conditions in microfluidic channels ensures 
that the reagent flux would be identical through each channel and across each array.  If the 
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experimental variance did not improve, fluid flow heterogeneities would be ruled out as a cause 
of the variance. 
 VEGF assays were performed with the multi-array chips using samples containing 0, 10, 
100, and 1000 pg/mL VEGF in PBS-BB.  Results from these chips were inferior to those from 
single-array chips; the %RSDs were no lower than ~21% and as high as ~45%, and the signal 
was lower than was usually seen for these concentrations of VEGF.  The fact that the assay 
variance remained high in spite of uniform flow conditions in all the arrays refuted the 
hypothesis that heterogeneity in fluid flow was a contributor to the high variance problem. 
3.3.2 Assay with internal standard 
 A technique commonly used in chromatography to account for irreproducible injection 
volumes is the inclusion of an internal standard.  An internal standard consists of a known 
amount of a compound different from the analyte added to a sample.  The signal from the analyte 
(A) is compared to the signal from the standard (S) to adjust for differences in the quantity of 
solution that are analyzed from experiment to experiment.8 
                       (3.1) 
The possibility of using an internal standard was explored as a way to account for the 
high variance.  For the microbead array experiments, an internal standard could potentially 
account for differences in the amount of reagent reaching the arrays.  For example, in a 
multiplexed internal standard experiment with both VEGF and ERK1/2 beads, a constant 
concentration of VEGF would be used along with varying concentrations of ERK1/2 so that the 
ERK1/2 signal could be normalized to the VEGF signal.  If successful, this would be a way of 
working around the high variance without having to determine the exact cause of the variance.  
This strategy requires the VEGF assay to be compatible with the ERK1/2 assay in terms of both 
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multiplexing and buffers.  If cross-reaction between antibodies occurs, then a multiplexed assay 
would not be feasible.  The VEGF antibodies must also be compatible with the denaturing ERK 
buffer.  Finally, this strategy requires the VEGF signal to correlate with the ERK1/2 signal in 
each sample; if it does not, then the ERK1/2 signal cannot be normalized to the VEGF signal. 
 Sample solutions containing varying concentrations of pERK2 and a constant 1 ng/mL 
level of VEGF were prepared in ERK buffer.  These solutions were assayed in single-array 100-
bead chips.  The dAb solution contained 3 µg/mL pERK1/2 dAb and 3 µg/mL VEGF dAb.  The 
results (Figure 3.5) depict the pERK2:VEGF signal ratios as a function of the pERK2 
concentration.  A random scatter of points at each pERK2 concentration is apparent, whereas a 
plot that satisfied all the conditions for an internal standard assay (including a correlation 
between the pERK2 and VEGF signals) would be linear.  These results indicate that VEGF is not 
suitable as an internal standard in conjunction with ERK1/2 assays.  They also suggest that 
internal standards in general might be unfeasible for these assays.   
3.3.3 Off-chip incubations to isolate error sources 
 A series of experiments was undertaken designed to isolate each aspect of the assay so its 
contribution to the variance could be assessed systematically.  In these experiments, sample 
incubations were performed in microcentrifuge tubes to ensure that the beads were exposed to a 
uniform amount of reagent.  The high number of bead-molecule collisions should also led to high 
amounts of analyte capture.4,5  Two initial experiments followed the same general format using 
VEGF and control beads.  In the first, the concentration of VEGF was varied at constant 
concentrations of dAb and SA-PE, while in the second, the concentrations of VEGF and SA-PE 
were constant while that of the dAb was varied.  In both, the sample was incubated for 2 h, the 
dAb for 45 min, and the beads were washed twice between incubation steps.  The 20-min SA-PE 
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incubation took place after loading the beads into 100-bead array chips filled with PBS-BB.  
After pulling PBS-BB through the channels via vacuum to remove all SA-PE solution, the arrays 
were imaged.  Four arrays were used per concentration. 
 The assay %RSDs did not improve for either experiment.  In the experiments with varied 
VEGF concentrations, %RSDs ranged from ~21% to ~117%.  The experiments with varied dAb 
concentrations yielded %RSDs from ~21% to ~57%.  As the %RSDs were not affected by 
performing the sample and dAb incubations off-chip, these were ruled out as sources of the high 
variance.   
3.3.4 Assay with off-chip dye incubation 
 This left two major candidates as the high variance causes: the dye incubation step and 
the process of mechanically loading the beads into the arrays.  Like the previous experiments 
with the sample and antibody incubations, the dye incubation was taken off-chip to assess its 
role.  The VEGF and detection antibody incubations were performed as in the previous section 
with a constant concentration of 500 pg/mL VEGF and 1 µg/mL dAb.  SA-PE was incubated for 
30 min on the mixer at concentrations ranging up to 2 µg/mL and the beads were washed twice.  
The beads were imaged after loading them into arrays.  While the %RSDs at one concentration 
was ~6%, all other concentrations had %RSDs ranging from ~17% to ~49%.  This ruled out the 
fluorescent dye incubation as the cause of the variance. 
 Two subsequent experiments looked at the variance from these fully off-chip experiments 
on a larger scale by loading the beads into more than the typical 4 arrays.  VEGF and control 
beads (2.5 µL each from bead stock) were incubated in a tube with 500 µL VEGF at 500 pg/mL.  
dAb and SA-PE concentrations were a constant 1 µg/mL and 0.8 µg/mL, respectively.  The 
beads were incubated in a single tube prior to loading them into arrays for imaging. 
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 In the first of these two experiments, the beads were loaded into twenty 100-bead arrays 
for imaging.  The data showed a high interarray variance of ~67%.  The intraarray (bead-to-bead) 
variance was high as well.  This is illustrated in Figure 3.6, where the locations of all the assay 
beads in an array are circled in red (Figure 3.6A), and in Figure 3.6B, the five brightest beads in 
that array remain circled in red while the five dimmest are circled in yellow.  The figure shows 
that some beads are very bright, others show almost no fluorescence, and many others contain 
both bright and dark spots.  This suggested that either the bead surface chemistry differs strongly 
from bead to bead – because given the high reagent concentration, all beads should show similar 
fluorescence if uniformly coated with antibodies – or some beads are being damaged while 
others are not. 
 To examine the intrabead signals on a larger scale than the 100-bead arrays, the 
experiment was repeated with the beads loaded into eight 1,024-bead arrays for imaging.  The 
interarray fluorescence %RSD was ~48%, and the distribution of bead brightness was also 
similar, but the large arrays revealed a phenomenon that was hidden in the smaller 100-bead 
ones: the majority of the bright beads lie in the lower half of the array (Figure 3.7).  Because of 
the array size and the number of beads loaded, it is almost impossible for all the bright beads to 
selectively load into a single band, especially in eight separate arrays.  It was noticed that the 
beads in the upper half of the arrays tended to load before the beads in the lower half.  This 
suggested that the mechanical loading process was adversely affecting either the beads or the 
antibodies/complexes on the early loading beads. 
 These experiments differed from prior ones in that the beads were loaded after reacting 
with the antigen, dAb, and fluorescent dye, not before.  As the capture antibodies are covalently 
bound to the beads while the antigen-antibody-dye complex is held together through weaker 
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noncovalent interactions, it is possible that the post-assay bead surfaces are vulnerable to 
mechanical damage while the pre-assay beads are not.  In order to determine whether the 
mechanical damage hypothesis applies to post-loading, pre-assay beads, a means of loading the 
beads without using physical force was developed. 
3.3.5 Assays with simple column chips 
 In order to image the beads without their having had physical contact with PDMS, 
straight-channel chips were fabricated with weirs that are impassible to the beads (Figure 3.3).  
With this chip design, beads were incubated with sample, antibody, and dye in the mixer and 
then packed into the chip columns against the weirs and imaged. 
 VEGF assays were run in tubes with 500 pg/mL VEGF, 1 µg/mL anti-VEGF dAb, and 
0.8 µg/mL SA-PE.  After the final wash step, the beads were pipetted into the inlet via of the 
column chips and packed on-chip.  They were then imaged.  Sample images from one of these 
chips are shown in Figure 3.8.  Not only is the VEGF signal obtained more than threefold higher 
than it was in array chips for this concentration, but the %RSD in signal from column to column 
is just ~3.5%.  This constitutes strong evidence that the bead immunoassays work well when not 
mechanically loaded. 
3.3.6 Assays with stage-weir chips 
 An improved type of column chip was fabricated for further studies with non-microwell 
bead loaded assays.  As the channels in the previous chip design are several µm deeper than the 
bead diameter, some beads pack into the columns out of focus.  This can significantly alter their 
apparent signal.  Stage-weir chips (Figure 3.4) were made to eliminate this focus issue.  These 
feature a zone immediately before the weir that is slightly deeper than the diameter of the beads 
forcing the beads into a monolayer on the same focal plane. 
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 The assay described in the previous section was repeated and the assayed beads were 
loaded into stage-weir chips.  Immediately before introducing the beads to the chips, non-
fluorescent, non-magnetic Luminex beads were mixed with the assay beads.  These beads served 
as spacers to spread out the assay beads in the column and help prevent overlap of their signals.  
Example images from one of these chips are shown in Figure 3.9.  At the same time, another set 
of 6.7-µm chips were pressed several times with the mechanical loading wand to simulate the 
microarray loading process.  The results shown in Figure 3.10 indicate that the vast 
improvements in signal and variance seen in the simple channel-weir chip were not a fluke; the 
%RSDs across the three different viewing stage sizes ranged from ~6% to 10.42%, while the 
chips that were pressed lost almost all their fluorescence.  Figure 3.11 shows example 
fluorescence images comparing the unpressed (Figure 3.11A) and pressed (Figure 3.11B) 6.7-µm 
stage-weir chips.  It is evident that the chips that were pressed with the wand lost almost all their 
fluorescence.  Their signal %RSDs were also over 138%.  This corroborates the notion that the 
loading process is mechanically damaging the bead surfaces. 
 One final experiment was run with the stage-weir chips to show that the low %RSDs 
from these chips were reproducible from experiment to experiment.  VEGF samples at 500 
pg/mL were prepared in four separate tubes from four separate stock solutions and assayed.  The 
beads were loaded into the stage-weir chips with the 7.8-µm stage, as the best results were 
achieved with them.  The results shown in Figure 3.12 show low variance, indicating 
reproducible results from experiment to experiment.  The %RSDs for each sample ranged from 
less than 1% to just over 5%, and the aggregate %RSD for all samples was ~6%. 
3.3.7 Mechanical damage assays 
 The stage-weir experiments showed that if the beads are mechanically pressed after 
73 
sample, detection antibody, and dye incubations, a considerable loss in fluorescence signal is 
seen.  At this point, the bead surfaces are coated with a non-covalent complex in the form of the 
antibody sandwich and streptavidin-biotin bond between the antibody and dye.  This differs from 
the initial array assays described in Chapter 2 in that the loaded array beads were coated solely 
with covalently-bound surface antibodies before anything else was introduced to them.  Covalent 
bonds would be harder to disrupt than non-covalent ones.  These experiments explored whether 
this mechanical damage did indeed carry over to the array beads during loading, and if so, 
whether the damage could be quantified. 
 Two major types of motions were used when loading chips and are referred to as presses 
and grinds.  Presses involved simple up-and-down motions with a thumb or the bead-loading 
magnetic wand.  Grinds involved pressing on the array with the wand and rotating it.  As beads 
were pulled over the arrays, they were subjected to these motions until 90% or higher bead 
loading; the number of presses and/or grinds required was not recorded.  For the purposes of 
being quantitative, pressing was defined as strictly up-and-down motions on the arrays, while 
grinds involved a single press and 90-degree rotation of the wand.  Two sets of 1,024-bead array 
chips were loaded with VEGF and control beads according to these loading definitions, and 
either pressing or grinding was used to evaluate the effect of each type of loading motion 
independently.  The number of presses or grinds was counted.  The chips were filled with PBS-
BB, sealed, and left to block for at least 24 h at 4 °C.  They were then assayed according to the 
long format assay from Chapter 2 with 500 pg/mL VEGF as the sample. 
 The results from the first chip set are shown in Figure 3.13.  It is evident that there is an 
indirect relationship between the number of presses and grinds and the amount of fluorescence 
obtained from the beads.  Grinds also appear to be more damaging than presses, with only 5 
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grinds being comparable to 30 presses in this regard.  The second chip set (Figure 3.14) showed 
similar results; signal steadily decreased as the number of presses or grinds increased, with 15-20 
grinds almost completely eliminating the signal altogether.  The %RSDs are high in all cases. 
3.4 Conclusions 
 In this chapter, sources of error leading to unacceptably high assay %RSDs were 
explored and eventually traced to the process of mechanically loading the beads into the arrays.  
While the mechanical damage assays showed that loading with very few movements minimized 
the bead damage, an extremely concentrated bead slurry would be necessary to rapidly load the 
arrays.  This is not practical due to the number of beads lost in this process and the associated 
costs.  Further development of the pERK1/2:ERK1/2 assay could therefore follow two diverging 
paths.  The arrays would either be kept and a gentler means of loading the chips would need to 
be developed, or an alternate chip design that did not require mechanical loading would be 
employed. 
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3.5 Figures 
 
Figure 3.1.  Schematic of a multi-array chip.  One via is used for reagents and bead delivery, 
while a second is used for waste and vacuum.  Four 1,024-bead arrays are located in the center of 
the chip. 
 
 
 
 
76 
 
Figure 3.2.  Top-down schematic of simple column chip.  Five channels share common vias.  
Beads and buffer are introduced to the chip through the left via.  Beads are packed against the 
weirs by applying vacuum through the right via.  The vias (3 mm diameter) and channels (70 µm 
width, 560 µm spacing, 4.1 cm length) are to scale but the weir locations are approximate. 
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Figure 3.3.  Cutaway schematic of a simple column chip.  The channels are 9 µm deep.  Beads 
(6.5-µm) are packed against a 6-µm weir.  The microscope objective during imaging is located 
under the beads. 
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Figure 3.4.  Schematic of stage-weir chips showing beads in the viewing zone (either 6.7, 7.2, or 
7.8 µm deep) packed against a 6-µm weir.  Due to the spatial constraints of the viewing zone, the 
beads are in more uniform focus than they are in the simple column chips.  The channel depth is 
otherwise 12 µm. 
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Figure 3.5.  pERK2:VEGF signal ratio with pERK2 concentration using VEGF as an internal 
standard.  While VEGF and its antibodies are compatible with the denaturing ERK1/2 buffer, the 
VEGF signal is not a function of the pERK2 signal at any concentration of pERK2 and thus not 
suitable as an internal standard. 
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Figure 3.6.  Assay images of a 100-bead array from large-scale variance experiment.  Both 
arrays are the same, but the red circles in (A) indicate the location of every VEGF bead in (B).  
Other locations in the array contain control beads or are unloaded.  In (B), the brightest five 
VEGF beads remain circled in red while five of the dimmest beads are circled in yellow.  It can 
be seen here that some beads are considerably brighter than others, while some show almost no 
fluorescence whatsoever. 
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Figure 3.7.  Fluorescence images of four 1,024-bead arrays after VEGF sandwich immunoassays 
showing “bright zones.”  Almost all of the high-fluorescence beads are located on the bottom 
half of the array.   
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Figure 3.8.  (A) Encoding image and (B) fluorescence assay image from simple column chip.  
The bright beads in the top image are control beads while the dimmer ones are VEGF beads.  
Three example control beads and VEGF beads are indicated by blue boxes and red circles, 
respectively, in each image.  The weir is located on the right side of the above images. 
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Figure 3.9.  (A) Encoding image and (B) fluorescence assay image from stage-weir chip assay.  
Three control beads are enclosed in blue boxes and three assay beads in red circles for 
comparison.  The beads in the stage-weir chips showed far less variance and far greater signal 
than those in the array chips.  Assay and control beads are spaced apart by non-fluorescent, non-
functionalized beads in order to mitigate signal overlap from neighboring beads. 
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Figure 3.10.  Fluorescence signal with viewing stage depths of three stage weir chips, plus one 
additional 6.7-µm set that had been pressed upon by the wand.  The 7.8-µm chips perform best, 
while almost all fluorescence in the mashed channels was lost.  The %RSDs (left to right) were 
6.53%, 10.42%, 6.15%, and 137.74%. 
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Figure 3.11.  (A) Fluorescence assay image from a stage-weir chip and (B) fluorescence assay 
image from a stage-weir channel in which the bead column was pressed upon by the magnetic 
loading wand prior to imaging.  The number of VEGF beads in (B) is on the order of that in (A), 
but almost no fluorescent beads can be seen in (B). 
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Figure 3.12.  Fluorescence assay signal comparing the reproducibility across four separate tubes 
with identical assay conditions.  The %RSDs of the four channels imaged per tube (left to right) 
were 5.37%, 5.24%, 0.89%, and 3.95%.  Each tube shows low variance, and the %RSD across 
all columns and tubes is 6.06%. 
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Figure 3.13.  Fluorescence signal with the number or presses or grinds used to load beads.  The 
assay appears to perform worse as more presses are performed on each array, and the grinding 
motion appears to be particularly damaging. 
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Figure 3.14.  Fluorescence signal with number of presses or grinds used to load beads.  There is 
a steady downward trend in signal as the number of presses and grinds increases.  Virtually no 
signal can be seen after 15-20 grinds. 
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CHAPTER 4 
 
DEVELOPMENT OF A pERK1/2:ERK1/2 SANDWICH IMMUNOASSAY USING  
ANTIBODY-BOUND BEADS AND MONOLAYER CHIPS 
 
4.1 Introduction 
 Based on the assay development work minimizing the variance, it was evident that a 
device where minimal mechanical contact with the antibody-bound beads was needed.  The use 
of a packed bead bed like those in the stage-weir chips was pursued for several reasons.  First, it 
is easy to prepare the chips; the beads can be packed into beds simply by introducing them to the 
chip and applying vacuum.  The design is also flexible because the beads are no longer fixed in a 
single position as they are in the loaded array chips.  Magnetic beads can be moved through 
different sections of a chip over the course of an experiment if necessary to perform reagent 
incubations, wash steps, or mixing.1–4 
 There are also disadvantages with using packed bed chips.  Given the close proximity of 
the beads to one another and the potential for overlapping signals from different analytes, it is 
more difficult to multiplex with this format.  Ideally for this work, one bead type would be used 
to determine both pERK1/2 and ERK1/2 in two imaging steps; the average fluorescence of the 
bead bed would be measured and overlapping signals would not pose problems.  Since the 
pERK1/2 beads are compatible with a pERK1/2 dAb and a total ERK2 (tERK2) dAb, this 
capture Ab-bead assay would be realizable if a compatible total ERK1 (tERK1) dAb were found.   
 Another potential issue with packed beds is when the channels are significantly deeper 
than the bead diameter, the beads may pack at different heights on the z-axis relative to the 
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microscope objective.  The 6.5-µm MagPlex beads have shown this phenomenon in some of our 
microfluidic chips, and this results in beads at different focal planes.  The fluorescence photons 
emitted from out-of-focus beads near in-focus ones are spread over a larger area, lowering their 
apparent fluorescent signal.  The depth of focus for a microscope is described mathematically as 
follows:5    
                                         (4.1)  
where df is the depth of field (in µm), λ is the wavelength of illuminating light (in µm), n is the 
refractive index of the medium, NA is the numerical aperture of the objective, M is the 
magnification level, and e is the smallest distance the detector can resolve for objects in the 
image plane (in µm).  For 600-nm light being imaged by the 0.5 NA air objective at 30x 
magnification and EM-CCD camera in our Nikon Ti-U Eclipse Microscope, df is approximately 
2.4 µm.  This is less than half the diameter of the MagPlex beads. 
 Keeping the beads in the same focal plane places design constraints on the channel 
dimensions, as the channels should be deep enough for the beads to pack into a monolayer, but 
not deep enough for them to pack out of focus.  Reducing the channel depth from 20 µm (as in 
the array chips from Chapters 2 and 3) to approximately 7 µm (appropriate for a monolayer with 
6.5-µm MagPlex beads) comes with a sharp reduction in flow rate.  For a channel of rectangular 
cross-section like those produced by DRIE fabrication, the hydraulic resistance follows equation 
4.2:6 
                                                                                      (4.2) 
where Rhyd is the hydraulic resistance (in 10
15 Pa·s/m3), η is the viscosity of the fluid (in Pa·s), L  
is the length of the channel (m), h is the depth of the channel (m), and w is the width of the 
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channel (m).  A 7 µm deep channel will thus have more than 21 times the hydraulic resistance of 
a 20 µm deep channel.  The hydraulic resistance of packed bed chips is further increased by the 
fact that packed columns of micrometer-scale beads have little interstitial space for fluid flow.  
This translates to a greatly reduced flow rate, as the flow rate of a fluidic conduit is inversely 
proportional to its hydraulic resistance.6  This is problematic in terms of leading to long 
incubation times and ensuring uniform reagent delivery to all the beads. 
 The flow-frit chip design was created to address the issue of flow rate with packed bead 
beds.  Like the stage-weir chips, there is a straight 100 µm-wide channel with a punched via at 
one end for introducing beads and reagents and a second via for vacuum and waste (Figure 
4.1A).  An individual channel with its frit location indicated is shown in Figure 4.1B.  The 
features distinguishing them from the stage-weir chips are their frit and flow bed.  Instead of a 
weir, these chips feature a frit for trapping the beads (Figure 4.2).  The frit consists of 12-µm-
wide PDMS pillars that span the channel depth.  These pillars are spaced 4 µm apart and trap the 
6.5-µm beads to create the packed bed.  The frit serves the same function as the weir from 
previous designs, but unlike the manually-fabricated weir, its fabrication through 
photolithography is reproducible from chip to chip.  The other distinctive feature of the flow-frit 
chips is the flow bed (shown on the left side of Figure 4.2).  The flow bed consists of spaced 
pillars that populate the entire channel lengthwise (except the frit region).  The purpose of the 
flow bed is to provide additional fluid flow space that is inaccessible to the beads, thus 
increasing the flow rate throughout the chip.  Like the previous column chip designs, the flow-
frit chips require no mechanical action in order to load beads; they are simply packed into a 
monolayer bed via vacuum-driven flow.   
 In addition to standard solutions, the analysis of pERK1/2 and ERK1/2 in human cell 
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lysate was undertaken.  Assaying cellular proteins with a bead-based immunoassay requires 
lysing the cells in order to recover the proteins.  Numerous methods have been demonstrated for 
accomplishing on-chip cell lysis.  These include disrupting the cell membrane by high-
temperature thermal lysis7 or with a high electric field.8,9  Thermal lysis, while simple to 
implement, is not amenable to the needs of this assay because it causes aggregation of the 
cellular proteins, making protein analyte recovery difficult.  Electrical lysis has the disadvantage 
of requiring areas of high field strength on the chips, which places constraints on the chip design.  
Cells can also be lysed chemically.  Here, a chemical agent is used to disrupt the cell membrane.  
Triton X-100 is one such agent; it is a nonionic surfactant that incorporates itself into the cell 
membrane and solubilizes its lipids and proteins, creating pores that eventually produce lysis.10  
At Triton X-100 concentrations in the range of 0.5% - 1%, lysis takes place in seconds.  This can 
be incorporated on-chip and is compatible with the ERK1/2 capture and detection antibodies.  
An ideal assay would incorporate an on-chip lysis method in a fully-integrated device, but such a 
device would also possess other factors that were developed in this project instead, including 
valving and the ability to assay multiple samples on a single chip. 
 In this chapter, sandwich immunoassays with pERK1/2 beads in packed bed devices 
instead of an array are investigated.  Preliminary experiments are run using stage-weir chips to 
validate the packed bed format, then an improved chip design incorporating a flow bed and frit is 
developed.  Sample incubations are performed on-chip and the compatibility of the pERK1/2 
beads with a total ERK1 detection antibody is established, making it possible to assay all 
phospho-forms of ERK1 and ERK2 with a single bead type.  Finally, the developed assay is used 
to determine pERK1/2:ERK1/2 in lysate from human Jurkat (acute T-cell leukemia) cells. 
 
94 
4.2 Materials and methods 
4.2.1 Materials and reagents 
 Sylgard 184 PDMS was purchased from Ellsworth Adhesives (Germantown, WI) and 
was prepared according to the manufacturer's instructions at a 10:1 elastomer/cross-linker ratio.  
MagPlex Luminex beads were purchased from Bio-Rad Laboratories (Hercules, CA).  Purified 
recombinant human vascular endothelial growth factor (VEGF), phosphorylated and non-
phosphorylated extracellular signal-related kinase 2 (pERK2 and nERK2), non-phosphorylated 
extracellular signal-related kinase 1 (nERK1), biotinylated detection antibodies for VEGF, 
pERK1/2, ERK1, and ERK2, capture antibodies for pERK1/2, VEGF, and a control capture 
antibody were purchased from R&D Systems (Minneapolis, MN).  All proteins and antibodies 
were reconstituted according to the manufacturer’s instructions.  Soda lime glass 
photolithography substrates (5” x 5”) were purchased from Telic (Valencia, CA).  Nano-Strip 
was purchased from KMG Chemicals (Fremont, CA).  Octyltrichlorosilane, sodium fluoride, 
ethylene diamine tetraacetic acid (EDTA), urea, Triton X-100, phorbol 12-myristate 13-acetate 
(PMA), leupeptin, phenylmethanesulfonyl fluoride (PMSF), aproptinin, sodium pyrophosphate, 
and sodium orthovanadate were purchased from Sigma-Aldrich (St. Louis, MO).  AZ-400K was 
purchased from AZ Electronic Materials USA (Somerville, NJ).  Chromium etchant and 10:1 
buffered oxide etch (BOE) were purchased from Transene Corp. (Danvers, MA).  Acetone, 10x 
phosphate-buffered saline (PBS, pH = 7.4), 10% bovine serum albumin (BSA) in PBS, optically 
clear polypropylene plate-sealing tape (PCR tape), Contrad 70, and microscope slides (75 mm x 
25 mm x 0.99 mm) were purchased from Thermo Fisher Scientific (Waltham, MA).  KMPR 
1010 photoresist and SU-8 thinner were purchased from MicroChem (Newton, MA); the SU-8 
thinner was mixed with KMPR 1010 to prepare 35% (w/w) KMPR solutions.  MF-319 
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photoresist developer was purchased from Rohm and Haas Electronic Materials (Marlborough, 
MA).  P-type 6” crystalline Si wafers were purchased from University Wafer (Boston, MA).  
Streptavidin-B-phycoerythrin (SA-PE), RPMI 1640 media, fetal bovine serum, penicillin, and 
streptomycin were purchased from Invitrogen (Carlsbad, CA).  Human Jurkat T-cells were 
acquired from American Type Culture Collection (Rockville, MD).   
 All aqueous solutions were prepared with deionized (DI) water from a NANOpure 
Diamond system (Barnstead International, Dubuque, IA).  Buffer solutions used include PBS-BB 
(PBS + 1% BSA), cell lysis buffer (PBS + 1 mM EDTA + 0.5% Triton X-100 + 5 mM sodium 
fluoride + 6 M urea + 10 µg/mL leupeptin + 100 µM PMSF + 3 µg/mL aprotinin + 2.5 mM 
sodium pyrophosphate + 1 mM activated sodium orthovanadate), ERK buffer (PBS + 5 mM 
sodium fluoride + 1 mM EDTA + 0.5% Triton X-100 + 1 M urea), and ERK diluent (ERK buffer 
with no urea). 
4.2.2 Design and fabrication of flow-frit chips 
 Experiments following the pilot stage-weir assays were performed with flow-frit chips 
(Figure 4.1 and Figure 4.2).  Chip designs were created in TurboCAD Professional 14 drafting 
software and the photolithography mask made with a Heidelberg Instruments DWL66 laser 
lithography system.  The master molds and PDMS/glass chips were fabricated as described in 
Chapter 2 using photolithography, DRIE on 6” Si wafers, soft lithography, and plasma bonding.  
In the first photolithography/DRIE step, the flow bed layer was patterned and etched into the 
wafer molds to a depth of 5 µm.  In the second step, the channel layer was patterned and etched 
to a depth of 7.5 µm, bringing the total channel depth to 12.5 µm.  Frit pillars were etched 
spanning the height of the channel.   
 As the flow-frit chips contained many high aspect-ratio features, the chips were filled 
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with PBS-BB immediately after bonding.  This was done to take advantage of the temporary 
hydrophilicity of the activated PDMS,11 as the chips were easily wettable in this state and air 
bubbles were not a concern.  PBS-BB filled chips were either used after 2 h of passivation at 
room temperature or sealed with PCR tape and stored at 4 °C for use after 24 h. 
4.2.3 Flow-frit chip assay method 
 Early proof-of-concept assays with the flow-frit chips used off-chip sample incubations 
in microcentrifuge tubes as described in Chapter 3.  This was done to maximize signal while 
developing assay protocols.   
 Sample solutions containing ERK1/2 were prepared in ERK buffer.  All other solutions 
were prepared in PBS-BB.  Solutions are introduced to the chips by removing the fluid in the 
chip inlets with vacuum, filling the inlets with 10 µL of new solution, and applying vacuum for 
15 s.  Washing is performed by filling the chip inlets with PBS-BB and applying vacuum for 1 
min in between each incubation step and before imaging steps.  Unless otherwise specified, all 
dAb solutions are at 3 µg/mL, all SA-PE solutions are at 2 µg/mL, and replicates of 5 assays are 
used for each sample.  Encoding and assay images were taken as described in Chapter 2. 
4.2.4 Data analysis 
 The preliminary experiments with stage-weir and flow-frit chips in Sections 4.3.1-4.3.2 
used control and VEGF or pERK1/2 beads and were decoded through the manual selection 
process described in Chapter 2.  Control beads were no longer used starting with the on-chip 
incubations with flow-frit chips in Section 4.3.3 onward.  The encoding dye in the beads was 
used to locate the bead beds, focus the microscope, and provide a fluorescent encoding image 
(Figure 4.3A).  Assay images of the sandwich complex were then taken with the SA-PE filter 
cube (Figure 4.3B).  The bead bed in the encoding image was selected in ImageJ (Figure 4.3C), 
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the selection was overlaid in the assay image (Figure 4.3D), and the aggregate fluorescence data 
was exported to Microsoft Excel as a 5000-bin histogram.  Formulas for grouped data12 were 
used to calculate the mean and standard deviation of the fluorescence: 
                                                  (4.3) 
                                                          (4.4) 
where µ represents the mean, x is the fluorescence value of a histogram bin,  f is the number of 
points in the bin, n is the total number of values across all bins, and s is the standard deviation.  
The iterative correction cycle process described in Chapter 3 was used to remove outliers, and 
the standard deviation and mean were calculated from the corrected data. 
4.2.5 Cell culture 
 Human Jurkat T-cells were cultured according to the vendor’s instructions13 in RPMI 
1640 media containing 10% (v/v) fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL 
streptomycin.  Cells were incubated at 37 °C and 5% CO2 and kept at concentrations between 1 x 
105 and 1 x 106 cells/mL. 
4.2.6 Cell lysis 
 The recipe for the lysis buffer was provided by R&D Systems.14  The cells are chemically 
lysed with 0.5% Triton X-100, a non-ionic surfactant that breaks down the cell membrane by 
solubilizing its proteins and lipids.10  The buffer also contains a cocktail of leupeptin, aprotinin, 
PMSF, sodium fluoride, sodium pyrophosphate, and activated sodium orthovanadate that 
preserves ERK1/2 phosphorylation by inhibiting cellular proteases and serine and tyrosine 
phosphatases.15  Cell lysate was obtained by first transferring cell aliquots to an Eppendorf Lo- 
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Bind microcentrifuge tube and washing them twice by centrifuging at 1000 rcf for 3 min, and 
resuspending in PBS.  After the second wash with PBS, the cells were centrifuged at 1000 rcf for 
3 min, the supernatant was removed, and the cells were resuspended in lysis buffer at 107 
cells/mL and incubated for 15 min on ice.  The lysed cells were centrifuged at 2000 rcf for 5 min 
and the supernatant was transferred to a fresh centrifuge tube.  It was then diluted six-fold with 
ERK diluent prior to making further dilutions in ERK buffer for analysis. 
4.3 Results and discussion 
4.3.1 Preliminary pERK2 and nERK2 assays with stage-weir chips 
 Preliminary experiments were conducted to evaluate the performance capabilities of bead 
monolayer chips for assaying pERK2 and nERK2.  In each experiment, the parameters for off-
chip incubations described in Chapter 3 were used, except the dAb concentration was 1 µg/mL.  
Stage-weir chips with a 7.8-µm viewing zone were used for imaging the beads. 
 The first experiment in this series investigated the detection limit of pERK2.  Solutions of 
pERK2 were prepared at concentrations ranging from 250 pg/mL to 5000 pg/mL.  As 250 pg/mL 
(S/N = 137) was easily distinguishable from the blank, the experiment was repeated with the 
pERK2 concentration ranging from 50 pg/mL to 250 pg/mL.  The lowest concentration of 
pERK2 (S/N = 37) was easily distinguishable from the blank in this experiment as well.  Using  
S/N =3 as the LOD, the limit of detection would be approximately 5 pg/mL.  Both sets of data 
are plotted in Figure 4.4 showing that the fluorescence as a function of the pERK2 concentration 
is linear (R2 = 0.9943) across the entire range of the curve.  The %RSDs are below the targeted 
10% limit for each sample as well.  The detection of nERK2 was examined next using the same 
methods and concentrations as the second pERK2 assay (50 to 250 pg/mL) and a tERK2 dAb.  
The results (Figure 4.5) are comparable to that of the second pERK2 assay in terms of signal 
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level for each concentration, and the limit of detection is approximately 50 pg/mL.  Only two 
samples have %RSDs above 10%, both because of a single datum that was not sufficiently 
anomalous to be removed via the q-test at 95% confidence.  These results show that with bead 
monolayer chips, pERK2 and nERK2 are detectable at concentrations (approximately picomolar) 
well below their physiological concentrations (approximately micromolar)16,17 with low %RSDs, 
validating the usefulness of bead monolayer type chips for the pERK1/2:ERK1/2 assays. 
 After the individual assays for pERK2 and nERK2, a multiplex assay for both analytes 
was performed.  Five samples were prepared with the total concentration of ERK2 held at a 
constant 250 pg/mL and differing percentages of pERK2 and nERK2.  Their sample 
compositions are noted in Table 4.1 as a representative example of the standards prepared for 
pERK1/2:ERK1/2 assays in other experiments.  Following the sample incubation step, the bead 
population for each concentration was divided into two microcentrifuge tubes.  One was 
incubated with 3 µg/mL pERK1/2 dAb, while the other was incubated with a 1:1 mix of 
pERK1/2 dAb and tERK2 dAb (3 µg/mL each).  Both bead populations were then incubated 
with SA-PE, loaded into chips, and imaged.  The results in Figure 4.6 show that for samples 
containing mixed ERK2 phosphorylation states, the fluorescence signal obtained from the 
pERK1/2 dAb as a function of the sample’s %pERK2 increases linearly (red triangles).  
Compared to the increase in fluorescence from the pERK1/2 dAb as a function of %pERK2, the 
fluorescence from the mixed dAbs (black circles) is relatively constant, although it still increases 
by nearly 19% from the 0% pERK to the 100% pERK samples.  The curve’s slight upward slope 
as a function of the %pERK thus indicates some cross reactivity of the pERK2 molecules with 
the pERK1/2 dAb and the total ERK2 dAb.  This cross-reactivity is accounted for when the ratio 
of the two signals is taken when determining the %pERK as shown in Figure 4.7.  The 
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fluorescence ratio increases linearly as a function of the %pERK in the sample.   
 Although the stage-weir chips produced reproducible results, several drawbacks to the 
devices are detrimental to their use as potential POC devices.  First, the manual fabrication of the 
weir for creating the packed beds is not reproducible, affecting the uniformity of fluid flow from 
one device to another.  Second, fabricating chips with the PDMS complement mold method is 
time-consuming, thus increasing fabrication costs.  Most importantly, the flow rates in these 
chips are very low because the packed beds have little interstitial fluidic space.  This 
considerably lengthens the time required for introducing sample and reagents.  While this has not 
been a problem with the stage-weir chips owing to sample incubations being performed off-chip, 
the goal of the project is to create an on-chip assay, so a chip design using short incubation times 
and a packed bead bed was developed. 
4.3.2 Preliminary flow-frit chip experiments 
  Flow-frit chips with square pillars in the flow beds featuring sides of 5 µm, 6 µm, 7 µm, 
or 8 µm, and spacings of either 4 µm or 6 µm were tested using the model analyte VEGF.  The 
purpose was to compare the assay performance of the different flow bed feature size 
configurations.  In the first of these assays, VEGF and control beads were packed into beds by 
pipetting a 10:1 dilution of stock VEGF and control beads in PBS-BB into the reagent vias and 
pulling vacuum and incubated for 2 h to passivate them.  The chips were then filled with 500 
pg/mL VEGF, incubated for 1 h followed by a 1 min wash, filled with anti-VEGF dAb, and 
incubated for 30 min.  The chips were washed again and incubated with SA-PE for 20 min, then 
washed and imaged. 
 A fluorescence gradient across the flow bed was seen for these on-chip sample-incubated 
beads, with the brightest beads being closest to the reagent via and the darkest beads closest to 
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the frit (Figure 4.8A).  As a result, the interchip %RSDs increased to greater than 10% (Figure 
4.8B) for all tested devices.  It appears that the beads at the head of the packed bed capture more 
sample molecules.  To eliminate this problem, beads should be incubated with sample prior to 
being packed to ensure uniform sample exposure.  In comparison, stage-weir devices used off-
chip sample incubation and uniform bead fluorescence across the length of the bed was 
exhibited.  As such, these experiments were repeated with modifications intended to reproduce 
conditions in the stage-weir assays.   
 First, the VEGF and control beads were incubated with samples in microcentrifuge tubes 
off-chip.  A vortexer was used to keep the beads in suspension over a 2 h period to ensure 
uniform exposure to the sample.  Second, after washing the sample-incubated beads, non-
fluorescent spacer beads were added to the bead solutions.  The purpose of the spacer beads was 
to prevent overlap of fluorescence signals from assay beads.  As the spacer beads do not contain 
fluorescent dyes, they manifest as dark spots in the images of the beds.  The bead mixture was 
packed into flow-frit chips and the assay was completed as in the previous experiment.  A 
representative fluorescence image of one flow bed exhibiting uniform fluorescence levels over 
the length of the bed is shown in Figure 4.9A.  The assay’s results in Figure 4.9B show that the 
flow bed feature sizes (height/spacing) all produce similar results in terms of fluorescence and 
variance, and so in subsequent experiments, all sizes were used interchangeably.  The absence of 
a fluorescence gradient in any of the bead beds is in spite of both the dAb and SA-PE incubations 
being done on-chip.  This is indicative of the antibody and dye being able to permeate the bed 
sufficiently to bind to the sandwich complex on the beads’ surfaces, with the limiting factor in 
the beads’ fluorescence being the amount of sample captured.  This suggests that to achieve 
consistent results, the sample incubation with the beads should be done outside of a packed bed 
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with all other incubations and imaging steps done post-packing. 
4.3.3 On-chip sample incubation 
 All experiments up to this point used off-chip sample incubations, but as the goal of the 
project is an on-chip assay, a method of doing sample incubations on-chip while exposing the 
beads to a uniform amount of sample was sought.  A simple means of accomplishing this was 
tried by incubating pERK2 samples with pERK1/2 beads in the bead inlet vias.  pERK2 samples 
were prepared at 0, 2.5, 5, 7.5, and 10 ng/mL in ERK buffer and combined with 0.5 µL pERK1/2 
beads.  Each solution was evenly distributed across five chip reagent vias and incubated for 30 
min.  The beads were then packed by applying vacuum and the beds were washed for 5 min with 
PBS-BB.  The chips were then incubated with dAb, SA-PE, and imaged.  The results are shown 
in Figure 4.10.  All %RSDs are below 5%, and the lowest assayed concentration of 2.5 ng/mL 
(average S/N = 154) is easily distinguishable from the blank.  This concentration of 
approximately 60 pM is many orders of magnitude below the micromolar concentrations found 
in cells.16,17  Although cell lysis results in dilution of the intracellular proteins, the concentration 
change and thus number of cells required is addressable through future refinements in chip 
design, particularly of the cell lysis/sample incubation regions.  These results show that this 
facile on-chip incubation method is sufficient for determining ERK2 in cell lysate, so all future 
flow-frit assays were conducted in this manner. 
 The packed beds imaged in these and subsequent flow-frit chip experiments typically had 
between 300-600 beads per bed.  Within this range, the signal was not found to be dependent 
upon the size of the bed.  This is likely because these immunoassays are operating in the ambient 
analyte regime in which <1.5% of molecules are captured from solution.18  In this regime, 
molecules in bulk solution are not significantly depleted during incubations and thus the number 
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of molecules captured per bead is not a function of the number of beads. 
4.3.4 Optimization of flow-frit assay steps 
 Additional experiments were run with VEGF to optimize assay parameters prior to 
determining pERK1/2:ERK1/2 in cells.  The first of these was designed to optimize the 
incubation time for the dAb.  VEGF beads were incubated with 500 pg/mL VEGF.  The chips 
were then filled with anti-VEGF dAb and incubated for 5, 10, 15, 20, 25, and 30 min.  An 
additional chip set was not incubated with any dAb.  The chips were imaged after being washed 
and incubated with SA-PE as usual.  Figure 4.11 shows that the assay signal steadily increases up 
to approximately the 20-min incubation mark, then diminishing returns set in; 30 min of dAb 
incubation yields approximately 10% more signal than 20 min, while 20-min dAb incubations 
yield approximately 64% more signal than 10-min incubations.  The dAbs were therefore 
incubated for 20 min in subsequent experiments as the 10-min reduction in incubation time 
equates to a 20-min reduction over the course of the two dAb incubation steps.  All %RSDs are 
below 5%, except the 25-min incubation  
 The incubation time for SA-PE was optimized next.  Beads were incubated off-chip with 
500 pg/mL VEGF, packed into the chips, and incubated with 1 µg/mL anti-VEGF for 20 min.  
After washing the chips, SA-PE at 2 µg/mL was incubated for 0, 4, 8, 12, 16, and 20 min.  The 
chips were washed for 5 min and imaged.  Figure 4.12 shows that a constant signal is seen for all 
incubation times.  This is consistent with the extremely fast binding kinetics between streptavidin 
and biotin.19  All %RSDs are below 10%, except the 16-min incubation which is 10.3%.  All 
subsequent experiments used 5 min SA-PE incubation time.  The increase from 4 to 5 min was 
done to make it easier to handle multiple chips simultaneously during experiments. 
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4.3.5 Detection of total ERK1 
 At this point, a dAb for total ERK1 was tested for its compatibility with the pERK1/2 
capture antibody.  Previous ERK1/2 experiments using stock pERK2 and nERK2 proteins did 
not test this, but the detection of nERK1 is a necessity in a cell assay for pERK1/2:ERK1/2.  The 
pERK1/2 capture antibody has been shown to target a common epitope on nERK1/2 and 
pERK1/2, but a detection antibody capable of binding to nERK1 captured by the pERK1/2 
antibody needed to be identified.  Such an antibody was pursued, as a nERK1 dAb compatible 
with the pERK1/2 capture antibody would facilitate assaying all phosphorylation states of 
ERK1/2 with a single bead type. 
 A biotinylated tERK1 dAb and nERK1 standard were obtained from R&D Systems.  
Samples of nERK1 were prepared at 0, 2.5, and 5 ng/mL.  nERK2 samples were prepared at 
these concentrations as well for comparison.  pERK1/2 beads were incubated with each sample 
and packed into flow-frit chips.  The chips containing nERK1-incubated beads were incubated 
with tERK1 dAb while the nERK2 chips were incubated with tERK2 dAb.  The chips were 
washed and incubated with SA-PE and imaged.  The results are shown in Figure 4.13, with the 
blue bar representing fluorescence from nERK1 and the red bar representing fluorescence from 
nERK2.  For each ERK concentration, signal levels are higher from nERK1 using the tERK1 
dAb than from nERK2 using the tERK2 dAb.  This shows that the total ERK1 dAb is capable of 
binding to ERK1 captured by the pERK1/2 beads, and to a greater degree than the tERK2 dAb 
binding to captured ERK2.  This can be caused by the tERK1 dAb having a greater affinity for 
its epitope than the tERK2 dAb, as well as by the epitope on captured ERK1 being more 
sterically accessible to the dAb than the corresponding epitope on ERK2.  All %RSDs are below 
10% except those for the highest ERK1 concentration. 
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4.3.6 Simultaneous nERK1 and nERK2 detection on-chip 
 While flow-frit assays successfully detected nERK1 in isolation, the simultaneous 
detection of nERK1 and nERK2 is required as part of the assay.  Samples containing equal parts 
nERK1 and nERK2 at 0, 5, 10, and 20 ng/mL were prepared and incubated on-chip with 
pERK1/2 beads.  After packing and washing, the chips were incubated with solution containing 1 
µg/mL each tERK1 and tERK2 dAb.  The chips were finally washed, incubated with SA-PE, and 
imaged.  The results in Figure 4.14 show the successful simultaneous detection of the two 
unphosphorylated proteins as the fluorescence obtained increases linearly as a function of the 
total ERK1/2 concentration with all %RSDs below 10%.   
4.3.7 Cell lysis assay 
 At this point, the reproducible detection of pERK1/2, nERK1, and nERK2 has been 
demonstrated with the flow frit chip.  This was followed up with the determination of 
pERK1/2:ERK1/2 in human cell lysate.  This assay followed the dual-dAb, pERK1/2 dAb-first 
strategy discussed in Chapter 2.  Jurkat cell aliquots containing ~1 million cells each were 
transferred to culture flasks and diluted to 5 mL with culture media with 200 nM phorbol 12-
myristate 13-acetate (PMA) added to one.  PMA is a tumor promoter that induces ERK1/2 
phosphorylation by activating the MAPK signaling cascade upstream at protein kinase C; this in 
turn activates the Raf  MEK1/2  ERK1/2 pathway.20  The use of PMA creates a high 
concentration pERK1/2 cell for comparison with an untreated control that should have a lower 
pERK1/2 concentration.  Both PMA-treated and untreated cells were incubated for 30 min, 
transferred to a microcentrifuge tube, and lysate was prepared as described in Section 4.2.6. 
 Five calibration standards containing pERK2 and nERK1/2 were prepared at a constant 
total ERK1/2 concentration of 10 ng/mL.  The %pERK in the samples was 0%, 25%, 50%, 75%, 
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and 100%.  A fifth standard containing no ERK1/2 served as a blank.  Each standard and lysate 
sample was incubated on-chip with ERK1/2 beads.  After packing the beads, pERK1/2 dAb (3 
µg/mL) was incubated.  The chips were imaged after the appropriate wash steps and SA-PE 
incubation.  The imaged chips were then incubated with the tERK1 and tERK2 dAbs (3 µg/mL 
each) and imaged a second time after the final SA-PE incubation and wash step. 
 Figure 4.7 shows the ratio of the pERK2:ERK2 phosphorylation fluorescence ratio with 
increasing pERK1/2 percentage in solution.  Also shown are the signals from PMA-treated cells 
and non-PMA treated cells.  The fluorescence ratio is linear as a function of the %pERK1/2 for 
the standards.  The pERK2:ERK2 fluorescence ratios for the untreated cells (black square) and 
PMA treated cells (upright triangle) fall on the standard curve with ratios of ~4% and ~30% 
respectively.  The higher ratio is as predicted because of the activation of the ERK1/2 signaling 
cascade by PMA.  Although this method of increasing ERK1/2 phosphorylation is artificial, in a 
real-world patient sample, increased ERK1/2 phosphorylation is often seen when upstream 
mutations occur in the ERK1/2 signaling cascade, as is the case in many cancers.21,22  Overall, 
these results show that the assay can determine pERK1/2:ERK1/2 at physiologically relevant 
concentrations, both in standards as well as human cell lysate.  The detection of increased 
ERK1/2 phosphorylation in the PMA-treated cells also shows that the assay is useful for 
detecting upstream mutations in the ERK1/2 signaling cascade. 
4.4 Conclusions 
 The flow-frit chip assays were successful in determining pERK1/2:ERK1/2.  In order to 
move the pERK1/2:ERK1/2 assay toward a self-contained, automatable LOC, a chip design with 
the necessary functional elements such as reagent delivery and valving was explored.  Such 
modifications include the placement of vias for all assay solutions and samples on a single chip – 
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that is, wash buffer, the pERK1/2 and total ERK1/2 dAbs, the fluorescent SA-PE complex, and 
the sample/bead incubations themselves.  Simultaneous inclusion of all these features on one 
chip requires a method of controlling which fluid is being delivered to the beads at any given 
time.  Development of a valving method for the pERK1/2:ERK1/2 device is thus the subject of 
the next chapter. 
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4.5 Tables and figures 
[pERK2] (pg/mL) [nERK2] (pg/mL) %pERK2  
0 250 0 
62.5 187.5 25 
125 125 50 
187.5 62.5 75 
250 0 100 
Table 4.1.  Sample compositions for preliminary pERK2:ERK2 assay.  The total ERK2 
concentration is 250 pg/mL in all samples while the pERK2 percentage is varied.  [pERK2] and 
[nERK2] are calculated from stock protein concentrations. 
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Figure 4.1.  Photographs of flow-frit chips filled with ink for visualization.  (A) Flow-frit chips 
with 10 channels.  Samples are analyzed in replicates across 5 channels each.  (B) Single flow-
frit channel showing location of frit and reagent/bead and vacuum/waste vias. 
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Figure 4.2.  Side and bottom views of flow-frit chips.  (A) Schematic of flow-frit chip with bead 
monolayer and (B) white light microscope image of chip with bead bed.  The flow bed pillars 
and channel depth force the beads into a monolayer as they pack against the frit.  (A) is not to 
scale. 
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Figure 4.3.  Data analysis process for flow-frit chips.  ex = 
631 nm) and (B) f ex = 532 nm).  (C) The encoding image is used to 
focus on the bead bed, select the signal area, and overlay the selection on the fluorescence signal 
image (D) for analysis.  The fluorescence data are exported in the form of a 5000-bin histogram 
and analyzed. 
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Figure 4.4.  Net fluorescence intensity with pERK2 concentration and stage-weir chips.  The 
detection limit is approximately 5 pg/mL (~0.12 pM). 
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Figure 4.5.  Net fluorescence intensity with nERK2 concentration taken with stage-weir chips.  
The fluorescence and variance results are similar to those for pERK2 detection.  All %RSDs are 
below 10% except those for the 50 pg/mL and 250 pg/mL samples, both of which owe their 
variance to a single anomalous data point that could not be removed via the q-test. 
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Figure 4.6.  Net fluorescence intensity with pERK2:ERK2 ratio taken with stage-weir chips.  
The fluorescence increase from the pERK1/2 dAb-incubated beads (red triangles) is linear as a 
function of the percentage of pERK2 in the sample.  The fluorescence from the combined 
pERK1/2 and total ERK2 dAb-incubated beads (black circles) slightly increases as pERK2 
increases because some pERK2 molecules bind to both dAbs at the same time. 
 
115 
 
Figure 4.7.  pERK2:ERK2 fluorescence ratio with %pERK in the sample using a stage weir 
device.  The left axis reflects the fluorescence from the combined pERK1/2 and total ERK2 
antibodies divided by the fluorescence from the pERK1/2 antibody.  The result is linear as a 
function of the %pERK in the sample.  In actual clinical samples, the %pERK would be very low 
in healthy patients.  In samples from patients with cancer, the %pERK would generally be higher 
but would vary considerably depending on the disease and the treatments being received. 
 
 
 
 
 
 
 
 
 
116 
 
Figure 4.8.  Results from initial attempt at on-chip incubation with packed bead bed in flow-frit 
chips.  (A) Fluorescence image of a packed bed with on chip sample incubation.  The beads 
closest to the reagent via are brightest.  (B) Assay results showing high variance due to the 
fluorescence gradient. 
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Figure 4.9.  Results of experiment evaluating each configuration of flow bed features with off-
chip sample incubations.  (A) Fluorescence image of flow bed with uniform fluorescence due to 
off-chip incubations.  (B) Assay results showing similar fluorescence and %RSDs for each 
configuration of flow bed features. 
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Figure 4.10.  Fluorescence response with pERK2 concentration using on-chip sample 
incubation.  The sensitivity is such that various sample concentrations (pM-range) well below 
physiological concentrations (µM-range) can be distinguished from one another, showing that 
this assay is suitable for assaying human cell lysate.  The exact number of cells required for the 
assay is something subject to optimization through chip design, since lysing the cells results in 
dilution of their contents. 
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Figure 4.11.  Fluorescence signal with dAb incubation time.  The signal increases steadily until 
approximately 20 min, then diminishing returns set in.  30 min incubations yield approximately 
10% more signal than 20-min incubations, while 20 min incubations yield approximately 64% 
more signal than 10-min incubations. 
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Figure 4.12.  Fluorescence signal with increasing SA-PE incubation time.  After 4 min, no 
further increase in the signal was seen.  5 min was used as the SA-PE incubation time in 
subsequent experiments. 
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Figure 4.13.  Fluorescence signal comparison between nERK1 and nERK2 at varying 
concentrations.  The signal obtained from the total ERK1 dAb shows that it is capable of binding 
to nERK1 captured by pERK1/2 beads.  It also produces somewhat more signal than the total 
ERK2 dAb. 
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Figure 4.14.  Fluorescence signal from the simultaneous detection of nERK1 and nERK2 at 
varying concentrations.  Samples contained equal concentrations of both analytes and the dAb 
solution contained equal concentrations of both total ERK dAbs.  Both analytes are detectable in 
a single imaging step. 
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Figure 4.15.  pERK1/2:ERK1/2 fluorescence ratio with increasing %pERK in standards and cell 
lysate samples.  The points from standard solutions are displayed as red inverted triangles and 
are linear as a function of the %pERK.  The untreated cell lysate (~3.6% phosphorylation) is 
shown as a black square.  The PMA-treated cell lysate is shown as a blue upright triangle (~30% 
phosphorylation).  The increased phosphorylation in the PMA-treated samples was a result of 
upstream activation of the MAPK signaling cascade, showing the utility of the assay for 
detecting mutations in the cascade that lead to increased ERK1/2 activation. 
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CHAPTER 5 
DEVELOPMENT OF A FREEZE-THAW VALVING SYSTEM  
FOR MICROFLUIDIC DEVICES 
 
5.1 Introduction 
 In microfluidic devices that use multiple reagent and sample solutions, valves are 
necessary to control and direct the fluid flow.  They serve purposes such as modulating which 
samples are being assayed at a given time or which reagents are flowing through the chips.  
Many valving strategies are possible depending upon the chip design.  Devices fabricated from 
the elastic material PDMS can be valved by using mechanical pressure to pinch the channel shut.  
The Whitesides group has demonstrated numerous designs for the purpose, including screw 
valves that are manually opened and closed and solenoid valves that use a magnetically-driven 
rod to pinch the channel shut.1  Another major class of valves for PDMS devices comes from the 
Quake group.  These use pneumatic pressure in multilayer devices to pinch shut default-open 
channels or push open default-closed channels.2,3  These designs all have the disadvantages of 
either requiring the fabrication of complicated chips, or in the case of the manual valves, of not 
being automatable.  For our purposes, the desired valves would be pre-fabricated and reusable, 
used with a simple single-layer device, and would require minimal alignment.  The Ramsey and 
Walt groups have demonstrated such a device, wherein an aligned PDMS/glass chip is locked 
into place underneath mechanically-actuated, computer-controlled pinch valves.4  That system 
used chips made from PDMS, but a valving system usable with solid materials such as glass or 
plastic would have broader applications. 
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 One possible valving method that meets our requirements is the freeze-thaw valve (FTV).  
For FTVs, the fluid in the channel is cooled until it freezes with the frozen plug preventing fluid 
flow.  In microfluidic devices fabricated from smooth materials like PDMS and glass, there are 
few nucleation sites for ice crystals to form so supercooling the liquid in order to freeze it may be 
necessary;5,6 small volumes (<1 µL) of pure water may require a temperature as low as -35 °C to 
freeze,5 while another study observed water freezing at -17 ºC.7  The frozen channel is opened by 
thawing, either through the application of heat or the removal of the cooling source.  While some 
early demonstrations of FTVs used cold fluids such as liquid nitrogen8 or carbon dioxide9,10 to 
accomplish the freezing, it is also possible to utilize Peltier devices to freeze and thaw 
channels.6,11   
 Peltiers consist of a layer of alternating semiconductors sandwiched between two parallel 
insulators.  The material used to make the semiconductors is thermoelectric and can carry heat in 
addition to electrons.12  Through the application of voltage, heat is pumped across the device and 
a temperature differential is created between the two insulating layers.  By stacking several 
Peltiers of successively smaller size, a cascading temperature differential can be created from tier 
to tier with the net effect of producing much colder temperatures than are possible with a single 
Peltier.  Temperatures sufficient to freeze supercooled water can be generated this way.  The use 
of multi-Peltier tiers also makes it possible to hold the first tier close to the supercooling 
temperature so that freezing may be rapidly effected by the second tier when desired.6  Figure 5.1 
shows one such 2-tier Peltier configuration that could be used as a FTV.  A constant-temperature 
water block is used as a heat sink for the base Peltier (BP).  It also functions as a constant hot-
side reference temperature for the base Peltier, which is critical for ensuring the stability and 
reproducibility of the Peltier’s cold-side temperatures.6  In a freeze cycle, the cold-side 
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temperature of the base Peltier, TBP, sets the hot-side temperature for the valve Peltier (VP).  TVP, 
the cold-side temperature of the valve, is thus colder than TBP.  Examples for TBP and TVP are -16 
°C and -40 °C, respectively.  Reversing the voltage polarity switches the hot side and cold side of 
a Peltier to induce thawing.  In this case, TBP sets the cold-side temperature for the valve, and 
TVP can easily reach +50 °C or more.  A major advantage of Peltier-based FTVs is that cooling 
and heating are actuated by simple low voltage control.  Multiple Peltier devices can be 
simultaneously used as valves with a single base Peltier to remove heat. 
 One disadvantage of the FTVs is that their response times are generally slower than other 
valves.6  Depending on the configuration of the system, opening and closing the valves can take 
seconds to tens of seconds, so they are not suitable for applications that demand immediate 
actuation.  The pERK1/2:ERK1/2 immunoassay developed to this point does not require rapid 
on/off valving action, so FTVs are acceptable as the valving mechanism. 
 In this chapter, a Peltier-based freeze-thaw microfluidic valving system under computer 
control is built and characterized.  A thermal camera is used to monitor the system for hot spots.  
Mixing tee chips for imaging the valving action are designed, fabricated, and employed to 
demonstrate the efficacy of the valves.  Ultimately, it is shown that freezing and thawing of a 
given valve is repeatable over many cycles with reproducible timescales suitable for the needs of 
the pERK1/2:ERK1/2 immunoassay. 
5.2 Materials and methods 
5.2.1 Materials and reagents 
 Sylgard 184 PDMS was purchased from Ellsworth Adhesives (Germantown, WI) and 
was prepared according to the manufacturer's instructions at a 10:1 elastomer/cross-linker ratio.  
Tween-20 was purchased from BioRad Laboratories (Hercules, CA).  Glass photolithography 
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substrates (5” x 5” soda lime) were purchased from Nanofilm (WestLake Village, CA).  Nano-
Strip 2X was purchased from KMG Chemicals (Fremont, CA).  AZ-400K was purchased from 
AZ Electronic Materials USA (Somerville, NJ).  Chromium etchant and 10:1 buffered oxide etch 
(BOE) were purchased from Transene Corp. (Danvers, MA).  SU-8 2050 photoresist and SU-8 
developer was purchased from MicroChem (Newton, MA).  MF-319 photoresist developer was 
purchased from Rohm and Haas Electronic Materials (Marlborough, MA).  P-type 6” crystalline 
Si wafers were purchased from University Wafer (Boston, MA).  D263 glass was purchased 
from S.I. Howard Glass Company (Worcester, MA).  Octyltrichlorosilane was purchased from 
Sigma-Aldrich (St. Louis, MO).  Contrad 70 detergent, 10x phosphate-buffered saline (PBS, pH 
= 7.4), 10% bovine serum albumin (BSA) in PBS, acetone, 200 proof ethanol, fluorescein, and 
polystyrene Petri dishes were purchased from Thermo Fisher Scientific (Waltham, MA). 
 The base Peltier (TE-63-1.4-1.15) was purchased from Thermoelectric Technology 
(Traverse City, MI).  The valve Peltiers (C2-04-0102) were purchased from Tellurex (Traverse 
City, MI).  Pyrolytic graphite (17 µm thick), thermally conductive silver epoxy, adjustable 10-Ω 
power resistors, and an Arduino UNO R3 were purchased from Digi-Key (Thief River Falls, 
MN).  Thermally conductive double-sided tape was purchased from Thor Labs (Newton, NJ).  
DP-805 waterproof acrylic adhesive was purchased from 3M (St. Paul, MN).  Power supplies 
were purchased from BK Precision (Yorba Linda, CA).  NPT-27 brass elbow fittings were 
purchased from Swagelok (Solon, OH).  A 4-channel motor controller was purchased from 
Jameco Electronics (Belmont, CA).  Tygon tubing was purchased from McMaster-Carr 
(Elmhurst, IL).   
 All aqueous solutions were prepared with deionized (DI) water from a NANOpure 
Diamond system (Barnstead International, Dubuque, IA), including PBS-BT (PBS + 1% BSA + 
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0.05% Tween-20) and PBS-BTF (PBS-BT + 5 µM fluorescein).  PBS-BT is referred to as 
“buffer” and PBS-BTF as “dye” throughout the text. 
5.2.2 Mixing tee chip design and fabrication 
 The chips used to study the freeze-thaw valves featured a mixing tee where the flow from 
two channels could be imaged.  The chips consisted of two sample inlets (buffer and dye) with 
serpentine valving regions that converge to form a tee-intersection or mixing tee.  A schematic of 
the chip is shown in Figure 5.2.  The channels are 40 µm deep and 100 µm wide.  The channels 
in the serpentine regions are 60 µm wide to increase the density of channels over the Peltiers.  
The mixing tee is circled in red.  Following initial studies with the 2-valve single mixing tee 
chips, a second generation chip was designed for studying four valves at once.  It features 4 inlet 
vias and 4 valving regions and thus three mixing tees.  A schematic of the chip is shown in 
Figure 5.3.  The mixing tees are again circled in red.  Switchbacks from the dye channels that 
equalize the volume between the dye/buffer channels are boxed in blue.  Channel dimensions are 
the same as the 2-valve single mixing tee chip. 
 Designs for the mixing tee chips were created in TurboCAD Professional 14.  Mixing tee 
designs were written into a 5” x 5” soda lime glass substrate coated with chromium and positive 
photoresist using a Heidelberg Instruments DWL66 laser lithography system.  The photoresist 
was developed for 45 s with AZ-400k and the exposed chromium was removed with chromium 
etchant.  The remaining bulk photoresist was stripped with acetone and residual resist was 
removed with 70% Contrad.  This substrate was then used as a mask to pattern designs into 
negative resist on a 6” silicon wafer.  To promote adhesion of the negative resist, the native 
oxide layer was removed from the wafer by immersing the wafer in the 10:1 BOE for 30 s prior 
to the photolithography steps.   
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 SU-8 2050 was then spun at 3200 rpm for 30 s and baked at 95 ºC for 10 min to produce 
a 40-µm thick layer of SU-8.  This wafer was exposed to UV light for 15 s in a mask aligner 
(approximately 160 mJ/cm2 radiation dose) and post-exposure baked at 95 °C for 6 min.  
Development was performed in SU-8 developer for 5 min.  The wafer was finally hard-baked at 
160 °C for 30 min and silanized with octyltrichlorosilane in a vacuum oven (Thermo Fisher 
Scientific) at 115 °C for 1 h.  PDMS/glass chips were fabricated from the wafer molds as 
described in Chapter 2, except 2” x 3” x 0.0082” D263 glass was used instead of microscope 
slides.   
5.2.3 Valve construction 
 To dissipate the heat generated by the Peltiers, the base Peltier is mounted on a custom 
water block constructed from a block of brass (2.6” x 1.8” x 1”).  Serpentine water channels were 
machined in its underside and sealed with a Lexan cover, screws, and waterproof acrylic 
adhesive (DP805; 3M, St. Paul, MN).  A refrigerated bath circulator (4100R20; Thermo Fisher 
Scientific) operated with 15 °C water was attached to the water block.  Screw holes were drilled 
into the top of the water block to secure the block to a custom-made acrylic stage.  A side view 
of the water block with its water tubing and stage attached is shown in Figure 5.4A.  The stage 
sits above the block and is designed to fit on the stage of a Nikon Ti-U Eclipse microscope.  
Figure 5.4B shows a top-down view of the stage and block with a 20 mm x 40 mm Peltier 
(referred to as the base Peltier) mounted on the block.  Thermally-conductive silver epoxy (Resin 
Technology Group LLC, South Easton, MA) was used to permanently bond the hot side of the 
base Peltier to the water block. 
 The valves operate well below the dew point, so the Peltiers were sealed in PDMS to 
protect their internal semiconductors from water condensation.  This was accomplished by 
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submerging the Peltiers into uncured PDMS, degassing the PDMS, and curing overnight at 65 
°C.  After curing, excess PDMS was cut away from the Peltiers’ surfaces and sides such that the 
only remaining PDMS was encasing the internal semiconductors. 
 A 2-tier, 5-Peltier setup forms the core of the freeze-thaw valve system.  The first tier 
consists of the base Peltier with a sheet of pyrolytic graphite (17 µm thick) attached to the cold 
(upper) side.  Pyrolytic graphite has extremely high lateral thermal conductivity,13 and is used to 
spread out the heat pumped by the valve Peltiers (4.3 mm x 4.3 mm), four of which are mounted 
on the graphite with thermally conductive double-sided tape.  A photo of the system is shown in 
Figure 5.5.  A chip is affixed to the stage with rare-earth magnets and one of its mixing tees 
(boxed in red) is directly over the microscope objective.  The valves and valving regions are 
circled in white.  The surface of the base Peltier surrounding the valve Peltiers is insulated by 
styrofoam pellets embedded in PDMS to prevent condensation buildup. 
5.2.4 Peltier control electronics 
 Two power supplies (9110; BK Precision, Yorba Linda, CA) are used to power the 
Peltiers and freeze-thaw electronics.  The base Peltier is run at a constant DC current of 5.1 A.  A 
second power supply is set to a constant voltage of 4.5 V with a maximum current of 3.9 A and 
provides power for the four valve Peltiers via the electronics used to modulate their 
temperatures.  This supply is connected to a motor controller (RS011MC; Jameco Electronics, 
Belmont, CA) with 4 output channels.  Each channel consists of an H-bridge that is used to 
power one valve Peltier.  While the voltage applied by these H-bridges is constant, the motor 
controller includes logic circuitry that modulates each channel’s polarity and duty cycle.  
Changing the duty cycle of a channel alters its current output by setting the percentage of time 
the Peltier is actively pumping heat and thus drawing power.  Also, as the motor controller’s 
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outputs have a minimum voltage that exceeds the valve Peltiers’ maximum operating voltage, a 
2.8-Ω power resistor (Vishay Huntington Electric, Malvern, PA) is wired in series between the 
positive leads of each channel and its corresponding Peltier in order to serve as a voltage divider.  
An Arduino UNO R3 (SmartProjects, Ivrea, Italy) microcontroller board is used to control the 
logic on the motor controller.  A 5-Volt Vcc pin provides the power for the motor controller’s 
logic circuitry.  Digital output pins regulate the polarity of each channel by applying either +5 V 
for freeze mode or 0 V for thaw mode, and pulse-width modulation (PWM) pins set the 
channels’ duty cycles in increments of approximately 0.392%.   
 The Arduino is powered and controlled by a USB connection to a PC.  Custom software 
for controlling the freeze-thaw valves was written in LabVIEW (National Instruments, Austin, 
TX).  National Instruments’ LabVIEW Interface for Arduino Toolkit was utilized to connect 
LabVIEW and the Arduino microcontroller.   
5.2.5 Image collection 
 The complete imaging setup is shown in Figure 5.6.  Chips were placed atop the valves 
and custom stage on a Nikon Ti-U Eclipse inverted fluorescence microscope.  A Nikon B-2E/C 
optical filter cube was used to select excitation/emission wavelengths for imaging the fluorescein 
in the channels.  Fluorescence videos of the microchannels were recorded with an ExwaveHAD 
Color Video Camera (Sony Corporation of America, New York, NY) using GrabBee software 
(VideoHome Technology Corp., New Taipei City, Taiwan).  An A35sc infrared camera (FLIR 
Systems, Wilsonville, OR) was mounted above the chips and used to take thermal images of the 
valves.  Thermal pictures and videos were recorded with FLIR Tools+ software (FLIR Systems). 
5.3 Results and discussion 
   The valves are based on a 2-tier Peltier configuration that creates a cascaded temperature 
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differential where the top valve Peltier can reach temperatures suitable for freezing and thawing 
aqueous solutions in microfluidic channels.  Four valves are needed for the pERK1/2:ERK1/2 
assay to control the flow of wash buffer, pERK1/2 dAb, tERK1/2 dAb, and SA-PE.  The valve 
Peltiers were spaced evenly on a base Peltier to prevent or minimize the overlap of heat from 
their hot sides.  Though initial testing placed all four valves at the base Peltier’s edge closest to 
the microscope objective, two were moved backwards to take advantage of colder surface 
temperatures on the base (Section 5.3.2).  The unused topside of the base Peltier is insulated with 
PDMS and styrofoam, and the Peltier pumps the system’s heat into a chilled water block.  The 
system is affixed to a custom stage and mounted inside an inverted microscope for imaging the 
chips.  The completed system is shown in Figure 5.5 and is characterized here. 
5.3.1 Temperature characterization of valving system 
 In order to produce valve temperatures suitable for freezing and thawing, each 
component of the freeze-thaw block was characterized during its construction to determine 
which parameters produce the coldest temperatures.  The temperature of the water in the block 
was set to 15 °C.  Lower temperatures were initially tried, but condensation buildup near the 
system’s electronics proved to be problematic as there was no straightforward way of insulating 
the water block.  The 15 °C water was not cold enough to produce condensation and proved 
effective for generating sufficiently cold temperatures for valve freezing. 
 The base Peltier was characterized first.  Early in the construction process, the topside of 
the base Peltier was imaged with the FLIR A35sc infrared camera with and without pyrolytic 
graphite in place.  The thermal images showed a nonuniform surface temperature of the base 
Peltier with some areas significantly warmer than others.  These are shown in Figure 5.7.  Figure 
5.7A depicts the base Peltier near the microscope objective and is shown to provide a reference 
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orientation for the images.  The warm spots (boxed in white) were present at currents >0.4 A for 
the base Peltier.  This is shown in Figure 5.7B-G, with B-D showing thermal images of the base 
Peltier with graphite and E-G showing images without it.  These hot spots likely arise because 
their locations are farthest from the cooling channel in the water block as well as from the center 
of the base Peltier, and thus they do not dissipate heat as efficiently as the rest of the base Peltier.  
While this study was qualitative and measurements of the base Peltier’s temperature were not 
determined, the warm regions were insufficiently cold to freeze water.  Due to the temperature 
heterogeneity across the base Peltier and the regions not suitable for valving, the temperature 
across the base Peltier was measured to locate potential sites for the FTVs. 
 To find colder regions suitable for mounting the valve Peltiers, the base Peltier was 
further characterized by directly measuring the temperature at various points along its surface 
using a Barnstead-Thermolyne pyrometer (Thermo Fisher Scientific) and thermocouple probe 
(Omega Engineering, Stamford, CT).  The thermocouple’s tip was sandwiched between the 
Peltier and a thick piece of styrofoam to ensure that the thermocouple would only be measuring 
the Peltier’s temperature.  These measurements located four cold regions (white squares in 
Figure 5.8) that were suitable for mounting the valve Peltiers, both in terms of their temperatures 
(-14 °C, -17 °C, -14 °C, and -7 °C for valves 1-4, respectively) and the spatial orientation of the 
valved regions on the intended assay chip design.  This study further revealed that the base 
Peltier as a whole was coldest (average temperature of approximately -16 °C) at a current of 5.1 
A.   
 Finally, styrofoam pellets embedded in PDMS were used to insulate the exposed surface 
of the base Peltier.  This prevented frost buildup and minimized condensation deposits on the 
base Peltier.  Also, as chips do not occupy the region of the base Peltier behind the valve Peltiers, 
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the styrofoam layer was made considerably thicker there in order to further reduce the amount of 
heat the Peltier would pump from the air.  Ultimately, valve Peltiers could reach temperatures 
several °C colder with an insulated base Peltier than with a non-insulated base Peltier.  
5.3.2 Temperature and thermal characterization of valve Peltier 
 Over the course of building the FTV system, its performance – namely, the temperatures 
produced by the Peltiers at various parameters – needed to be characterized.  This was necessary 
to establish that the Peltiers could produce temperatures appropriate for freezing and thawing on 
command.  It was also a means of determining the stability and reproducibility of temperatures 
produced by the system, i.e., whether a desired temperature could be reliably produced at any 
time with given settings, and whether that temperature would remain stable.   
 Peltiers have a voltage (Vmax) at which they produce their maximum temperature 
differential, and thus coldest cold-side temperature (TBP, TVP).  Applying voltages beyond this 
point will not reduce either TBP or TVP; their temperatures will instead increase due to the 
Peltiers’ ability to dissipate its waste heat being exceeded.12  To overcome this limitation, the 
best strategy is to use pulse-width modulation (PWM) to apply the Peltier’s Vmax at varying duty 
cycles.  In this strategy, the Peltier is either off where no current is generated or at Vmax.  The 
current, and thus temperature, is varied according to the fraction of time that the Peltier spends at 
Vmax.
12  At 100% duty cycle with Vmax, the current through a Peltier will be its Imax.  Vmax is a 
function of the hot-side temperature and was determined for each Peltier by increasing the 
applied voltage until the Peltier’s cold-side temperature no longer decreased with additional 
voltage. 
 The temperatures of the valve Peltiers were measured with a thermocouple in the same 
manner as the base Peltier.  The base Peltier was allowed to equilibrate for approximately 5 min 
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prior to measuring the valve temperatures.  The valve temperatures were calibrated by varying 
the PWM (at ~Vmax) on the Arduino between 0 (0% duty cycle) and 255 (100% duty cycle) by 
increments of 5.  Temperatures were measured first in closed (freeze) mode, then the voltage 
polarity was switched to set the valves to open (thaw) mode and the temperatures were measured 
again.  This process was repeated for all 4 valves.  Figure 5.9 shows the results, with valve 1 
represented by black circles, valve 2 by blue circles, valve 3 by red diamonds, and valve 4 by 
purple inverted triangles.  The lowest temperatures achieved were -38.5 °C for valve 1, -43.1 °C 
for valve 2, -38.6 °C for valve 3, and -31.3 °C for valve 4.  The open mode temperatures of the 
valves were not determined past +50 °C as temperatures beyond this are unneeded.  After the 
valves were characterized, temperatures were periodically monitored on random days to confirm 
the accuracy and reproducibility of the temperatures produced.  Measured temperatures were 
found to deviate from recorded temperatures by no more than a few tenths of 1 °C.   
 During this process, only the valve being measured was powered on; all others were off.  
This mimics assay conditions, as the valves will only be active when freezing or thawing.  When 
powered off, they are cold enough to maintain the default frozen or closed state because the top 
surface of the valve Peltier will equilibrate to a temperature close to that of the base Peltier 
underneath.  This temperature is well below the freezing point of water. 
5.3.3 Freeze/thaw valve efficacy with single mixing tee chips 
  The first generation of chips designed to study and demonstrate the efficacy of the 
freeze-thaw valves featured a single mixing tee (Figure 5.2).  Prior to experimentation, bonded 
chips were filled with 200 proof ethanol to wet their channels and ensure the removal of air 
bubbles.  The sample vias were then vacuumed empty, one was filled with 10 µL PBS-BT 
(buffer solution), the other with PBS-BTF (dye solution), and vacuum was applied to the waste 
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via for 30 s to replace the ethanol.  The prepared chip was placed atop the freeze-thaw block with 
the serpentine valving regions sitting over the two valve Peltiers (Figure 5.5).  A vacuum line 
with a 25-gauge needle was placed in the chip’s vacuum via as shown in Figure 5.6.  This line 
was controlled with a remote valve so that fluid flow could be turned on and off without 
disturbing the chip. 
 The serpentine valving regions of the channels pass over separate valve Peltiers.  The 
serpentines add to the channel length providing more potential nucleation sites for freezing and 
increasing the fluid/valve contact time.  Four potential valving scenarios are possible: dye valve 
open:buffer valve open (DO:BO, Figure 5.10A), dye valve open:buffer valve closed (DO:BC, 
Figure 5.10B), dye valve closed:buffer valve open (DC:BO, Figure 5.10C) and both valves 
closed (DC:BC, not shown).  The fluid flow directions for each case are shown in Figure 5.10A-
C.  As the two channels leading to the mixing tee are identical in length and volume, and as the 
flow rate from each side of the tee is identical, fluorescence images of the mixing tee will appear 
half fluorescent and half dark for the DO:BO case (Figure 5.10A), completely fluorescent for the 
DO:BC case (Figure 5.10B), and completely dark for the DC:BO (Figure 5.10C).  Arrows 
indicate direction of flow, and the arrow size indicates relative flow rate.  The complete 
fluorescence in the DO:BC case and complete darkness in the DC:BO case is due to the open-
valve’s reagent diffusing into the closed-valve reagent’s side of the tee. 
 The mixing tee was monitored for the duration of every experiment, beginning with both 
valves in the open state (DO:BO) (shown in Figure 5.11A) where there is a 50/50 flow from the 
dye and buffer channels into the tee.  Valves were closed by setting them to their lowest possible 
temperature.  Thawing was induced by setting them to 25 °C.  When a valve closed, a pulse of 
fluid is generated that penetrates into the opposite channel (Figure 5.11B).  This is due to the 
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increased volume from the ice formation in the serpentine channels.  Likewise, when a valve is 
re-opened, the slightly reduced volume in the valve region from the thawing ice manifests as a 
retreat of fluid in the tee (Figure 5.12A-C) followed by the tee returning to its DO:BO state 
(Figure 5.12D).  Neither the freeze pulse nor the thaw retreat significantly affect the downstream 
bead regions in assay chips. 
 Figure 5.13 shows a time series of a freeze/thaw cycle (taken from a fluorescence video).  
Inset in each fluorescence image is a thermal image of the two valves, the locations of which are 
highlighted in white.  The thermal images were taken simultaneously with the fluorescence 
images.  The initial state of the system with both valves open (DO:BO) is shown in Figure 
5.13A.  In Figure 5.13B, a pulse from closing the buffer valve (DO:BC) is seen by the concave 
deflection of the dye solution back into the dye channel.  Closing of the buffer valve is shown by 
the increase in the depth of blue in the thermal image with the Peltier at its coldest temperature.  
In Figure 5.13C, the dye diffuses into the buffer channel while flowing down the tee channel.  
Figure 5.13D shows the beginning of the thaw process for DO:BO (orange area in thermal 
image) with the buffer valve set to room temperature.  In Figure 5.13E, thinning of the dye on 
the buffer side of the tee is evident as non-fluorescent buffer returns to the tee, and in Figure 
5.13F, the fluid flow is back to its initial state with the 50:50 mix flowing down the tee channel. 
5.3.4 Double mixing tee chips and reproducibility of valve times 
 The first generation of mixing tee chips featured only two valving regions.  This was 
suitable for establishing proof-of-concept for the FTVs, but for studying four valves 
simultaneously, a 4-valve chip was designed (Figure 5.3).  This was used to study the 
reproducibility of open/close times of 4 valves over the course of three experiments.  In all 
experiments, the time between setting the close temperature (-43 °C) and the appearance of the 
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freeze pulse (Figure 5.11) was used as the close actuation time, while the time between setting 
the open temperature (+25 °C) and the appearance of the reverse thaw pulse (Figure 5.12) was 
used as the open actuation time. 
 In the first experiment, the system was cycled between opening (+25 °C) and closing (-43 
°C).  Figure 5.14 shows that while the close time (represented by blue inverted triangles) trends 
slightly downward over time, the open time (red boxes) trends slightly upward.  The freeze/thaw 
times are reproducible within several seconds; the average close time was 37.1 s with a standard 
deviation of 4 s, while the average open time was 13.4 s with a standard deviation of 2 s.  Over 
the course of 9 freeze/thaw cycles, no valve closing took longer than 44 seconds and no valve 
opening took longer than 16 seconds.   
 In an actual assay, the valves cycling between the open and closed states in such a rapid 
fashion is not required.  Once closed, the valve Peltier can either be set to an intermediate 
temperature not conducive to initiate thawing, or shut off altogether.  This reduces the valve 
opening time and prevents excessive frost/condensation buildup.  If shut off, the valve would 
equilibrate to the base Peltier temperature; this varies from -8.3 °C to -16.7 °C depending on the 
valve.  This temperature variance between valves is a function of their proximity to the cooling 
block’s water channels and the base Peltier’s center (in both cases, closer sites are colder). 
 The performance of the freeze/thaw valves was next tested under assay-like conditions.  
In the first experiment, the valve Peltier was held at -2.5 °C for 20 s between each open and close 
event.  The results are shown in Figure 5.15, where the average close time was 31.8 s with a 
standard deviation of 6.7 s and the average open time was 7.3 s with a standard deviation of 3 s.  
These times are as expected when compared to the first experiment; close times were shorter as 
the Peltier was cooling down from -2.5 °C rather than room temperature, and open times were 
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shorter as the Peltier was warming up from -2.5 °C rather than -43 °C.  In the second, the valve 
Peltier was shut off and the base Peltier set to -16.7 °C for 20 seconds between each freeze/thaw.  
The results in Figure 5.16 show an average close time of 25.8 s with a standard deviation of 5.5 s 
and an average open time of 10.7 s with a standard deviation of 3.9 s.  These times are also as 
expected when compared to the previous experiments; compared to the -2.5 °C-equilibration 
experiment, the close time is shorter because the Peltier is starting from -16.7 °C, while the open 
time is longer.  The same slight upward trend in opening time with successive events is evident 
in both, as is an upward trend in the closing times, although this did not continue indefinitely; 
subsequent tests found that in all cases, freezing was effected in less than 45 s and thawing in 
less than 20 s.  All data presented here are from a single valve but are representative of all valve 
operations.  Vacuum was not applied to the chips during these three experiments, but in others, 
vacuum did not appear to affect open/close times. 
 Based on these results, a time buffer for each valve open/close sequence was 
incorporated.  For closing, a 50 s time frame was used while a 20 s time frame was used for 
opening.  This extra time ensures that the valve is in the desired state, but does not significantly 
impact the overall assay time.   
5.3.5 Verification of sustained valve closure over time 
 All valve tests so far examined valving with short-term closure (~20 s).  However, assays 
will require closure times approaching an hour.  To ensure there is no leakage through the valve 
for the required times under assay-like conditions, a valve leading to a mixing tee was closed 
(Figure 5.17A-B) and temperature set to -2.5 °C and left to sit for an hour.  The mixing tee was 
monitored for the entirety of this period for fluorescence dye leaking through the tee.  Vacuum 
was applied periodically to mimic assay conditions and in case of a leak, to pull the dye to the tee 
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intersection.  No fluorescent dye was seen at the tee once the valve was closed with Figure 5.17C 
showing a representative image of this time frame.  Once the valve was re-opened, fluorescent 
buffer flow with the 50/50 mix in the tee channel is present (Figure 5.17D). 
5.4 Conclusions 
 In this chapter, a simple Peltier-based freeze-thaw valve for microfluidic devices was 
developed.  A custom heat sink and stage were made for mounting the valves and chips.  It was 
found that casting the Peltiers with a layer of PDMS and styrofoam was an effective means of 
thermally insulating them and protecting them from condensation.  The electronics for the 
Peltiers were assembled and a custom LabVIEW program for controlling them was written.  
Following characterization of the Peltiers with a thermocouple and infrared camera, mixing tee 
chips for visualizing the valving were designed and fabricated.  Experiments with the mixing tee 
chips found that the valves behave reproducibly and open/close at timescales suitable for the 
needs of the pERK1/2:ERK1/2 assay device.  Once closed, they remain stable in that state as 
long as the Peltiers controlling them are held at a temperature slightly below the freezing point of 
water. 
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5.5 Figures 
 
 
Figure 5.1.  Schematic of a 2-tier cascaded Peltier setup.  The cold and hot sides of the Peltiers 
are shown in blue and red, respectively.  A constant-temperature water block is used as a heat 
sink and a reference temperature for the base Peltier’s hot side, which keeps its cold side 
temperatures stable.  The cold side of the larger Peltier removes heat from and is used as a hot-
side reference temperature (TBP) for the smaller Peltier, whose cold side (TVP) can then become 
much colder than if the Peltier were used as a single unit.  In our setup, example temperatures are 
15 °C for the water block, -16 °C for TBP, and -40 °C for TVP.  If the polarity of the top valve 
Peltier is reversed, it is capable of generating temperatures well over 50 ºC for opening valves. 
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Figure 5.2.  Schematic of mixing tee chip used for valve development.  The main channels are 
40 µm deep and 100 µm wide.  The serpentine regions increase the fluidic space across the 
Peltiers and provide more potential nucleation sites, and the channels here are 60 µm wide to 
allow more channel lengths to occupy the same area.  Dye and buffer channels converge in the 
mixing tee (circled in red) and are used to visualize the valving. 
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Figure 5.3.  Schematic of triple mixing tee chip used to study all four valves.  This chip 
possesses four FTVs (V1-V4).  Tees are circled in red.  The switchbacks (highlighted in blue 
boxes) in the two dye channels equalize the channel lengths to ensure equal fluid flow between 
buffer and dye channels. 
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Figure 5.4.  Photographs of water block with mounted base Peltier.  (A) Side view of water 
block with water lines, base Peltier and attached stage.  (B) Top view of water block with stage 
and mounted base Peltier. 
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Figure 5.5.  Triple mixing tee chip placed on freeze-thaw valve platform.  The valving regions 
of the chip (circled in white) sit atop the valves (4.3 mm x 4.3 mm), which are mounted on the 
20 mm x 40 mm base Peltier and the water block.  One of the chip’s mixing tees (boxed in red) is 
located over the microscope objective.  Thin pieces of metal covered in yellow tape are attached 
to the stage (circled in blue) and are used to secure the chip with magnets. 
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Figure 5.6.  Imaging setup for simultaneous fluorescence/thermal studies.  The chip sits atop the 
valves and the channels imaged with the inverted fluorescence microscope (shown emitting λex 
for fluorescein).  An infrared camera images the valves from above.  A vacuum line is secured in 
place and is manipulated remotely to control flow without disturbing the chip. 
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Figure 5.7.  Schematic for thermal camera study of base Peltier at various currents.  The color-
based temperature scale is precise but not accurate and exact temperatures were not measured in 
this study.  (A) Thermal image of microscope objective and base Peltier.  The valve Peltiers have 
been removed.  This image illustrates the viewing perspective for the subsequent images as the 
base Peltier’s orientation is the same in all of them.  (B) – (D) Thermal images of base Peltier 
with pyrolytic graphite at the indicated current levels.  (E) – (G) Thermal images of base Peltier 
at indicated current levels with the pyrolytic graphite stripped.  Note the presence of warmer 
areas in the upper corners in (D) and (G).  These begin to appear in (C) and (F) as well.  These 
regions are warmer than the freezing point of water.  
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Figure 5.8.  Thermal images of base Peltier at 5.1 A showing new mounting locations for the 
valves (outlined in white).  The temperature of the base Peltier at each mounting location is 
noted.  The region outlined in black is covered with pyrolytic graphite. 
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Figure 5.9.  Valve temperatures as a function of their duty cycle and polarity.  Positive duty 
cycles are closed valves while negative duty cycles are open valves.  Valve #1 is represented by 
black circles, valve #2 is represented by blue circles, valve #3 is represented by red diamonds, 
and valve #4 is represented by purple inverted triangles.  Their maximally cold temperatures 
vary (-38.5 °C for valve 1, -43.1 °C for valve 2, -38.6 °C for valve 3, and -31.3 °C for valve 4), 
but all are cold enough to rapidly freeze microfluidic channels. 
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Figure 5.10.  Visualization schematic for valve states in mixing tee.  Arrows indicate direction 
of flow, and relative size of the arrows indicates relative flow rate.  (A) Both the dye and buffer 
valves are open (DO:BO) and are flowing in equal quantities into the tee.  The channel appears 
half fluorescent and half dark.  (B) The tee appears completely fluorescent after the buffer 
valve’s closure (DO:BC) due to the dye flowing into both sides of the channel.  (C) The tee 
appears completely dark after the dye valve’s closure (DC:BO).  
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Figure 5.11.  Fluorescence images of freeze event.  The tee is outlined in white.  (A) Mixing tee 
with both valves open (DO:BO) showing equal fluid flow from the dye and buffer channels.  (B) 
Mixing tee immediately after closing the dye channel valve (DC:BO) showing a pulse of dye 
extending into the buffer channel from the dye’s valve region freezing and expanding.  
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Figure 5.12.  Fluorescence images showing thaw event.  (A) Mixing tee just as dye valve is 
opened (DC:BO to DO:BO).  (B) Mixing tee as the dye initially retreats back into the channel, 
and (C) further retreat of the dye.  The dye retreats back as the fluid contraction in the valve as 
its contents thaw.  The total timescale of these events is approximately 4 seconds.  (D) The fluid 
flow on either side of the tee has equalized after approximately 18 seconds. 
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Figure 5.13.  Time series of freezing and thawing with inset from thermal camera.  (A) 
Fluorescence image of mixing tee with both valves open.  The locations of the buffer channel, 
dye channel, and mixing channel are indicated.  Inset: thermal image (simultaneous with 
fluorescence image) of the two Peltiers controlling the valves for the buffer and dye.  The 
locations of the Peltiers themselves are boxed in white.  (B) Freeze pulse from buffer channel 
into dye channel.  The buffer’s Peltier appears deep blue in the thermal image because it is at its 
maximally cold temperature.  (C) Dye has taken over the buffer side of the tee due to diffusion 
following the buffer valve closure.  (D) The buffer’s Peltier is set to room temperature.  It now 
appears orange in the thermal image.  (E) Buffer is beginning to flow back into the tee following 
the thawing of its valving region.  Note the dimmer fluorescence on the buffer side of the tee.  
(F) The buffer’s flow is back to normal after its valve was opened. 
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Figure 5.14.  Event times for multiple freeze/thaw cycles of the same valve.  Freeze events are 
indicated with blue inverted triangles and thaw events with red boxes.  The valve Peltier was 
switched directly between -43 °C and 25 °C to induce freezing and thawing, and the event times 
were determined based on the appearance of the freeze pulse shown in Figure 5.11B and the 
thaw retreat shown in Figure 5.12A.  The average freeze time was 37.1 s with a standard 
deviation of 4 s.  The average thaw time was 13.4 s with a standard deviation of 2 s. 
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Figure 5.15.  Event times for multiple freeze/thaw cycles in which the system was held at -2.5 
°C for 20 s between each event.  The average freeze time was 31.8 s with a standard deviation of 
6.7 s.  The average thaw time was 7.3 s with a standard deviation of 3 s. 
 
158 
 
Figure 5.16.  Event times for multiple freeze/thaw cycles in which the system was shut off for 
20 s between each event.  The average freeze time was 25.8 s with a standard deviation of 5.5 s.  
The average thaw time was 10.7 s with a 3.9 s standard deviation. 
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Figure 5.17.  Time series of sustained valve closure experiment.  Channel walls are outlined in 
white.  (A) Mixing tee prior to valve closure (BO:DO).  (B) Freeze pulse as the dye valve closes 
(BO:DC).  The tee was video recorded continuously for an hour to confirm sustained closure of 
the dye valve.  (C) Representative image of tee from t = 1 min to t = 60 min.  (D) Final image of 
tee 1 minute after re-opening of dye valve (BO:DO).  It has returned to its t = 0 state. 
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CHAPTER 6 
ASSAYS WITH MULTI-SAMPLE CHIPS AND FREEZE-THAW VALVES  
AND FUTURE DIRECTIONS 
6.1 Introduction 
 The project discussed in this dissertation aimed to develop an automated microfluidic 
device for determining pERK1/2:ERK1/2 in a sample.  Early immunoassay development 
experiments focused on the testing of various reagents, buffers, and assay protocols using a 
simplified single-channel, single-array chip and the model antigen VEGF.  In testing detection 
fluorophore labels, approximately 10 times more signal was obtained from B-phycoerythrin than 
from the label previously used, AlexaFluor 488.  Longer incubation times (1 h for sample, 30 
min for dAb, 20 min for SA-PE) at room temperature were shown to yield 3 times more signal 
than shorter incubation times (30 min sample, 20 min dAb, 10 min SA-PE) at 37 °C.  A 
preliminary protocol for determining pERK2:ERK2 in a sample was developed that involved 
incubating a dAb for pERK1/2 before a dAb for total ERK2.  Upon discovery that the process of 
mechanically loading the beads into the PDMS arrays induced a large variance, a new chip 
without the need for harsh loading conditions was design and fabricated. 
 The new “flow-frit” chips featured flow beds, a continuous pattern of spaced pillars 
designed to focus beads into a monolayer while providing additional fluidic space for reagents.  
A frit consisting of pillars spanning the channel height traps the beads, forming a detection zone.  
These chips were found to perform well in terms of signal and experimental variance, although 
on-chip bead-sample incubations performed in the packed beds led to a fluorescence gradient 
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across the bed.  Incubating beads with samples in sample vias prior to forming the packed bed 
solved the problem.  
 The flow-frit chips required extensive user interaction to perform assays.  Solutions were 
manually removed from and pipetted onto the chips before each incubation step with manually 
applied vacuum and imaging steps as well.  The development of freeze/thaw valves for 
automating the reagent delivery was then undertaken.  A chip featuring serpentine channel 
valving regions was developed that utilized the flow-frit pack bed design.  The FTV system was 
found capable of opening and closing microfluidic channels on timescales suitable for the 
pERK1/2:ERK1/2 assay’s needs.  It did so under computer control, making that component of 
the system readily automatable. 
 Having developed a workable valving system, the next step was to develop an assay chip 
incorporating the valving system and addressing additional assay needs.  In addition to 
possessing four valves for four reagents (buffer, the pERK1/2 dAb, the tERK1/2 dAbs, and SA-
PE), a chip capable of analyzing multiple simultaneous samples would be desirable.  Examples 
of microfluidic immunoassay devices capable of handling multiple simultaneous samples are 
abundant in the literature.1–5  In contrast to the single-channel, single-array chips, with which 
replicate measurements required multiple devices, these are capable of taking replicate 
measurements with a single device.  This potentially reduces the time and material requirements 
for device fabrication, and thus, the overall cost of the device.  Taking replicate measurements on 
a single device also has the potential for minimizing the experiment’s variance since samples on 
a chip will experience the same experimental conditions.  It is also possible to use a multi-sample 
device to generate a calibration curve for each experiment while concurrently measuring 
unknown samples.  Coupled with the fact that many of the extant devices are automated through 
164 
the use of computer-controlled valving and imaging, it is thus possible to make quantitative 
determinations of many samples with a single self-contained device that does not require user 
intervention once the experiment has begun. 
 In this chapter, a chip that couples the developed pERK1/2:ERK1/2 assay with the 
freeze-thaw valves is developed and tested.  The chip features 4 reagent valves for modulating 
the flow of buffer, pERK1/2 dAb, tERK1/2 dAb, and SA-PE.  The chip also features 8 flow-frit 
sample regions so that pERK1/2:ERK1/2 can be determined simultaneously in both calibration 
solutions and cell lysate samples.  Assays with these sample types are demonstrated and the 
sensitivity of the assay with the current system is determined.  This device represents a 
significant step toward fully automating the assay and, with different beads and detection 
antibodies, it can be used to determine other analytes as well.  Finally, various avenues for 
improving the assay are suggested as directions for future research. 
6.2 Materials and methods 
6.2.1 Materials and reagents 
 Sylgard 184 PDMS was purchased from Dow Corning (Midland, MI) and was prepared 
according to the manufacturer's instructions at a 10:1 elastomer/cross-linker ratio.  MagPlex 
Luminex beads were purchased from Bio-Rad Laboratories (Hercules, CA).  Purified 
phosphorylated and non-phosphorylated extracellular signal-related kinase 2 (pERK2 and 
nERK2), phosphorylated and non-phosphorylated extracellular signal-related kinase 1 (pERK1 
and nERK1), biotinylated detection antibodies for pERK1/2, ERK1, and ERK2, and capture 
antibodies for pERK1/2 were purchased from R&D Systems (Minneapolis, MN).  All proteins 
and antibodies were reconstituted according to the manufacturer’s instructions.  Soda lime glass 
photolithography substrates (5” x 5”) were purchased from Nanofilm (WestLake Village, CA).  
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Nano-Strip was purchased from KMG Chemicals (Fremont, CA).  Pluronic F-127 (PF-127), 
sodium chloride, octyltrichlorosilane, sodium fluoride, ethylene diamine tetraacetic acid 
(EDTA), urea, Triton X-100, phorbol 12-myristate 13-acetate (PMA), leupeptin, 
phenylmethanesulfonyl fluoride (PMSF), aproptinin, sodium pyrophosphate, and sodium 
orthovanadate were purchased from Sigma-Aldrich (St. Louis, MO).  AZ-400K was purchased 
from AZ Electronic Materials USA (Somerville, NJ).  Chromium etchant and 10:1 buffered 
oxide etch (BOE) were purchased from Transene (Danvers, MA).  Acetone, 10x phosphate-
buffered saline (PBS, pH = 7.4), 10% bovine serum albumin (BSA) in PBS, 200 proof ethanol, 
optically clear polypropylene plate-sealing tape (PCR tape), and microscope slides (75 mm x 25 
mm x 0.99 mm) were purchased from Thermo Fisher Scientific (Waltham, MA).  Contrad 
detergent was purchased from Decon Labs (King of Prussia, PA).  KMPR 1010 photoresist and 
SU-8 thinner was purchased from MicroChem (Newton, MA); the SU-8 thinner was mixed with 
KMPR 1010 to prepare 35% (w/w) KMPR solutions.  MF-319 photoresist developer was 
purchased from Rohm and Haas Electronic Materials (Marlborough, MA).  P-type 6” crystalline 
Si wafers were purchased from University Wafer (Boston, MA).  D263 glass was purchased 
from S.I. Howard Glass Company (Worcester, MA).  Streptavidin-B-phycoerythrin (SA-PE), 
RPMI 1640 media, fetal bovine serum, penicillin, and streptomycin were purchased from 
Invitrogen (Carlsbad, CA).  Human Jurkat T-cells were acquired from American Type Culture 
Collection (Rockville, MD).   
 All aqueous solutions were prepared with deionized (DI) water from a NANOpure 
Diamond system (Barnstead International, Dubuque, IA).  Buffer solutions used include PBS-BT 
(PBS + 1% BSA + 0.05% Tween-20), cell lysis buffer (PBS + 1 mM EDTA + 0.5% Triton X-
100 + 5 mM sodium fluoride + 6 M urea + 10 µg/mL leupeptin + 100 µM PMSF + 3 µg/mL 
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aprotinin + 2.5 mM sodium pyrophosphate + 1 mM activated sodium orthovanadate), ERK 
buffer (PBS + 5 mM sodium fluoride + 1 mM EDTA + 0.5% Triton X-100 + 1 M urea), and 
ERK diluent (ERK buffer with no urea).   
6.2.2 Design & fabrication of freeze-thaw chips 
 The chips designed for running the pERK1/2:ERK1/2 assays with FTVs (Figure 6.1) 
feature 4 valved reagent vias for introducing buffer, pERK1/2 dAb, tERK1/2 dAb, and SA-PE 
solutions.  The reagent channels distribute their contents across channels for 8 different samples, 
and the sample vias are spaced 9 mm apart so that all can be loaded simultaneously with an 8-
channel pipette.  The regions in which the beads are incubated and packed into beds have flow-
frit features.  The flow bed pillars are 7 µm x 7 µm, the frit pillars are 12 µm in diameter, and all 
are spaced 4 µm apart edge-to-edge. 
 The wafer molds for the FTV chips were fabricated in the same way as the flow-frit chips 
from Chapter 4 with one exception.  Following the first photolithography/DRIE step in which the 
flow bed, frit, and channels were etched to a depth of approximately 22 µm, the first photoresist 
layer was not removed as it was in previous fabrication procedures.  This was done to keep resist 
on the high aspect-ratio flow bed/frit features.  While they were coated with an additional layer 
of resist in the next photolithography step, keeping the first layer of resist on circumvented any 
errors associated with alignment during the second exposure.  In the second 
photolithography/DRIE step, the channel layer of the chips was etched an additional 8 µm for a 
total depth of approximately 30 µm. 
 The soft lithography procedure for the PDMS chips did not utilize spin coating as in 
previous chapters.  Aluminum foil was wrapped around the wafer to seal off the unused regions, 
and degassed PDMS was poured over the chip features to a thickness of approximately 3 mm.  
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The mold was degassed under vacuum and cured for 10 minutes on a 150 °C hotplate.  The 
PDMS was removed from the wafer, the vias were created with a biopsy punch, and the 
individual chips were cut out of the bulk PDMS with a razor.  They were then plasma-treated 
along with Contrad-cleaned D263 glass (2” x 3” x 0.0082”) and bonded together.  These chips 
were left at room temperature for at least 24 h to stabilize; more rapid stabilization through 
heating was not done as that caused the thick PDMS to warp upwards in the middle of the chip. 
 Variants of the full chip were used in early experiments for optimization and testing.  
These were prepared by fabricating the full chips in PDMS, using a razor to cut off the unused 
regions, creating vias with a biopsy punch, and bonding the PDMS to microscope slides.  Stray 
channels leading to removed portions of the chip were sealed by placing the bonded chip on a 
150 °C hot plate, applying uncured 10:1 PDMS to the unneeded channels, and allowing the 
PDMS to cure.  These optimization chips are shown in Figure 6.2.  All have had the valving 
regions removed and a single via is used to manually introduce reagents and buffer to the chips.  
The optimization chip in Figure 6.2A does not have sample vias and was used to demonstrate 
consistency in fluid flow between chips and between different beds on the same chip.  The 
optimization chip in Figure 6.2B adds sample vias to the first optimization chip and was used to 
develop the freeze-thaw assay manually, as the experimental throughput was much higher with 
that design and multiple chips could be run simultaneously.  Finally, the full chip from Figure 
6.1 was subdivided into two chips (Figure 6.2C), one possessing sample vias while the other 
does not.  This chip was used to demonstrate that the method to seal the sample vias post-sample 
incubation did not interfere with the assay in any way. 
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6.2.3 Assay procedures with optimization chips 
 Assays with the freeze-thaw valves used the chip layout shown in Figure 6.1.  Valves 
were closed by setting them to their maximally cold temperature (between approximately -31 °C 
and -43 °C depending on the valve) for 50 s to rapidly effect freezing, then setting them to -3 °C 
to maintain the closure.  Valves were opened by setting them to +25 °C and were kept at that 
temperature until closed.  Valves were only opened once all other valves were closed. 
 Sample solutions containing ERK1/2 were prepared in ERK buffer.  All other reagents 
were prepared in PBS-BT.  Prior to assays, the chips were passivated with PBS-BT for 2 h at 
room temperature, and the frits in chips were plugged with 10-µm nonfluorescent beads to 
enable the ERK1/2 beads to form packed beds.  Samples were incubated in their vias for 30 min.  
Vacuum was applied to the chips for 10 min to pack the beads into beds.  The buffer valve was 
open during this time.  After packing the beads, vacuum was used to remove remaining sample 
solution from each sample via, and the vias were sealed by filling them with a solution of 25% 
Pluronic F-127 (w/v) + 3.5% sodium chloride (w/v).  Each valved reagent via contained 20 µL of 
solution.  Reagent incubations were performed by opening the corresponding valve and applying 
vacuum for 30 s.  The valve was left open for the duration of the incubation.  Washes were 
performed by opening the buffer valve and applying vacuum for 30 s.  Incubation times were 20 
min for the dAb, and 10 min for SA-PE.  Unless otherwise specified, all dAb solutions are at 1 
µg/mL and all SA-PE solutions are at 2 µg/mL.  Encoding and assay images were taken as 
described in Chapter 2.   
 For acquiring cell lysate samples, human Jurkat T-cells were cultured and lysed as 
described in Chapter 4, both with and without PMA stimulation. 
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6.2.4 Data analysis 
 Assays in this chapter were decoded with a WEKA algorithm in ImageJ.  The WEKA 
plugin6 can be trained to distinguish beads from background, as well as in-focus beads from out-
of-focus ones (Figure 6.3A-B).  The algorithm is applied to an encoding image (Figure 6.3C) to 
select all the in-focus beads (Figure 6.3D) and its selection is overlaid on the assay image (Figure 
6.3EF).  The fluorescence data from the selected beads is then exported to Excel and analyzed as 
in Chapter 4.  The use of WEKA as opposed to manual bead selection allows a consistent 
standard to be applied to all data. 
6.3 Results and discussion 
6.3.1 Automated chip design and the use of plug beads 
 In order to automate the assay, a new chip design with 4 reagent reservoirs and 8 sample 
vias was developed.  Each reagent channel incorporated the serpentine channels for the FTVs 
(Figure 6.1) for controlling the delivery of wash buffer, pERK1/2 dAb, tERK1/2 dAb, and SA-
PE.  Instead of a single sample via, a total of eight sample vias were incorporated.  These could 
be used to assay either multiple samples or to produce a calibration curve for single-sample use.  
The eight sample vias are spaced in increments of 9 mm so that all can be filled using an 8-
channel pipette.  Sample channels from the sample vias feed into bead regions with the flow-frit 
design from Chapter 4.  Their location on the chip was set according to the distance from the 
FTVs to the microscope objective’s viewing space.  All eight sample regions feed into a common 
outlet via for waste/vacuum which should ensure identical fluid flow.  While the single-channel 
flow-frit chips worked well at a depth of 12.5 µm, the large footprint of these 8 sample devices 
required deeper channels to maintain an adequate flow rate in light of their significantly higher 
hydraulic resistance due to the increase in the number of channels and channel lengths.   
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 Initially, multiple chips with varying depths were fabricated and a preliminary qualitative 
experiment examined the flow rate of the chips.  Only a single reagent via was created to 
simulate a three valves closed + one valve open configuration.  The via was filled with 10 µL of 
buffer and vacuum was applied to the chip.  The 30-µm deep devices (flow bed depth ~9 µm), 
like the first-generation flow-frit chips, required approximately 5 min to fully deplete the sample 
via and so were used in future experiments.  An unexpected outcome, however, was the MagPlex 
beads did not pack into beds against the frits.  Visually monitoring the chips showed the beads 
passed under the frits as the pillars turned out to be too short to block the bead flow.  This is 
likely because of the high aspect ratio of the frit features with the deeper chips.  The frits are 
pillars in the PDMS chips, so in the corresponding master mold, they are trenches.  While they 
were nominally etched to the same depth as the channels during the DRIE process and thus 
should have been tall enough to occlude bead flow, in many DRIE recipes, aspect ratio and 
relative depth change the uniformity of mass transfer of ions and etchant gases, slowing the etch 
rate of the deeper features.7  It was thus hypothesized that the frit trenches did not etch to the 
same depth as the channels.  This was corroborated by environmental scanning electron 
micrographs taken of the chips, showing that the frit pillars were not as tall as the channel walls 
in the PDMS chips. 
 Instead of further developing the DRIE recipe, which would have been time-consuming 
and expensive, this issue was addressed by simply using 10-µm polystyrene beads as plug beads.  
These nonfluorescent beads pack against the frits acting as a stop for the antibody-based beads.  
They are stored in PBS-BT to passivate them prior to use in assays.  Initially (in the consistency 
of fluid flow experiment in Section 6.3.2 and the initial assay with PF-127 sealed chips in 
Section 6.3.4), plug beads were mixed with ERK1/2 beads in a 1:100 (plug:ERK) ratio prior to 
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packing the beads.  Packed beds of ERK1/2 beads did result, but the stochastic mixing with plug 
beads resulted in many of the ERK1/2 beads packing out of focus.  A different protocol was 
developed in which the plug beads were packed prior to the assay through the sample vias and 
stored in PBS-BT until used.  This resulted in the ERK1/2 beads packing in the same focal plane 
and was used in every experiment following the initial assays with on-chip sample incubations 
(Section 6.3.5 onward). 
6.3.2 Consistency of fluid flow from chip to chip 
 The 8-sample chips use a symmetrical design relative to the bead regions such that the 
fluidic resistance, and thus the flow rate, should be identical across the bead beds.  This would be 
ideal for ensuring the identical delivery of reagents to the bead beds and maintain reproducibility 
of results within chips and between chips.  As sample incubations take place inside the sample 
vias and not in the bead beds, the consistency of fluid flow was of concern with respect to the 
dAb and SA-PE incubations as well as the wash steps.  To evaluate the consistency from bed to 
bed and chip to chip, ERK1/2 beads were incubated with samples (pERK2 at 0, 10, and 20 
ng/mL) off-chip at 1000 rpm for 30 min.  This was to maximize signal as well as ensure that the 
beads being assayed were exposed to the same sample amount.  The beads were mixed with 
spacer beads and packed into beds using the single-via chips in Figure 6.2A.  These chips do not 
have sample vias and rely on the symmetrical design to deliver equal number of beads to the 8 
bed regions from the sample/reagent via.  The chips were then filled with pERK1/2 dAb and 
incubated for 20 min, washed for 1 min, incubated with SA-PE for 10 min, washed for 1 min, 
and imaged.  A single concentration was used per 8-channel chip to evaluate the signal across 
each chip.  Three chips were used for the 10 ng/mL samples and two chips for the 20 ng/mL 
samples to evaluate the chip-to-chip variance. 
172 
 The results in Figure 6.4 show that the fluorescence is consistent between measurements.  
The aggregate %RSD for all measurements at 10 ng/mL (N=19 beds) was 8.14%, while it was 
6.25% for the 20 ng/mL chips (N=14 beds).  The intrachip (bed-to-bed on the same chip) 
%RSDs are 7.02% or below in all cases.  As both the interchip and intrachip %RSDs were below 
10%, the reproducibility of the fluorescence in these results was judged to be sufficient to justify 
the use of the 8-sample chips in the pERK1/2:ERK1/2 assays. 
6.3.3 Sample channel sealing with Pluronic F-127 
 After packing the beads, it is necessary to close the sample vias so no additional fluid 
flow from the vias occurs.  This prevents any reagent dilution and eliminates the need to keep 
fluid in the vias.  Sealing the eight sample vias also greatly reduces the pressure drop across the 
sample regions and increases the flow rate from the reagent vias.  In an automated version of this 
device, FTVs could be used to seal the sample channels following sample incubation and 
packing the beads into beds.  Small (~1-2 mm square) Peltiers may be able to accomplish this 
without any modifications to the chip design by placing one under each sample via.  However, 
due to spatial constraints with the inverted microscope, the addition of FTVs on the sample 
channel was not feasible.  An alternative method of sealing the channels was pursued.  Efforts 
were undertaken to use a sealant that would block the channel when added to the sample via.  
The sealant itself should not have adverse effects on the assay (in the event of its leaking into the 
bead beds), and it should be capable of indefinitely preventing flow into or out of the sample 
incubation regions.  This is necessary not only to stop the channels influencing the assay once 
they are no longer being used, but additionally, eight unsealed samples vias create a sufficient 
pressure drop to prevent applied vacuum from drawing fluid from the reagent vias into the chip. 
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 PF-127 is a tri-block copolymer of poly(ethylene oxide) and poly(propylene oxide).  
When solutions containing approximately 20% (w/v) or greater in water are heated above 
approximately 15 °C, its viscosity increases dramatically, forming a gel.8  This is due to the 
formation of micelles approximately 17-19 nm in diameter9 that swell and desolvate upon 
heating, causing their hydroxyl groups to undergo hydrogen bonding.8  The viscosity increase is 
tunable as a function of both the concentration8 of PF-127 and the ionic strength10 of its solution; 
adding 5% (w/v) sodium chloride to a 30% (w/v) PF-127 solution increases its viscosity 
approximately tenfold.  This is likely the result of the electrolyte solvating water, thus further 
desolvating PF-127 and enabling the formation of more hydrogen bonds between hydroxyl 
groups on the micelles.  As the viscosity of the PF-127 gel is potentially enough to seal a 
microfluidic channel, it was hypothesized that the addition of chilled PF-127 to the sample via 
would seal the channel as the PF-127 warmed to room temperature and its viscosity increased. 
 To test this hypothesis, solutions of 25% (w/v) PF-127 were prepared containing NaCl in 
concentrations from 2.5% to 5% (w/v).  The solutions were chilled during mixing to keep them 
in the liquid phase.  The 8-sample chip shown in Figure 6.2B with a single reagent reservoir and 
8 sample vias was filled with black ink for ease of visualization.  The ink was then removed from 
the sample vias by vacuum and replaced with a PF-127/NaCl solution (Figure 6.5A).  The 
reagent via was then filled with buffer and vacuum was applied.  If the PF-127 solution gelled 
sufficiently, the ink should be removed from all channels except the sample channels.  The 
image in Figure 6.5B clearly shows that all channels were flushed clear by the buffer but the 
sample channels remained filled with ink, indicating no fluid flow or successfully sealed 
channels by the gel.  The vacuum was shut off following this and the chips were left to sit, with 
vacuum reapplied every 30 minutes for 20 seconds.  Visual inspection of the chips sealed by PF-
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127 solutions containing 3.0% - 3.5% NaCl found the seals to hold for at least 4 h.  Times longer 
than that were not tested as they are beyond the timescale of the assay.  Lower NaCl 
concentrations were insufficiently viscous to seal the channels, while higher concentrations were 
found to be more difficult to work with due to their higher viscosity. 
6.3.4 Initial assays with Pluronic F127-sealed chips 
 Following the successful sealing of sample channels with PF-127 gel, the next step was 
determining whether the gel would interfere with the assay.  While pressure-driven flow from the 
channel was prevented by the seal, solvated PF-127 could potentially diffuse toward the bead 
beds.  PF-127 is biocompatible with immunoassays and is usable as a reagent for reducing an 
assay’s non-specific binding,11 but assay-compatible reagents can still cause changes in the 
assay’s signal, so this issue was explored by comparing assays run with PF-127 and without.   
 The hybrid valveless chips shown in Figure 6.2C were used for this assay.  The right half 
of the chip features sample inlet vias that will be sealed by PF-127.  The left half introduces 
beads and reagents through the via at the top of the chip.  To test the effects of PF-127 on the 
assay, ERK1/2 beads were incubated with pERK2 samples at 0, 5, 10, and 20 ng/mL off-chip on 
the vortexer for 30 min.  They were then mixed with spacer beads and packed into beds in each 
of the detection regions.  Once the bead beds were packed, the chips with sample vias were 
sealed with PF-127.  The assay was then completed with a pERK1/2 dAb incubation, a wash, an 
SA-PE incubation step, a final wash, and an imaging step. 
 The results for this experiment are shown in Figure 6.6.  The signals from the beads 
incubated with PF-127 seals (red inverted triangles) are indistinguishable from the beads 
incubated without PF-127 (black squares).  These results show that using PF-127 to seal the 
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sample channels is viable in conjunction with assays as the results from both methods are 
effectively identical. 
6.3.5 On-chip incubations 
 Following the successful demonstration of closing the sample via after bead packing, 
experiments were done to show the efficacy of incubating the sample on-chip.  Figure 6.7 shows 
the 3 steps to prepare the chip for incubation with the assay reagents.  In step 1, the samples are 
incubated with the beads directly in the sample vias (Figure 6.7A) and packed into beds by 
applying vacuum in step 2 (Figure 6.7B).  The sample channels would then be sealed with PF-
127 following bed formation (Figure 6.7C) in step 3.  While this bears many similarities to the 
on-chip sample incubations that were performed with the flow-frit chips from Chapter 4, a major 
difference is that the flow-frit chips featured only one sample per chip, while these feature eight 
samples per chip.  Beyond determining if the sample can be incubated in the sample vias with 
beads, these experiment can evaluate whether any cross-talk occurs between sample beds.  This 
cross-talk could potentially occur during the sample incubations as the sample vias are directly 
connecting during the sample incubation.  Due to the length of channels (9 mm) between sample 
vias, no cross-reactivity was expected.  Validating the chips in this manner represents the final 
hurdle before running assays with the FTVs. 
 Four 8-sample valveless chips shown in Figure 6.7A were used to test the on-chip sample 
incubations.  ERK1/2 samples were prepared with 0%, 5%, 10%, 25%, 33%, 40%, 66%, and 
100% pERK at a constant total ERK1/2 of 10 ng/mL.  The samples were mixed with ERK1/2 
beads and an 8-channel pipet was used to fill the sample vias with all eight samples 
simultaneously.  After incubating for 30 min, vacuum was applied to pack the beads.  The 
sample vias were sealed with PF-127 and the assay was completed with incubations of pERK1/2 
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dAb, total ERK1/2 dAb, SA-PE, 30-s washes, and two imaging steps.  Figure 6.8 shows no 
adverse effects with on-chip incubations, as the resultant calibration curve has an R2=0.999 and 
the %RSDs are all below 10%.  Cross-talk between detection regions does not appear to be a 
significant factor.  This is consistent with the fact that sample vias all contain the same volume 
and thus any flow that does occur between them should be a result of diffusion alone.  It is also 
consistent with the rate of diffusion for a protein across the dimensions of the chip.  The time t 
(s) required for a molecule with diffusion coefficient D (cm2/s) to diffuse distance x (cm) is 
governed by Equation 6.1:12 
                                                                                                   (6.1) 
The diffusion coefficient in water for a protein similar in size to ERK1/2 would be13 
approximately 7.5 x 10-7 cm2/s and the distance from one sample via to another along the length 
of the channels is approximately 1.8 cm.  It would therefore take approximately 2,100,000 s (or 
~24 days) for the protein to traverse that distance through diffusion alone.  This is the fastest 
possible diffusion time under the most favorable circumstances for diffusion to occur; the 
presence of other proteins in the buffer further slows the diffusion rate.  Also, the fluid levels in 
each sample via are the same, so there is not likely to be any migration from via to via due to 
misleveling of the reagent droplets. 
 The final experiment run using an optimization chip tested the inclusion of pERK1 in the 
standard calibration matrix.  Previous experiments in both this chapter and Chapter 4 utilized 
only pERK2, nERK1, and nERK2, but cell lysate would also contain pERK1.  Further, the 
pERK1/2 dAb recognizes both pERK2 and pERK1, separate dAbs for total ERK1 and total 
ERK2 are used and may not have the same affinity for their epitopes on their respective targets.  
Omitting pERK1 from the standards thus gives the total ERK1 dAb progressively fewer 
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molecules to bind to as a function of the %pERK in the solution (since ERK1 is only present as 
nERK1).  pERK1 should thus be included in the standards in order to generate an accurate 
calibration curve. 
 A pERK1/2:ERK1/2 assay was run with samples containing 0%, 33%, 66%, and 100% 
pERK1/2 at a constant total ERK1/2 = 10 ng/mL.  The pERK1/2 and nERK1/2 samples 
contained equal amounts of ERK1.  The samples were mixed with ERK1/2 beads, pipetted into 
sample vias to begin the first incubation, and assayed as with previous pERK1/2:ERK1/2 
experiments.  The results in Figure 6.9 show a well-defined fit (R2=0.9996) and low %RSDs 
with relative fluorescence ratios similar to the previous on-chip assay.  Based on these results, 
the assay format was ready for implementation on the full freeze-thaw valve chip. 
6.3.6 pERK1/2:ERK1/2 assay with full freeze-thaw valve chip and automated fluid delivery 
 Following the proof-of-concept work with the optimization chips, the 8-sample chips 
with the serpentine valve regions (Figure 6.1) were used to determine pERK1/2:ERK1/2 in both 
standard solutions and lysate from Jurkat cells.  The 4 assay reagents are loaded in their 
respective vias and their delivery to the packed bead bed controlled by automated 
opening/closing of the appropriate valve.  Five calibration samples were prepared consisting of a 
blank (beads in ERK buffer only) and 10 ng/mL total ERK1/2 at 0%, 25%, 50%, 75%, and 100% 
pERK1/2.  Two cell lysate samples were acquired from Jurkat cells, one of which was treated 
with 200 nM PMA for 30 min to induce ERK1/2 phosphorylation.  The lysate in each via came 
from approximately 20,000 cells.  The freeze-thaw platform assays a single chip at a time and the 
data acquired represent three chips assayed in one day.   
 The results in Figure 6.10 show the pERK1/2:ERK1/2 fluorescence ratio in the cell lysate 
(black square) along with the ratio in the PMA-treated lysate (blue triangle) and the calibration 
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standards (red inverted triangles).  The calibration points fit strongly (R2 =0.992) to a sigmoid 
curve, showing that the pERK1/2:ERK1/2 fluorescence ratio increases predictably as a function 
of the %pERK in the sample.  As in the previous pERK1/2:ERK1/2 determination from cell 
lysate, the PMA-treated Jurkat cells showed a higher phosphorylation ratio (~67%) than their 
untreated counterparts (~2%).  One major difference between the results in Figure 6.10 and the 
previous cell lysis assay from Chapter 4 is the degree of phosphorylation of the PMA-treated 
cells.  While both experiments showed low-single-digit pERK1/2:ERK1/2 ratios in the untreated 
cells (~4% in Chapter 4 and ~2% in this experiment), in the previous experiment the PMA-
treated cells showed approximately 30% phosphorylation while here they are approximately 67% 
phosphorylated.  This difference may be the result that two different cell populations were used 
for the experiments.  Though nominally from the same line, the cells that exhibited 30% 
phosphorylation post-PMA were cultured and passed dozens of times prior to use in the 
experiment, while the cells used in this experiment had been passed fewer than 10 times.  The 
cells in the first line thus had much more time to mutate, potentially affecting their susceptibility 
to PMA.    
 Regardless of the cause of the phosphorylation differences, this assay, like its predecessor 
in the flow-frit chips, successfully measured pERK1/2:ERK1/2 in standard calibration solutions 
(at physiologically relevant concentrations) as well as in cell lysate samples.  The demonstration 
of this assay on the 8-sample freeze-thaw valve chips represents a significant step toward 
automating the assay and the concomitant reduction in user error. 
6.4 Conclusions and future directions 
 An automated microfluidic device for the measurement of pERK1/2:ERK1/2 was 
developed using freeze/thaw valves.  Chips were developed for 8 samples and 4 reagents so that 
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either multiple real-world samples could be assayed at once, or a combination of samples and 
standards could be analyzed on the same chip.  Initial experiments showed reproducible fluid 
flow between chips and between bead regions (%RSDs <10%).  It was also shown that despite 
the frits being unable to pack the 6.5-µm ERK1/2 to into beds, the frits could be plugged with 
nonfluorescent 10-µm beads prior to generating a bed with the assay beads.  Following that, it 
was shown that the beads could be incubated with sample directly on-chip without cross-
reactivity between samples and that the sample vias could be sealed with PF-127 gel after the 
beads were pulled into packed beds.  No interference was seen with using the PF-127 gel to seal 
the sample vias, and thus pERK1/2:ERK1/2 assays with on-chip sample incubations were 
demonstrated.  Finally, the determination of pERK1/2:ERK1/2 in standards and cell lysates using 
automated reagent delivery was demonstrated on chips actuated by the freeze-thaw valves.  The 
assay’s sensitivity was comparable or superior to previous efforts with the flow-frit chips and the 
efforts in this chapter represented a major step toward automating the device.   
 Overall, the assay developed takes less than two hours to complete and is significantly 
faster than methods that require several multi-hour or even overnight incubations (e.g. plate 
ELISAs and Western blots).  The assay performed its analysis on approximately 20,000 cells, 
while some methods require up to millions of cells.  It is semi-automated and is ready for full 
automation, which would significantly reduce labor requirements over methods that require 
extensive user manipulation of their systems. 
 To fully automate the assay with the 8-sample chips, several additional steps are needed.  
The first and simplest to implement would be the automation of vacuum steps, as a solenoid-
driven vacuum line could be attached to the chips and controlled by computer software.  
Automating the imaging step would be possible through use of a computer-controlled stepper 
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motor that translates the stage from bead region to bead region.  Imaging step automation would 
also require a means of automatically focusing the microscope at each individual bead bed or of 
ensuring that the chip is sufficiently level to be in the same focal plane throughout the 
experiment.  The use of a different magnification level might facilitate this (and render 
unnecessary the use of an autofocus system), as its depth of field would be greater than that of 
the 30x magnification used here.  These additional steps do add complexity to the system and not 
all would be necessary to automate a single-sample device, but the benefits of the 8-sample chip 
outweigh the drawbacks.  Namely, the ability to generate a calibration curve on the same device 
as the sample analysis, or to perform simultaneous replicate measurements of the same sample. 
 Another important step in automating the assay would involve an elimination of the 
manual PF-127 sample channel sealing.  Freeze-thaw valves for actuating the sample channels 
would be one method of accomplishing this.  This strategy was not possible with the inverted 
microscope setup due to space constraints imposed by the microscope objective turret.  Using a 
custom detection with a top-down optical imaging system would open more space for valve 
placement, would allow the sample and bead regions to sit atop the valves and water block, and 
would thus enable the integration of sample valves.  The LabVIEW program for valve control 
could be updated to include the sample channel valves, open/close the valves according to preset 
timers and drive the vacuum line and stepper motor for translating the chip into the optical 
pathway.  At this point, the assay would be fully automated following the addition of reagents 
and samples to the chip.  The assay can be further simplified by removing the need for plug 
beads as well.  This can be done by optimizing the DRIE fabrication procedure for the wafer 
molds so that the 6.5-µm beads can pack against the frits, or by coupling capture antibodies to 
suitable ~10-µm beads, as these do not pass through the current frits. 
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 Additional improvements to the assay beyond full automation are also possible.  
Switching to the top-down optical setup would allow Peltiers to be placed directly under the 
sample and bead regions to heat the beads during incubation steps.  This strategy was shown to 
be effective during early assay development in the Ramsey group as diffusion is a limiting step 
for most immunoassays14 and the diffusion rate is directly proportional to temperature.12  Heating 
the beads to physiological temperature (37 °C) during incubations while keeping the incubation 
times the same should therefore increase the sensitivity.  The incubation times could also 
potentially be lengthened in conjunction with the use of the higher temperature.  These steps may 
improve the sensitivity of the assay and would enable it to determine pERK1/2:ERK1/2 in 
samples with fewer cells. 
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6.5 Figures 
 
Figure 6.1.  Diagram of 8-sample chip.  Four vias for reagents (SA-PE, tERK1/2 dAbs, 
pERK1/2 dAb, wash buffer) feed through four serpentine valve regions before reaching the bead 
regions of the chip.  Sample vias are spaced 9 mm apart so that all can be loaded simultaneously 
with an 8-channel pipette.  The bead channels use the flow-frit design with 7 µm x 7 µm pillars 
spaced 4 µm edge-to-edge. 
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Figure 6.2.  Three variations on the multi-sample chip design used for assay development and 
optimization.  The four reagent vias and valves have been removed from all three and replaced 
with a single via for reagent and/or sample.  (A) Chip used to assess the reproducibility of fluid 
flow across and between chips.  The sample channels leading to the bead regions are not used.  
(B) Chip used to develop pERK1/2:ERK1/2 assay.  This most closely resembles the full freeze-
thaw chip.  (C) Chip used to test the effect of sealing the sample channels with PF-127 by direct 
comparison with a chip that had no sample vias and thus required no sealing. 
 
 
 
 
 
 
 
 
 
184 
 
Figure 6.3.  Diagram of WEKA analysis.  (A) The program is trained to distinguish in-focus 
beads (blue circles) from out-of-focus beads/background (red).  (B) The program generates a 
selection of the in-focus beads (blue) and excludes everything else (red).  (C) Encoding image of 
bead bed from which (D) a selection mask is created by the WEKA algorithm.  This is applied to 
the assay image (E) for that bead bed and (F) the in-focus beads are selected.  Their fluorescence 
is exported to Excel in the form of a 5000-bin histogram and the mean/standard deviation 
determined following outlier removal. 
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Figure 6.4.  Net fluorescence signal with [pERK2] from experiments examining the consistency 
of fluid flow from chip to chip.  The %RSDs for the samples (left to right) are 7.02%, 5.45%, 
2.46%, 3.02%, and 5.77%.  The aggregate %RSD for the 10 ng/mL samples (N=19) was 8.14% 
and was 6.25% (N=14) for the 20 ng/mL samples. 
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Figure 6.5.  Optimization chip before and after Pluronic F-127 sealing of sample channels.  (A) 
Optimization chip with sample vias filled with ink for visualization.  (B) Optimization chip after 
sealing sample vias with PF-127 and the reagent inlet filled with buffer and vacuum applied.  
This washed the ink from the chip, except in the sample channels (circled in red) which were 
sealed by the gel. 
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Figure 6.6.  Fluorescence signal with [pERK2] with linear fits from experiments comparing 
fluorescence from chips with and without PF-127 sealed sample channels.  Data from the PF-127 
sealed channels are represented by the red inverted triangles while those without PF-127 are 
denoted by the black squares.  The curves are effectively identical and indicate that PF-127 
sealing does not interfere with the assay. 
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Figure 6.7.  The three steps involved in preparing a chip for incubation with the assay reagents.  
(A) Step 1: Samples are incubated with beads in the sample vias (red circles).  (B) Step 2: 
Vacuum is applied to pack the beads against the frits (red arrows leading to red boxes).  (C) Step 
3: sample vias are filled with PF-127, effectively closing the channel to fluid flow.  Reagents are 
introduced through the buffer via located at the top of the chip. 
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Figure 6.8.  pERK1/2:ERK1/2 fluorescence ratio with %pERK with on-chip sample incubations.  
The calibration curve follows a well-defined (R2 = 0.999) sigmoidal fit. 
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Figure 6.9.  pERK1/2:ERK1/2 fluorescence ratio with %pERK after inclusion of pERK1 in the 
calibration standards.  The curve also follows a well-defined sigmoid fit. 
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Figure 6.10.  pERK1/2:ERK1/2 fluorescence ratio with %pERK using the 8-sample microfluidic 
chip, freeze-thaw valves, and cell lysate.  The calibration standards are represented by red 
inverted triangles, the cell lysate sample by the black square, and the PMA-treated cell lysate by 
the blue triangle.  The red line is a sigmoidal fit to the standards.  The PMA-treated cells show 
over 30x the phosphorylation of the untreated cells.  Approximately 100,000 cells were used to 
produce each lysate sample. 
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